Lineberger Comprehensive Cancer Center – Administration and Program Leaders

University of North Carolina at Chapel Hill, School of Medicine

1000 Grants

This is a chronological listing of grants held by this department, with the most recent listed first. New grants appear in this list weekly and contribute related to the department's Research Profile. The source of grants for this application comes directly from your institution.

• 1.

  Ben Philpot; Terry Magnuson; Bryan Roth

  A Chemical Genetic Approach for Activating the Dormant Gene Associated with Rett Syndrome

  2/1/2013 - 1/31/2016

  Sponsor: Rett Syndrome Research Trust

  Funding: $ 1,874,800.00

• 2.

  Thomas Shea; Paul Armistead; James Coghill; Amber Essenmacher; Don Gabriel; Katarzyna Jamieson; Alicia Pinto; Stefanie Sarantopoulos; Erin Schmid; Jonathan Serody; William Wood; Rebekah Craver; Mary Owen

  115523 (ZOSTER-2) A phase III, randomized, observer-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals? herpes zoster gE/AS01B candidate vaccine when administered intramuscularly on a two-dose schedule to adult autologous haematopoietic stem cell transplant (HCT) recipients

  1/28/2013 - 6/30/2018

  Sponsor: Industry Sponsor

  Funding: $ 4,000.00

• 3.

  Joseph Pagano

  The Function of EBV LMP1 CTAR3 in Sumolation and Oncogenesis.

  1/7/2013 - 12/31/2014

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 82,811.00

• 4.

  Gary Johnson

  Targeted therapy for MAP3K1 and MAP2K4 Mutant Estrogen Receptor Positive Breast Cancer

  9/30/2012 - 9/29/2014

  Sponsor: DOD DA Army Medical Research Acquisition Activity

  Funding: $ 236,501.00

• 5.

  Satish Gopal; Thomas Shea

  Developing a prospective clinical cohort of histopathologically characterized lymphoma patients in Malawi

  9/20/2012 - 6/30/2017

  Sponsor: NIH Fogarty International Center for Advanced Study in the Health Sciences

  Funding: $ 140,175.00

• 6.

  Terry Magnuson; Jennifer Brennan

  Mutant Mouse Regional Resource Center Annual Meeting

  9/18/2012 - 7/31/2017

  Sponsor: NIH Office of the Director

  Funding: $ 18,000.00

• 7.

  Jill Fisher; Arlene Davis; Malika Roman Isler; Rebecca Walker

  Factors Affecting Healthy Volunteers' Long-Term Participation in Clinical Trials

  9/5/2012 - 5/31/2017

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 376,232.00

• 8.

  Peng Liu; Teresa Tarrant; Jenny Ting

  Differential regulation of autoimmune arthritis by monocyte subsets

  8/1/2012 - 7/31/2017

  Sponsor: NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD)

  Funding: $ 333,000.00

• 9.

  Jonathan Serody

  Targeting CCR7 for the Prevention/Treatment of GvHD

  7/2/2012 - 5/31/2016

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 370,000.00

• 10.

  Jenny Ting

  Role of inflammasome in neuro-inflammation disease

  7/1/2012 - 6/30/2015

  Sponsor: National Multiple Sclerosis Society (NMSS)

  Funding: $ 169,946.00

• 11.

  Jonathan Serody

  In vivo assessment of T cell and DC interaction by two photon microscopy in GvHD

  7/1/2012 - 6/30/2015

  Sponsor: Leukemia and Lymphoma Society (LLS)

  Funding: $ 55,000.00

• 12.

  Joseph Pagano

  PREVENTION AND ANTIVIRAL TREATMENT FOR EBV LYMPHOMAGENESIS

  7/1/2012 - 6/30/2014

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 228,000.00

• 13.

  Yue Xiong; Jing Wu

  Mechanisms of Oncometabolites in Epigenetics and Cancer

  7/1/2012 - 6/30/2013

  Sponsor: Samuel Waxman Cancer Research Foundation (SWCRF)

  Funding: $ 100,000.00

• 14.

  Andrew Olshan

  Epidemiology and Evaluation Services

  6/1/2012 - 5/31/2013

  Sponsor: NCDHHS Division of Public Health (DPH)

  Funding: $ 90,805.00

• 15.

  Carol Golin; Malika Roman Isler

  HIV Prevention Trials Network Scholars Program

  6/1/2012 - 5/31/2013

  Sponsor: Family Health International

  Funding: $ 63,581.00

• 16.

  Jonathan Serody

  Th1/Th17 Macrophage Interactions in Cutaneous GVHD

  5/9/2012 - 3/31/2017

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 309,342.00

• 17.

  Jonathan Serody

  Th1/Th17 Macrophage Interactions in Cutaneous GVHD

  5/9/2012 - 3/31/2017

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 139,204.00

• 18.

  Lisa Carey

  BO25126/BIG 4-11/TOC4939GB025126 A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer

  5/1/2012 - 4/30/2014

  Sponsor: Mayo Clinic

  Funding: $ 6,500.00

• 19.

  Lisa Carey

  BO25126/BIG 4-11/TOC4939GB025126 A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer

  5/1/2012 - 4/30/2014

  Sponsor: Mayo Clinic

  Funding: $ 780.00

• 20.

  Robert Millikan; Lisa Carey

  Carolina Breast Cancer Study: PHASE III

  5/1/2012 - 4/30/2013

  Sponsor: Susan G Komen for the Cure

  Funding: $ 301,054.00

• 21.

  Norman Sharpless

  In vivo murine models of metastasis for therapeutic testing

  4/16/2012 - 3/31/2017

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 412,209.00

• 22.

  Norman Sharpless

  In vivo murine models of metastasis for therapeutic testing

  4/16/2012 - 3/31/2017

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 180,095.00

• 23.

  Gary Johnson; Shelton Earp; Shawn Gomez; Lee Graves; Jian Jin; Pei-Fen Kuan

  Kinome Reprogramming in Response to Targeted Kinase Inhibitors

  4/15/2012 - 1/31/2016

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 278,929.00

• 24.

  Gary Johnson; Shawn Gomez; Lee Graves; Jian Jin; Pei-Fen Kuan

  Kinome Reprogramming in Response to Targeted Kinase Inhibitors

  4/15/2012 - 1/31/2016

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 249,720.00

• 25.

  Shelton Earp; Albert Baldwin

  The 36th Annual UNC Lineberger Comprehensive Cancer Center Symposium - Cancer Therapies and New Drug Targets

  4/3/2012 - 4/30/2012

  Sponsor: North Carolina Biotechnology Center (NCBC)

  Funding: $ 3,000.00

• 26.

  Gary Johnson

  FELLOW:WHITTLE, M Defining mechanisms of MEK1/2 inhibitor response in triple negative breast cancer

  4/1/2012 - 3/31/2015

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 29,383.00

• 27.

  Gary Johnson

  FELLOW:WHITTLE, M Defining mechanisms of MEK1/2 inhibitor response in triple negative breast cancer

  4/1/2012 - 3/31/2015

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 29,383.00

• 28.

  Yue Xiong; Derek Chiang; Jing Wu

  Mechanisms of Metabolic Gene Mutations in Cancer

  3/1/2012 - 2/28/2017

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 307,100.00

• 29.

  Yue Xiong

  Mechanisms of Metabolic Gene Mutations in Cancer

  3/1/2012 - 2/28/2017

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 50,000.00

• 30.

  Yue Xiong

  Mechanisms of Metabolic Gene Mutations in Cancer

  3/1/2012 - 2/28/2017

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 138,195.00

• 31.

  Fred Jarskog; Thomas Shea

  NN25310 A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebocontrolled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double-blind treatment period

  3/1/2012 - 2/15/2016

  Sponsor: Industry Sponsor

  Funding: $ 5,000.00

• 32.

  Thomas Shea; Michael Young

  Interactive Cancer Access Network

  1/24/2012 - 1/23/2015

  Sponsor: Department of Agriculture (USDA)

  Funding: $ 81,324.00

• 33.

  Jenny Ting

  Regulation of Colitis-associated Cancer by NLRX1

  1/1/2012 - 12/31/2014

  Sponsor: Cancer Research Institute

  Funding: $ 164,500.00

• 34.

  Lisa Carey

  mec116180 Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212

  11/15/2011 - 11/14/2014

  Sponsor: Industry Sponsor

  Funding: $ 13,010.00

• 35.

  Thomas Shea; Amber Essenmacher; Robert Irons; Marisa DeBurkarte; Mary Owen

  SGN35-005 A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT)

  11/10/2011 - 11/9/2014

  Sponsor: Industry Sponsor

  Funding: $ 15,000.00

• 36.

  Thomas Shea; Amber Essenmacher; Robert Irons; Marisa DeBurkarte; Mary Owen

  SGN35-005 A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT)

  11/10/2011 - 11/9/2014

  Sponsor: Industry Sponsor

  Funding: $ 13,601.00

• 37.

  Thomas Shea; Amber Essenmacher; Robert Irons; Marisa DeBurkarte; Mary Owen

  SGN35-005 A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT)

  11/10/2011 - 11/9/2014

  Sponsor: Industry Sponsor

  Funding: $ 9,801.00

• 38.

  Thomas Shea; Amber Essenmacher; Robert Irons; Marisa DeBurkarte; Mary Owen

  SGN35-005 A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT)

  11/10/2011 - 11/9/2014

  Sponsor: Industry Sponsor

  Funding: $ 4,250.00

• 39.

  Thomas Shea; Amber Essenmacher; Robert Irons; Marisa DeBurkarte; Mary Owen

  SGN35-005 A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT)

  11/10/2011 - 11/9/2014

  Sponsor: Industry Sponsor

  Funding: $ 500.00

• 40.

  Jenny Ting

  The roles of new innate immune mediators in neuroinflammation

  9/30/2011 - 9/30/2014

  Sponsor: National Multiple Sclerosis Society (NMSS)

  Funding: $ 526,789.00

• 41.

  Norman Sharpless

  Fellow:William, Jeck Endogenous Circular RNAs and the Control of Expression of Aging-related genes

  9/16/2011 - 9/15/2015

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 32,539.00

• 42.

  Norman Sharpless

  Fellow:William, Jeck Endogenous Circular RNAs and the Control of Expression of Aging-related genes

  9/16/2011 - 9/15/2015

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 32,971.00

• 43.

  Jenny Ting

  NLR Regulation of Gastrointestinal Inflammation and Tumorigenesis

  9/15/2011 - 6/30/2016

  Sponsor: NIH National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDKD)

  Funding: $ 129,685.00

• 44.

  Jenny Ting; Irving Allen

  NLR Regulation of Gastrointestinal Inflammation and Tumorigenesis

  9/15/2011 - 6/30/2016

  Sponsor: NIH National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDKD)

  Funding: $ 129,685.00

• 45.

  Jenny Ting; Glenn Matsushima

  GSK Research Testing Agreement

  8/28/2011 - 8/27/2013

  Sponsor: Industry Sponsor

  Funding: $ 145,478.00

• 46.

  Amy Herring; Arthur Aylsworth; Andrew Olshan

  Bayesian Methods for High-Dimensional Epidemiologic Data

  8/24/2011 - 5/31/2016

  Sponsor: NIH National Institute of Environmental Health Sciences (NIEHS)

  Funding: $ 307,510.00

• 47.

  Amy Herring; Arthur Aylsworth; Andrew Olshan

  Bayesian Methods for High-Dimensional Epidemiologic Data

  8/24/2011 - 5/31/2016

  Sponsor: NIH National Institute of Environmental Health Sciences (NIEHS)

  Funding: $ 322,786.00

• 48.

  Thomas Shea

  The Ohio State Blood and Marrow Transplant Research Consortium

  8/8/2011 - 6/30/2017

  Sponsor: Ohio State University

  Funding: $ 16,650.00

• 49.

  Thomas Shea

  The Ohio State Blood and Marrow Transplant Research Consortium

  8/8/2011 - 6/30/2017

  Sponsor: Ohio State University

  Funding: $ 17,050.00

• 50.

  Andrew Olshan; Robert Millikan; Jeannette Bensen; Danyu Lin; Charles Perou

  Epidemiology of Breast Cancer Subtypes in African-American Women: a Consortium

  8/1/2011 - 7/31/2012

  Sponsor: SUNY Buffalo Roswell Park Cancer Institute

  Funding: $ 167,415.00

• 51.

  Andrew Olshan; Robert Millikan; Jeannette Bensen; Danyu Lin; Charles Perou

  Epidemiology of Breast Cancer Subtypes in African-American Women: a Consortium

  8/1/2011 - 7/31/2012

  Sponsor: SUNY Buffalo Roswell Park Cancer Institute

  Funding: $ 96,786.00

• 52.

  Andrew Olshan; Robert Millikan; Jeannette Bensen; Danyu Lin; Charles Perou

  Epidemiology of Breast Cancer Subtypes in African-American Women: a Consortium

  8/1/2011 - 7/31/2012

  Sponsor: SUNY Buffalo Roswell Park Cancer Institute

  Funding: $ 276,183.00

• 53.

  Andrew Olshan; Robert Millikan; Jeannette Bensen; Danyu Lin; Charles Perou

  Epidemiology of Breast Cancer Subtypes in African-American Women: a Consortium

  8/1/2011 - 7/31/2012

  Sponsor: SUNY Buffalo Roswell Park Cancer Institute

  Funding: $ 321,798.00

• 54.

  Andrew Olshan; Robert Millikan; Jeannette Bensen; Danyu Lin; Charles Perou

  Epidemiology of Breast Cancer Subtypes in African-American Women: a Consortium

  8/1/2011 - 7/31/2012

  Sponsor: SUNY Buffalo Roswell Park Cancer Institute

  Funding: $ 47,725.00

• 55.

  Andrew Olshan; Robert Millikan; Jeannette Bensen; Danyu Lin; Charles Perou

  Epidemiology of Breast Cancer Subtypes in African-American Women: a Consortium

  8/1/2011 - 7/31/2012

  Sponsor: SUNY Buffalo Roswell Park Cancer Institute

  Funding: $ 18,127.00

• 56.

  Andrew Olshan; Robert Millikan; Jeannette Bensen; Danyu Lin; Charles Perou

  Epidemiology of Breast Cancer Subtypes in African-American Women: a Consortium

  8/1/2011 - 7/31/2012

  Sponsor: SUNY Buffalo Roswell Park Cancer Institute

  Funding: $ 920,669.00

• 57.

  Gary Johnson

  Endothelial Progenitor-derived Endothelial Cells as a Model for Familial CCM

  7/1/2011 - 6/30/2015

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 30,866.00

• 58.

  Gary Johnson

  Endothelial Progenitor-derived Endothelial Cells as a Model for Familial CCM

  7/1/2011 - 6/30/2015

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 31,503.00

• 59.

  Nancy Raab-Traub

  Molecular properties of exosomes secreted from cancer cells expressing LMP1

  7/1/2011 - 6/30/2014

  Sponsor: American Cancer Society (ACS)

  Funding: $ 150,000.00

• 60.

  Yue Xiong; Jing Wu

  MECHANISMS OF ONCOMETABOLITES IN EPIGENETICS AND CANCER

  7/1/2011 - 6/30/2012

  Sponsor: Samuel Waxman Cancer Research Foundation (SWCRF)

  Funding: $ 100,000.00

• 61.

  Thomas Shea; Marisa DeBurkarte; Julia Whitley

  IV-ATG-SCT-01 A randomized, prospective, double blind, placebo-controlled, phase 3 study of US-ATG-F prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic GVHD in adult acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome patients after allogeneic stem cell transplantation from unrelated donors

  6/16/2011 - 6/15/2014

  Sponsor: Industry Sponsor

  Funding: $ 3,500.00

• 62.

  Thomas Shea; Marisa DeBurkarte; Julia Whitley

  IV-ATG-SCT-01 A randomized, prospective, double blind, placebo-controlled, phase 3 study of US-ATG-F prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic GVHD in adult acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome patients after allogeneic stem cell transplantation from unrelated donors

  6/16/2011 - 6/15/2014

  Sponsor: Industry Sponsor

  Funding: $ 15,562.00

• 63.

  Thomas Shea; Marisa DeBurkarte; Julia Whitley

  IV-ATG-SCT-01 A randomized, prospective, double blind, placebo-controlled, phase 3 study of US-ATG-F prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic GVHD in adult acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome patients after allogeneic stem cell transplantation from unrelated donors

  6/16/2011 - 6/15/2014

  Sponsor: Industry Sponsor

  Funding: $ 7,943.00

• 64.

  Thomas Shea; Marisa DeBurkarte; Julia Whitley

  IV-ATG-SCT-01 A randomized, prospective, double blind, placebo-controlled, phase 3 study of US-ATG-F prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic GVHD in adult acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome patients after allogeneic stem cell transplantation from unrelated donors

  6/16/2011 - 6/15/2014

  Sponsor: Industry Sponsor

  Funding: $ 1,100.00

• 65.

  Thomas Shea; Marisa DeBurkarte; Julia Whitley

  IV-ATG-SCT-01 A randomized, prospective, double blind, placebo-controlled, phase 3 study of US-ATG-F prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic GVHD in adult acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome patients after allogeneic stem cell transplantation from unrelated donors

  6/16/2011 - 6/15/2014

  Sponsor: Industry Sponsor

  Funding: $ 3,324.00

• 66.

  Shelton Earp; Arlin Rogers; Young Whang

  Ack1: Activation and Consequences in Prostate Cancer

  6/1/2011 - 5/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 296,823.00

• 67.

  Shelton Earp; Arlin Rogers; Young Whang

  Ack1: Activation and Consequences in Prostate Cancer

  6/1/2011 - 5/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 296,195.00

• 68.

  Andrew Olshan

  Epidemiology and Evaluation Services

  6/1/2011 - 5/31/2012

  Sponsor: NCDHHS Division of Public Health (DPH)

  Funding: $ 92,021.00

• 69.

  Jenny Ting

  Colitis, colon cancer and the NLR family

  5/1/2011 - 3/31/2016

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 332,235.00

• 70.

  Jenny Ting

  Colitis, colon cancer and the NLR family

  5/1/2011 - 3/31/2016

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 331,397.00

• 71.

  Jenny Ting

  Colitis, colon cancer and the NLR family

  5/1/2011 - 3/31/2016

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 148,756.00

• 72.

  Jonathan Serody

  Regulation of Acute Graft-versus-host Disease by Coronins

  5/1/2011 - 4/30/2015

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 28,390.00

• 73.

  Jonathan Serody

  Regulation of Acute Graft-versus-host Disease by Coronins

  5/1/2011 - 4/30/2015

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 420.00

• 74.

  Jonathan Serody

  Regulation of Acute Graft-versus-host Disease by Coronins

  5/1/2011 - 4/30/2015

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 29,242.00

• 75.

  Jonathan Serody

  Regulation of Acute Graft-versus-host Disease by Coronins

  5/1/2011 - 4/30/2015

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 29,242.00

• 76.

  Shelton Earp

  The 35th Annual UNC Lineberger Comprehensive Cancer Center Symposium: Cell Metabolism and Cancer

  4/15/2011 - 4/30/2011

  Sponsor: North Carolina Biotechnology Center (NCBC)

  Funding: $ 3,000.00

• 77.

  Jenny Ting

  Role of NLRX1 in Dengue Virus Infection

  3/2/2011 - 9/30/2012

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 47,606.00

• 78.

  Jenny Ting

  Role of NLRX1 in Dengue Virus Infection

  3/2/2011 - 9/30/2012

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 792.00

• 79.

  Jenny Ting

  Role of NLRX1 in Dengue Virus Infection

  3/2/2011 - 9/30/2012

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 26,095.00

• 80.

  Manzoor Bhat; Jenny Ting

  FELLOW:THAXTON, C Organization and Maintenance of Axonal Domains

  2/1/2011 - 7/31/2012

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 55,670.00

• 81.

  Bert O'Neil; Richard Goldberg

  LCCC 1029 A Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination with FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) Versus Placebo with FOLFIRI as Second-Line Therapy in Patients with K-RAS or BRAF Mutant Metastatic Colorectal Cancer

  12/6/2010 - 12/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 1,200,516.00

• 82.

  Lisa Carey

  Translating Biology Into Therapeutic Advances

  10/20/2010 - 10/19/2012

  Sponsor: Susan G Komen for the Cure

  Funding: $ 250,000.00

• 83.

  Lisa Carey

  Translating Biology Into Therapeutic Advances

  10/20/2010 - 10/19/2012

  Sponsor: Susan G Komen for the Cure

  Funding: $ 249,431.00

• 84.

  Jenny Ting

  Role of NLRs in multiple sclerosis

  10/1/2010 - 5/31/2011

  Sponsor: Multiple Sclerosis Society of Canada

  Funding: $ 37,867.00

• 85.

  Lisa Carey; Amy Drobish

  Genomics, Genetics, and Clinical Breast Cancer Behavior

  10/1/2010 - 9/30/2013

  Sponsor: Breast Cancer Research Foundation

  Funding: $ 223,000.00

• 86.

  Lisa Carey

  Genomics, Genetics, and Clinical Breast Cancer Behavior

  10/1/2010 - 9/30/2013

  Sponsor: Breast Cancer Research Foundation

  Funding: $ 225,000.00

• 87.

  Lisa Carey

  Genomics, Genetics, and Clinical Breast Cancer Behavior

  10/1/2010 - 9/30/2013

  Sponsor: Breast Cancer Research Foundation

  Funding: $ 240,000.00

• 88.

  Hyman Muss; Norman Sharpless

  The Effect of Chemotherapy on Aging in Older Women with Breast Cancer

  10/1/2010 - 9/30/2013

  Sponsor: Breast Cancer Research Foundation

  Funding: $ 223,000.00

• 89.

  Hyman Muss; Norman Sharpless

  The Effect of Chemotherapy on Aging in Older Women with Breast Cancer

  10/1/2010 - 9/30/2013

  Sponsor: Breast Cancer Research Foundation

  Funding: $ 225,000.00

• 90.

  Hyman Muss; Norman Sharpless

  The Effect of Chemotherapy on Aging in Older Women with Breast Cancer

  10/1/2010 - 9/30/2013

  Sponsor: Breast Cancer Research Foundation

  Funding: $ 240,000.00

• 91.

  Shelton Earp

  UNC Lineberger Comprehensive Cancer Center & Breast Cancer SPORE

  10/1/2010 - 9/30/2013

  Sponsor: Breast Cancer Research Foundation

  Funding: $ 223,000.00

• 92.

  Shelton Earp

  UNC Lineberger Comprehensive Cancer Center & Breast Cancer SPORE

  10/1/2010 - 9/30/2013

  Sponsor: Breast Cancer Research Foundation

  Funding: $ 225,000.00

• 93.

  Shelton Earp

  UNC Lineberger Comprehensive Cancer Center & Breast Cancer SPORE

  10/1/2010 - 9/30/2013

  Sponsor: Breast Cancer Research Foundation

  Funding: $ 240,000.00

• 94.

  Jonathan Serody

  Blocking T-cell Effector Activity in the Treatment of GVHD

  10/1/2010 - 9/30/2013

  Sponsor: Leukemia and Lymphoma Society (LLS)

  Funding: $ 594,143.00

• 95.

  Shelton Earp; Shrikant Bangdiwala; Noel Brewer; William Funkhouser; Marilie Gammon; Paul Godley; Derek Hales; Gary Johnson; Laura Linnan; Felicia Mebane; Wizdom Powell; Allen Rinas; Gwen Sancar; Nicholas Shaheen; Jennifer Smith; Anthony Viera; Dianne Ward; Melissa Spacek

  NCCU-LCCC Partnership In Cancer Research (2 of 2)

  9/28/2010 - 8/31/2015

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 942,632.00

• 96.

  Shelton Earp; Noel Brewer; Keith Burridge; Marilie Gammon; Derek Hales; Gary Johnson; David Jolly; Hong Jin Kim; Laura Linnan; Felicia Mebane; Somnath Mukhopadhyay; Wizdom Powell; Allen Rinas; Gwen Sancar; Nicholas Shaheen; Jennifer Smith; Anthony Viera; Dianne Ward

  NCCU-LCCC Partnership In Cancer Research (2 of 2)

  9/28/2010 - 8/31/2015

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 898,285.00

• 97.

  Shelton Earp; Keith Burridge; Gary Johnson; Hong Jin Kim; Laura Linnan; Gwen Sancar; Nicholas Shaheen; Jennifer Smith; Ada Wilson; Marilie Gammon; Derek Hales; Wizdom Powell; Anthony Viera; Dianne Ward

  NCCU-LCCC Partnership In Cancer Research (2 of 2)

  9/28/2010 - 8/31/2015

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 857,847.00

• 98.

  Joseph Pagano

  The Induction of Interferon Regulatory Factor 7 Sumoylation by EBV LMP1

  9/24/2010 - 9/23/2011

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 52,154.00

• 99.

  Rebecca Fry; Zuzana Drobna; Xiaojun Guan; Andrew Olshan; Mirek Styblo; Fei Zou

  In utero exposure to arsenic, links to epigenetic alterations and disease

  9/20/2010 - 5/31/2015

  Sponsor: NIH National Institute of Environmental Health Sciences (NIEHS)

  Funding: $ 529,284.00

• 100.

  Shelton Earp

  HER4 Cyt1 and Cyt2 isoforms regulate transcription through differential interact

  9/15/2010 - 9/14/2012

  Sponsor: Army Research Office (ARO)

  Funding: $ 202,890.00

• 101.

  Jenny Ting

  NLRP12 Regulation of COX-2 in Colitis and Colon Cancer Development

  9/1/2010 - 8/31/2012

  Sponsor: NIH National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDKD)

  Funding: $ 47,606.00

• 102.

  Jenny Ting

  NLRP12 Regulation of COX-2 in Colitis and Colon Cancer Development

  9/1/2010 - 8/31/2012

  Sponsor: NIH National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDKD)

  Funding: $ 51,326.00

• 103.

  Jonathan Serody

  Modeling TH17 Cells in Acute GVHD

  9/1/2010 - 8/31/2011

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 371,962.00

• 104.

  Paul Godley; Dirk Dittmer; Thomas Shea; Anissa Vines

  Carolina Community Network Center to Reduce Cancer Health Disparities (CCN II)

  9/1/2010 - 8/31/2015

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 179,888.00

• 105.

  Marschall Runge; James Anderson; Corbin Jones; William Marzluff; Michael Topal

  CTSA Core Consolidation Supplement

  8/5/2010 - 8/4/2011

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 730,861.00

• 106.

  Norman Sharpless; Christin Burd

  A Novel p16INK4a Reporter System to Assess Aging In Vivo

  8/1/2010 - 12/31/2012

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 73,009.00

• 107.

  Norman Sharpless; Christin Burd

  A Novel p16INK4a Reporter System to Assess Aging In Vivo

  8/1/2010 - 12/31/2012

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 74,389.00

• 108.

  Jenny Ting; Willie Brickey

  Inflammation and Radiation-Induced Lung Injury

  8/1/2010 - 7/31/2012

  Sponsor: Duke University

  Funding: $ 264,789.00

• 109.

  Jenny Ting; Willie Brickey

  Inflammation and Radiation-Induced Lung Injury

  8/1/2010 - 7/31/2012

  Sponsor: Duke University

  Funding: $ 256,784.00

• 110.

  Jenny Ting; Willie Brickey

  Inflammation and Radiation-Induced Lung Injury

  8/1/2010 - 7/31/2013

  Sponsor: Duke University Medical Center

  Funding: $ 251,648.00

• 111.

  Jonathan Serody

  Zoster 001, Zoster 006, Zoster 015 Plasma and PBMC Processing

  7/31/2010 - 3/31/2012

  Sponsor: Industry Sponsor

  Funding: $ 9,576.00

• 112.

  Jonathan Serody

  Zoster 001, Zoster 006, Zoster 015 Plasma and PBMC Processing

  7/31/2010 - 3/31/2012

  Sponsor: Industry Sponsor

  Funding: $ 30,840.00

• 113.

  Yue Xiong; Stephen Frye; Russ Mumper; William Janzen; Dmitri Kireev

  Task Order#4- BOA under 5-58589 as a Comprehensive Chemical Biology Scree

  7/23/2010 - 4/30/2013

  Sponsor: Industry Sponsor

  Funding: $ 799,420.00

• 114.

  Yue Xiong; William Janzen; Dmitri Kireev; Jing Liu; Mischa Machius; Michael Miley; Jacqueline Norris-Drouin; Xiaodong Wang

  Task Order#4- BOA under 5-58589 as a Comprehensive Chemical Biology Scree

  7/23/2010 - 4/30/2013

  Sponsor: Industry Sponsor

  Funding: $ 1,136,995.00

• 115.

  Jonathan Serody; Elizabeth Dees; Karen McKinnon

  Combined Modality Therapies for the Treatment of Metastatic Breast Cancer

  7/19/2010 - 7/18/2013

  Sponsor: Susan G Komen for the Cure

  Funding: $ 599,119.00

• 116.

  Stephen Frye; H Shelton Earp; William Janzen; Gary Johnson; Mischa Machius; Michael Miley; Xiaodong Wang; William Zamboni

  Task Order#7- BOA under 5-58589 as a Comprehensive Chemical Biology Scree

  7/13/2010 - 3/15/2013

  Sponsor: Industry Sponsor

  Funding: $ 1,614,000.00

• 117.

  Stephen Frye; Shelton Earp; William Janzen; Gary Johnson; Mischa Machius; Michael Miley; Xiaodong Wang

  Task Order#7- BOA under 5-58589 as a Comprehensive Chemical Biology Scree

  7/13/2010 - 3/15/2013

  Sponsor: Industry Sponsor

  Funding: $ 1,780,000.00

• 118.

  Stephen Frye; Shelton Earp; William Janzen; Gary Johnson; Mischa Machius; Michael Miley; Xiaodong Wang

  Task Order#7- BOA under 5-58589 as a Comprehensive Chemical Biology Scree

  7/13/2010 - 3/15/2013

  Sponsor: Industry Sponsor

  Funding: $ 79,000.00

• 119.

  Stephen Frye; Shelton Earp; William Janzen; Gary Johnson; Mischa Machius; Michael Miley; Xiaodong Wang

  Task Order#7- BOA under 5-58589 as a Comprehensive Chemical Biology Scree

  7/13/2010 - 3/15/2013

  Sponsor: Industry Sponsor

  Funding: $ 678,062.00

• 120.

  Stephen Frye; Shelton Earp; William Janzen; Gary Johnson; Mischa Machius; Michael Miley; Xiaodong Wang

  Task Order#7- BOA under 5-58589 as a Comprehensive Chemical Biology Scree

  7/13/2010 - 3/15/2013

  Sponsor: Industry Sponsor

  Funding: $ 51,847.00

• 121.

  Bill Marzluff

  Determining the Role of the Stem-loop Binding Protein in Histone mRNA Decay

  7/1/2010 - 6/30/2012

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 47,606.00

• 122.

  Bill Marzluff

  Determining the Role of the Stem-loop Binding Protein in Histone mRNA Decay

  7/1/2010 - 6/30/2012

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 51,326.00

• 123.

  Jenny Ting

  The Role and Mechanism of Plexin-A4 in Colitis-Associated Cancer

  7/1/2010 - 6/30/2013

  Sponsor: Cancer Research Institute

  Funding: $ 145,500.00

• 124.

  Norman Sharpless

  Norman Sharpless Glenn Foundation

  7/1/2010 - 6/30/2012

  Sponsor: Glenn Foundation for Medical Research

  Funding: $ 60,000.00

• 125.

  Norman Sharpless

  Attenuation of Chemo-Induced Myelosuppression by Pharmacological Quiescence

  7/1/2010 - 6/30/2012

  Sponsor: American Cancer Society (ACS)

  Funding: $ 102,000.00

• 126.

  William Irvin; Lisa Carey; James Evans; Christine Walko; Karen Weck-Taylor; Madlyn Ferraro

  Validating CYP2D6 Genotype-guided Tamoxifen Therapy for a Multiracial U.S. Popul

  5/18/2010 - 5/17/2013

  Sponsor: Susan G Komen for the Cure

  Funding: $ 449,714.00

• 127.

  Terry Magnuson

  Transcription, Choice and the 3D Architecture of the Inactive S-Chromosome

  5/6/2010 - 5/5/2012

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 47,606.00

• 128.

  Terry Magnuson

  Transcription, Choice and the 3D Architecture of the Inactive S-Chromosome

  5/6/2010 - 5/5/2012

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 50,474.00

• 129.

  Terry Magnuson

  Transcription, Choice and the 3D Architecture of the Inactive S-Chromosome

  5/6/2010 - 5/5/2012

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 852.00

• 130.

  Jan Busby-Whitehead; Norman Sharpless; Philip Sloane

  UNC-CH Summer Research Training in Aging for Medical Students

  5/1/2010 - 4/30/2015

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 54,821.00

• 131.

  Jan Busby-Whitehead; Norman Sharpless

  UNC-CH Summer Research Training in Aging for Medical Students

  5/1/2010 - 4/30/2015

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 54,821.00

• 132.

  Jan Busby-Whitehead; Norman Sharpless

  UNC-CH Summer Research Training in Aging for Medical Students

  5/1/2010 - 4/30/2015

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 907.00

• 133.

  Jan Busby-Whitehead; Norman Sharpless; Philip Sloane

  UNC-CH Summer Research Training in Aging for Medical Students

  5/1/2010 - 4/30/2015

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 56,661.00

• 134.

  Xin Hai Pei; Charles Perou; Yue Xiong

  BRCA1 Controls Mammary Stem/Progenitor Differentiation and Proliferation, Epithe

  4/15/2010 - 12/31/2010

  Sponsor: Army Medical Research and Material Command

  Funding: $ 544,491.00

• 135.

  Jen Jen Yeh; Adrienne Cox; Channing Der; Norman Sharpless; Keith Volmar; Fred Wright

  Targeting Ras-Ral GEF-Ral Effector Signaling for Pancreatic Cancer Treatment

  4/8/2010 - 1/31/2015

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 307,100.00

• 136.

  Michael Kosorok; James Auman; Jianwen Cai; William Carpenter; Haitao Chu; Jason Fine; Richard Goldberg; Joseph Ibrahim; Danyu Lin; Yufeng Liu; Howard McLeod; Robert Sandler; Mark Socinski; Wei Wang; Fred Wright; Donglin Zeng; Haibo Zhou

  Statistical Methods for Cancer Clinical Trials

  4/1/2010 - 3/31/2015

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 2,542,900.00

• 137.

  Michael Kosorok; James Auman; Jianwen Cai; William Carpenter; Jason Fine; Richard Goldberg; Joseph Ibrahim; Danyu Lin; Yufeng Liu; Howard McLeod; Robert Sandler; Mark Socinski; Wei Wang; Fred Wright; Donglin Zeng; Haibo Zhou; Hongtu Zhu

  Statistical Methods for Cancer Clinical Trials

  4/1/2010 - 3/31/2015

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 2,116,531.00

• 138.

  Michael Kosorok; James Auman; Jianwen Cai; William Carpenter; Jason Fine; Richard Goldberg; Joseph Ibrahim; Danyu Lin; Yufeng Liu; Howard McLeod; Robert Sandler; Mark Socinski; Wei Wang; Fred Wright; Donglin Zeng; Haibo Zhou; Hongtu Zhu

  Statistical Methods for Cancer Clinical Trials

  4/1/2010 - 3/31/2015

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 98,181.00

• 139.

  Thomas Shea

  Brigham and Women's Hospital Service Agreement--CALGB

  4/1/2010 - 9/30/2014

  Sponsor: Industry Sponsor

  Funding: $ 600.00

• 140.

  Thomas Shea

  MCC12215 Phase I Trial of Bortezomib and Romidepsin in Patients with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

  3/18/2010 - 3/17/2012

  Sponsor: Virginia Commonwealth University (VCU)

  Funding: $ 16,845.00

• 141.

  Thomas Shea; Robert Irons; Julia Whitley

  OPDC 273-08-201 A Multi-Center, Phase 2, Single-Arm, Open-Label Exploratory St

  3/8/2010 - 3/7/2013

  Sponsor: Industry Sponsor

  Funding: $ 4,000.00

• 142.

  Thomas Shea; Robert Irons; Julia Whitley

  OPDC 273-08-201 A Multi-Center, Phase 2, Single-Arm, Open-Label Exploratory St

  3/8/2010 - 3/7/2013

  Sponsor: Industry Sponsor

  Funding: $ 16,607.00

• 143.

  Thomas Shea; Robert Irons; Julia Whitley

  OPDC 273-08-201 A Multi-Center, Phase 2, Single-Arm, Open-Label Exploratory St

  3/8/2010 - 3/7/2013

  Sponsor: Industry Sponsor

  Funding: $ 750.00

• 144.

  Thomas Shea; Robert Irons; Julia Whitley

  OPDC 273-08-201 A Multi-Center, Phase 2, Single-Arm, Open-Label Exploratory St

  3/8/2010 - 3/7/2013

  Sponsor: Industry Sponsor

  Funding: $ 20,288.00

• 145.

  Thomas Shea; Robert Irons; Julia Whitley

  OPDC 273-08-201 A Multi-Center, Phase 2, Single-Arm, Open-Label Exploratory St

  3/8/2010 - 3/7/2013

  Sponsor: Industry Sponsor

  Funding: $ 8,540.00

• 146.

  Thomas Shea; Robert Irons; Julia Whitley

  OPDC 273-08-201 A Multi-Center, Phase 2, Single-Arm, Open-Label Exploratory St

  3/8/2010 - 3/7/2013

  Sponsor: Industry Sponsor

  Funding: $ 1,998.00

• 147.

  Thomas Shea; Robert Irons; Julia Whitley

  OPDC 273-08-201 A Multi-Center, Phase 2, Single-Arm, Open-Label Exploratory St

  3/8/2010 - 3/7/2013

  Sponsor: Industry Sponsor

  Funding: $ 6,352.00

• 148.

  Thomas Shea; Robert Irons; Julia Whitley

  OPDC 273-08-201 A Multi-Center, Phase 2, Single-Arm, Open-Label Exploratory St

  3/8/2010 - 3/7/2013

  Sponsor: Industry Sponsor

  Funding: $ 15,295.00

• 149.

  Rich Goldberg

  APO4565g A Phase Ib Study of the Safety and Pharmacokinetics of APO2L/TRAIL A

  1/19/2010 - 1/18/2013

  Sponsor: Industry Sponsor

  Funding: $ 12,240.00

• 150.

  Rich Goldberg

  APO4565g A Phase Ib Study of the Safety and Pharmacokinetics of APO2L/TRAIL A

  1/19/2010 - 1/18/2013

  Sponsor: Industry Sponsor

  Funding: $ 18,620.00

• 151.

  Rich Goldberg

  APO4565g A Phase Ib Study of the Safety and Pharmacokinetics of APO2L/TRAIL A

  1/19/2010 - 1/18/2013

  Sponsor: Industry Sponsor

  Funding: $ 7,523.00

• 152.

  Rich Goldberg

  APO4565g A Phase Ib Study of the Safety and Pharmacokinetics of APO2L/TRAIL A

  1/19/2010 - 1/18/2013

  Sponsor: Industry Sponsor

  Funding: $ 17,210.00

• 153.

  Rich Goldberg

  APO4565g A Phase Ib Study of the Safety and Pharmacokinetics of APO2L/TRAIL A

  1/19/2010 - 1/18/2013

  Sponsor: Industry Sponsor

  Funding: $ 19,631.00

• 154.

  Rich Goldberg

  APO4565g A Phase Ib Study of the Safety and Pharmacokinetics of APO2L/TRAIL A

  1/19/2010 - 1/18/2013

  Sponsor: Industry Sponsor

  Funding: $ 7,738.00

• 155.

  Jenny Ting

  NLR Regulation of Gastrointestinal Inflammation and Tumorigenesis

  1/1/2010 - 6/30/2011

  Sponsor: American Cancer Society (ACS)

  Funding: $ 150,000.00

• 156.

  Hank Van Deventer; Jonathan Serody; Jenny Ting

  Chemokines: Connecting Stromal Cells to Metastasis

  1/1/2010 - 12/31/2013

  Sponsor: American Cancer Society (ACS)

  Funding: $ 720,000.00

• 157.

  Nancy Raab-Traub

  EBV BART miRNAs: Identification of Targets and Characterization of the Effects

  12/1/2009 - 11/30/2014

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 305,763.00

• 158.

  Nancy Raab-Traub

  EBV BART miRNAs: Identification of Targets and Characterization of the Effects

  12/1/2009 - 11/30/2014

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 275,187.00

• 159.

  Nancy Raab-Traub

  EBV BART miRNAs: Identification of Targets and Characterization of the Effects

  12/1/2009 - 11/30/2014

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 21,403.00

• 160.

  Nancy Raab-Traub

  EBV BART miRNAs: Identification of Targets and Characterization of the Effects

  12/1/2009 - 11/30/2014

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 266,932.00

• 161.

  Nancy Raab-Traub

  EBV BART miRNAs: Identification of Targets and Characterization of the Effects

  12/1/2009 - 11/30/2014

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 29,658.00

• 162.

  Nancy Raab-Traub

  EBV BART miRNAs: Identification of Targets and Characterization of the Effects

  12/1/2009 - 11/30/2014

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 148,295.00

• 163.

  Lisa Carey

  20090301 A Phase 3, Multi-Center, Open-Label, Randomized Study of Gemcitabine

  11/30/2009 - 11/29/2012

  Sponsor: Industry Sponsor

  Funding: $ 12,240.00

• 164.

  Lisa Carey

  20090301 A Phase 3, Multi-Center, Open-Label, Randomized Study of Gemcitabine

  11/30/2009 - 11/29/2012

  Sponsor: Industry Sponsor

  Funding: $ 38,500.00

• 165.

  Lisa Carey

  20090301 A Phase 3, Multi-Center, Open-Label, Randomized Study of Gemcitabine

  11/30/2009 - 11/29/2012

  Sponsor: Industry Sponsor

  Funding: $ 126,600.00

• 166.

  Lisa Carey

  20090301 A Phase 3, Multi-Center, Open-Label, Randomized Study of Gemcitabine

  11/30/2009 - 11/29/2012

  Sponsor: Industry Sponsor

  Funding: $ 13,301.00

• 167.

  Lisa Carey

  20090301 A Phase 3, Multi-Center, Open-Label, Randomized Study of Gemcitabine

  11/30/2009 - 11/29/2012

  Sponsor: Industry Sponsor

  Funding: $ 4,200.00

• 168.

  Lisa Carey

  20090301 A Phase 3, Multi-Center, Open-Label, Randomized Study of Gemcitabine

  11/30/2009 - 11/29/2012

  Sponsor: Industry Sponsor

  Funding: $ 2,850.00

• 169.

  Thomas Shea; Julia Whitley

  MAMO0509-2 Health Outcome in Patients Mobilized for Autologous Stem Cell Tran

  11/20/2009 - 11/19/2012

  Sponsor: Industry Sponsor

  Funding: $ 26,000.00

• 170.

  Thomas Shea; Julia Whitley

  MAMO0509-2 Health Outcome in Patients Mobilized for Autologous Stem Cell Tran

  11/20/2009 - 11/19/2012

  Sponsor: Industry Sponsor

  Funding: $ 14,000.00

• 171.

  Rich Goldberg; Janine Davies

  20070411 A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combina

  11/9/2009 - 11/8/2012

  Sponsor: Industry Sponsor

  Funding: $ 6,500.00

• 172.

  Rich Goldberg; Janine Davies

  20070411 A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combina

  11/9/2009 - 11/8/2012

  Sponsor: Industry Sponsor

  Funding: $ 6,017.00

• 173.

  Lisa Carey

  Genomics, Genetics, and Clinical Breast Cancer Behavior

  10/1/2009 - 9/30/2010

  Sponsor: Breast Cancer Research Foundation

  Funding: $ 200,000.00

• 174.

  Hyman Muss; Norman Sharpless

  THE EFFECT OF CHEMOTHERAPY ON AGING IN OLDER WOMEN WITH BREAST CANCER

  10/1/2009 - 9/30/2010

  Sponsor: Breast Cancer Research Foundation

  Funding: $ 200,000.00

• 175.

  Bill Marzluff; Roopa Thapar

  Phosphorylation Dependent Recognition of a Histone mRNA Hairpin by SLBP (ARRA)

  9/30/2009 - 12/31/2010

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 162,630.00

• 176.

  Shelton Earp

  Early Stage Investigator Recruitment in Cancer Research

  9/30/2009 - 8/31/2012

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 615,426.00

• 177.

  Shelton Earp; Ben Major

  Early Stage Investigator Recruitment in Cancer Research

  9/30/2009 - 8/31/2012

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 615,426.00

• 178.

  Terry Magnuson

  A Carolina Center to Characterize and Maintain Mutant Mice (ARRA)

  9/4/2009 - 3/3/2012

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 246,555.00

• 179.

  Jenny Ting

  NLR Regulation of Innate Immune Responses to Respiratory Virus Infection

  9/1/2009 - 12/31/2009

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 50,054.00

• 180.

  Norman Sharpless; William Kim

  LKB1 tumor suppressor and human cancer

  9/1/2009 - 8/31/2012

  Sponsor: University of Texas Southwestern Medical Center

  Funding: $ 191,306.00

• 181.

  Norman Sharpless; William Kim

  LKB1 tumor suppressor and human cancer

  9/1/2009 - 8/31/2012

  Sponsor: University of Texas Southwestern Medical Center

  Funding: $ 218,682.00

• 182.

  Norman Sharpless; William Kim

  LKB1 tumor suppressor and human cancer

  9/1/2009 - 8/31/2012

  Sponsor: University of Texas Southwestern Medical Center

  Funding: $ 195,035.00

• 183.

  Norman Sharpless; William Kim

  LKB1 tumor suppressor and human cancer

  9/1/2009 - 8/31/2012

  Sponsor: University of Texas Southwestern Medical Center

  Funding: $ 192,961.00

• 184.

  Marci Campbell; Michael O Malley

  Cancer Health Disparities Training Program

  9/1/2009 - 8/31/2014

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 164,158.00

• 185.

  Haibo Zhou; John Buse; Lisa Lavange; Til Stuermer; Timothy Carey; David Clemmons; Richard Goldberg; Howard McLeod; Andrew Olshan; Laura Raftery

  Risks of cancers in relation to insulin therapy in people with diabetes

  9/1/2009 - 6/30/2013

  Sponsor: Industry Sponsor

  Funding: $ 1,497,600.00

• 186.

  Haibo Zhou; John Buse; Lisa Lavange; Jianwen Cai; Timothy Carey; David Clemmons; Richard Goldberg; Howard McLeod; Andrew Olshan; Laura Raftery; Til Stuermer

  Risks of cancers in relation to insulin therapy in people with diabetes

  9/1/2009 - 6/30/2013

  Sponsor: Industry Sponsor

  Funding: $ 2,324,555.00

• 187.

  Norman Sharpless

  SBIR-NIAID Advanced Technology SBIR

  9/1/2009 - 8/31/2013

  Sponsor: Industry Sponsor

  Funding: $ 95,306.00

• 188.

  Norman Sharpless

  SBIR-NIAID Advanced Technology SBIR

  9/1/2009 - 8/31/2013

  Sponsor: Industry Sponsor

  Funding: $ 71,164.00

• 189.

  Norman Sharpless

  SBIR-NIAID Advanced Technology SBIR

  9/1/2009 - 8/31/2013

  Sponsor: Industry Sponsor

  Funding: $ 72,448.00

• 190.

  Geni Eng; Michael O Malley

  Cancer Health Disparities Training Program

  9/1/2009 - 8/31/2014

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 77,372.00

• 191.

  Thomas Shea

  Phase I Trial of Bortezomib and Romidepsin in CLL and Small Cell Lymphoma

  8/6/2009 - 7/31/2013

  Sponsor: Virginia Commonwealth University (VCU)

  Funding: $ 58,757.00

• 192.

  Thomas Shea

  Phase I Trial of Bortezomib and Romidepsin in CLL and Small Cell Lymphoma

  8/6/2009 - 7/31/2013

  Sponsor: Virginia Commonwealth University (VCU)

  Funding: $ 18,757.00

• 193.

  Thomas Shea

  Phase I Trial of Bortezomib and Romidepsin in CLL and Small Cell Lymphoma

  8/6/2009 - 7/31/2013

  Sponsor: Virginia Commonwealth University (VCU)

  Funding: $ 15,000.00

• 194.

  Yue Xiong

  Mechanism and Mouse Model for IDHI-Mediated Suppression of Human Secondary Gliom

  8/1/2009 - 8/1/2012

  Sponsor: James S McDonnell Foundation

  Funding: $ 449,732.00

• 195.

  Yue Xiong

  Mechanism and Mouse Model for IDHI-Mediated Suppression of Human Secondary Gliom

  8/1/2009 - 8/1/2012

  Sponsor: James S McDonnell Foundation

  Funding: $ 1,264.00

• 196.

  Terry Magnuson

  SWI/SNF & Yolk Sac Development

  8/1/2009 - 7/31/2011

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 370,000.00

• 197.

  Terry Magnuson

  SWI/SNF & Yolk Sac Development

  8/1/2009 - 7/31/2011

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 367,352.00

• 198.

  Andrew Olshan

  Control Selection Methods for Childhood Cancer Studies

  8/1/2009 - 7/31/2010

  Sponsor: Childrens Hospital of Philadelphia

  Funding: $ 7,045.00

• 199.

  Rich Goldberg

  EZN-2208-04 A Phase 2 Study of EZN-2208 (PEG SN38) Administered With or Witho

  7/21/2009 - 7/20/2012

  Sponsor: Industry Sponsor

  Funding: $ 11,740.00

• 200.

  Rich Goldberg

  EZN-2208-04 A Phase 2 Study of EZN-2208 (PEG SN38) Administered With or Witho

  7/21/2009 - 7/20/2012

  Sponsor: Industry Sponsor

  Funding: $ 13,152.00

• 201.

  Rich Goldberg

  EZN-2208-04 A Phase 2 Study of EZN-2208 (PEG SN38) Administered With or Witho

  7/21/2009 - 7/20/2012

  Sponsor: Industry Sponsor

  Funding: $ 22,932.00

• 202.

  Rich Goldberg

  EZN-2208-04 A Phase 2 Study of EZN-2208 (PEG SN38) Administered With or Witho

  7/21/2009 - 7/20/2012

  Sponsor: Industry Sponsor

  Funding: $ 2,342.00

• 203.

  Rich Goldberg

  EZN-2208-04 A Phase 2 Study of EZN-2208 (PEG SN38) Administered With or Witho

  7/21/2009 - 7/20/2012

  Sponsor: Industry Sponsor

  Funding: $ 8,200.00

• 204.

  Rich Goldberg

  EZN-2208-04 A Phase 2 Study of EZN-2208 (PEG SN38) Administered With or Witho

  7/21/2009 - 7/20/2012

  Sponsor: Industry Sponsor

  Funding: $ 6,714.00

• 205.

  Rich Goldberg

  EZN-2208-04 A Phase 2 Study of EZN-2208 (PEG SN38) Administered With or Witho

  7/21/2009 - 7/20/2012

  Sponsor: Industry Sponsor

  Funding: $ 2,767.00

• 206.

  Rich Goldberg

  EZN-2208-04 A Phase 2 Study of EZN-2208 (PEG SN38) Administered With or Witho

  7/21/2009 - 7/20/2012

  Sponsor: Industry Sponsor

  Funding: $ 1,040.00

• 207.

  Rich Goldberg

  EZN-2208-04 A Phase 2 Study of EZN-2208 (PEG SN38) Administered With or Witho

  7/21/2009 - 7/20/2012

  Sponsor: Industry Sponsor

  Funding: $ 3,807.00

• 208.

  Terry Magnuson

  Respective Roles of Baf250a and Baf250b in Mouse

  7/1/2009 - 6/30/2012

  Sponsor: American Cancer Society (ACS)

  Funding: $ 138,000.00

• 209.

  Terry Magnuson

  Chromosome-wide Analysis of X-inactivation in the Mouse.

  7/1/2009 - 6/30/2012

  Sponsor: American Cancer Society (ACS)

  Funding: $ 138,000.00

• 210.

  Bill Marzluff; William Hyslop; Carol Lucas; Michael Mill; Brooke Steele; Michael Stella

  TUTase mediated degradation of histone mRNA

  7/1/2009 - 12/31/2010

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 47,210.00

• 211.

  Bill Marzluff

  TUTase mediated degradation of histone mRNA

  7/1/2009 - 12/31/2010

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 25,237.00

• 212.

  Norman Sharpless

  FELLOW:JOHNSON, SOREN-Genetic regulation of hematopoiesis during aging

  7/1/2009 - 5/31/2012

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 29,192.00

• 213.

  Norman Sharpless

  FELLOW:JOHNSON, SOREN-Genetic regulation of hematopoiesis during aging

  7/1/2009 - 5/31/2012

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 29,396.00

• 214.

  Norman Sharpless

  FELLOW:JOHNSON, SOREN-Genetic regulation of hematopoiesis during aging

  7/1/2009 - 5/31/2012

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 33,535.00

• 215.

  Gary Johnson

  Defining the role of MEKK2/3 in tumor progression, vascularization and metastasi

  7/1/2009 - 6/30/2012

  Sponsor: Canadian Institute of Health Research

  Funding: $ 133,434.00

• 216.

  Gary Johnson

  Defining the role of MEKK2/3 in tumor progression, vascularization and metastasi

  7/1/2009 - 6/30/2012

  Sponsor: Canadian Institute of Health Research

  Funding: $ 2,883.00

• 217.

  Gary Johnson

  Defining the role of MEKK2/3 in tumor progression, vascularization and metastasi

  7/1/2009 - 6/30/2012

  Sponsor: Canadian Institute of Health Research

  Funding: $ 10,446.00

• 218.

  Thomas Shea; Julie Blatt; Edward Foster; Stuart Gold; Anne Stephens

  Transition of Care for Adolescent and Young Adults Survivors of Childhood Cancer

  7/1/2009 - 12/31/2010

  Sponsor: American Society of Hematology (ASH)

  Funding: $ 50,000.00

• 219.

  Jenny Ting

  GSK Collaborative Agreement

  6/30/2009 - 6/29/2010

  Sponsor: Industry Sponsor

  Funding: $ 296,000.00

• 220.

  Shelton Earp; Arlin Rogers; Young Whang

  Ack1: Activation and Consequences in Prostate Cancer

  6/4/2009 - 5/31/2011

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 306,531.00

• 221.

  Shelton Earp; Arlin Rogers; Young Whang

  Ack1: Activation and Consequences in Prostate Cancer

  6/4/2009 - 5/31/2011

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 306,496.00

• 222.

  Andrew Olshan; Amy Herring

  ARRA - Maternal Genetic Variation and Risk of Adverse Pregnancy Outcomes

  5/15/2009 - 4/30/2011

  Sponsor: Mount Sinai School of Medicine

  Funding: $ 254,812.00

• 223.

  Andrew Olshan; Amy Herring

  ARRA - Maternal Genetic Variation and Risk of Adverse Pregnancy Outcomes

  5/15/2009 - 4/30/2011

  Sponsor: Mount Sinai School of Medicine

  Funding: $ 44,854.00

• 224.

  Andrew Olshan; Amy Herring

  ARRA - Maternal Genetic Variation and Risk of Adverse Pregnancy Outcomes

  5/15/2009 - 4/30/2011

  Sponsor: Mount Sinai School of Medicine

  Funding: $ 44,854.00

• 225.

  Andrew Olshan; Amy Herring

  ARRA - Maternal Genetic Variation and Risk of Adverse Pregnancy Outcomes

  5/15/2009 - 4/30/2011

  Sponsor: Mount Sinai School of Medicine

  Funding: $ 13,401.00

• 226.

  Shelton Earp

  Role of non-receptor tyrosine kinase Ack1 in prostate cancer

  5/1/2009 - 5/31/2011

  Sponsor: Army Medical Research and Material Command

  Funding: $ 100,918.00

• 227.

  Lisa Carey

  The Breast Cancer Research Consortium (TBCRC)

  4/30/2009 - 6/30/2013

  Sponsor: Johns Hopkins University

  Funding: $ 46,500.00

• 228.

  Lisa Carey; Amy Garrett

  The Breast Cancer Research Consortium (TBCRC)

  4/30/2009 - 6/30/2013

  Sponsor: Johns Hopkins University

  Funding: $ 37,500.00

• 229.

  Lisa Carey

  The Breast Cancer Research Consortium (TBCRC)

  4/30/2009 - 6/30/2013

  Sponsor: Johns Hopkins University

  Funding: $ 100,000.00

• 230.

  Terry Magnuson

  Roles of Histone H3K27 demethylases in germ cell epigenetic development

  4/1/2009 - 3/31/2011

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 49,646.00

• 231.

  Terry Magnuson

  Roles of Histone H3K27 demethylases in germ cell epigenetic development

  4/1/2009 - 3/31/2011

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 408.00

• 232.

  Terry Magnuson

  Roles of Histone H3K27 demethylases in germ cell epigenetic development

  4/1/2009 - 3/31/2011

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 52,154.00

• 233.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 8,000.00

• 234.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 1,292.00

• 235.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 2,824.00

• 236.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 2,052.00

• 237.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 2,630.00

• 238.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 3,345.00

• 239.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 9,320.00

• 240.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 1,674.00

• 241.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 1,753.00

• 242.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 2,415.00

• 243.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 5,818.00

• 244.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 1,281.00

• 245.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 1,543.00

• 246.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 1,007.00

• 247.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 2,410.00

• 248.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 1,753.00

• 249.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 3,884.00

• 250.

  Thomas Shea

  OMB110927 A Single Arm, Safety and Efficacy Study of Ofatumumab in Combinatio

  2/26/2009 - 2/25/2012

  Sponsor: Industry Sponsor

  Funding: $ 4,569.00

• 251.

  Thomas Shea; Robert Irons; Julia Whitley

  110258 A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicen

  2/6/2009 - 2/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 3,200.00

• 252.

  Thomas Shea; Robert Irons; Julia Whitley

  110258 A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicen

  2/6/2009 - 2/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 5,708.00

• 253.

  Thomas Shea; Robert Irons; Julia Whitley

  110258 A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicen

  2/6/2009 - 2/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 2,253.00

• 254.

  Thomas Shea; Robert Irons; Julia Whitley

  110258 A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicen

  2/6/2009 - 2/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 1,792.00

• 255.

  Thomas Shea; Robert Irons; Julia Whitley

  110258 A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicen

  2/6/2009 - 2/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 3,649.00

• 256.

  Thomas Shea; Robert Irons; Julia Whitley

  110258 A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicen

  2/6/2009 - 2/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 3,851.00

• 257.

  Thomas Shea; Robert Irons; Julia Whitley

  110258 A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicen

  2/6/2009 - 2/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 3,447.00

• 258.

  Thomas Shea; Robert Irons; Julia Whitley

  110258 A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicen

  2/6/2009 - 2/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 3,181.00

• 259.

  Thomas Shea; Robert Irons; Julia Whitley

  110258 A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicen

  2/6/2009 - 2/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 260.

  Thomas Shea; Robert Irons; Julia Whitley

  110258 A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicen

  2/6/2009 - 2/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 261.

  Thomas Shea; Robert Irons; Julia Whitley

  110258 A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicen

  2/6/2009 - 2/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 3,117.00

• 262.

  Thomas Shea; Robert Irons; Julia Whitley

  110258 A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicen

  2/6/2009 - 2/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 3,188.00

• 263.

  Thomas Shea; Robert Irons; Julia Whitley

  110258 A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicen

  2/6/2009 - 2/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 3,844.00

• 264.

  Thomas Shea; Robert Irons; Julia Whitley

  110258 A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicen

  2/6/2009 - 2/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 1,590.00

• 265.

  Thomas Shea; Robert Irons; Julia Whitley

  110258 A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicen

  2/6/2009 - 2/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 2,915.00

• 266.

  Thomas Shea; Robert Irons; Julia Whitley

  110258 A Phase I/IIa Randomized, Observer-Blind, Placebo-Controlled, Multicen

  2/6/2009 - 2/5/2012

  Sponsor: Industry Sponsor

  Funding: $ 1,987.00

• 267.

  Shelton Earp; Joseph Desimone; Young Whang

  Application of nanotechnology to novel models of prostate cancer

  2/1/2009 - 1/31/2010

  Sponsor: Prostate Cancer Foundation

  Funding: $ 100,000.00

• 268.

  Angelique Whitehurst; Gary Johnson

  Harnessing Functional Genomics to Reveal Cancer Specific Determinants of Mitosis

  1/15/2009 - 12/31/2012

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 249,000.00

• 269.

  Thomas Shea; Robert Irons; Julia Whitley

  CT0-2007-01 Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-0

  1/15/2009 - 1/14/2011

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 270.

  Thomas Shea; Robert Irons; Julia Whitley

  CT0-2007-01 Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-0

  1/15/2009 - 1/14/2011

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 271.

  Thomas Shea; Robert Irons; Julia Whitley

  CT0-2007-01 Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-0

  1/15/2009 - 1/14/2011

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 272.

  Thomas Shea; Robert Irons; Julia Whitley

  CT0-2007-01 Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-0

  1/15/2009 - 1/14/2011

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 273.

  Andrew Olshan

  Genetics of Tobacco and Alcohol Related Cancers

  1/1/2009 - 12/31/2009

  Sponsor: International Agency for Research on Cancer (IARC)

  Funding: $ 60,000.00

• 274.

  Andrew Olshan; Arthur Aylsworth; Jeannette Bensen; William Funk; Amy Herring; Anna Maria Siega-Riz

  The North Carolina Center for Birth Defects Research and Prevention

  12/1/2008 - 11/30/2013

  Sponsor: Centers for Disease Control and Prevention (CDC)

  Funding: $ 999,679.00

• 275.

  Andrew Olshan; William Funk

  The North Carolina Center for Birth Defects Research and Prevention

  12/1/2008 - 11/30/2013

  Sponsor: Centers for Disease Control and Prevention (CDC)

  Funding: $ 999,680.00

• 276.

  Andrew Olshan

  The North Carolina Center for Birth Defects Research and Prevention

  12/1/2008 - 11/30/2013

  Sponsor: Centers for Disease Control and Prevention (CDC)

  Funding: $ 945,000.00

• 277.

  Andrew Olshan; Arthur Aylsworth; Amy Herring

  The North Carolina Center for Birth Defects Research and Prevention

  12/1/2008 - 11/30/2013

  Sponsor: Centers for Disease Control and Prevention (CDC)

  Funding: $ 712,000.00

• 278.

  Andrew Olshan; Arthur Aylsworth; Amy Herring

  The North Carolina Center for Birth Defects Research and Prevention

  12/1/2008 - 11/30/2013

  Sponsor: Centers for Disease Control and Prevention (CDC)

  Funding: $ 188,000.00

• 279.

  Andrew Olshan; Arthur Aylsworth; Amy Herring

  The North Carolina Center for Birth Defects Research and Prevention

  12/1/2008 - 11/30/2013

  Sponsor: Centers for Disease Control and Prevention (CDC)

  Funding: $ 393,600.00

• 280.

  Rich Goldberg

  Phase 1B Study of Sorafenib for Patients with Locally Advanced or Metastatic Hep

  11/19/2008 - 11/18/2010

  Sponsor: Alberta Heritage Foundation for Medical Research

  Funding: $ 50,500.00

• 281.

  Rich Goldberg

  Phase 1B Study of Sorafenib for Patients with Locally Advanced or Metastatic Hep

  11/19/2008 - 11/18/2010

  Sponsor: Alberta Heritage Foundation for Medical Research

  Funding: $ 50,500.00

• 282.

  Rich Goldberg

  Phase 1B Study of Sorafenib for Patients with Locally Advanced or Metastatic Hep

  11/19/2008 - 11/18/2010

  Sponsor: Alberta Heritage Foundation for Medical Research

  Funding: $ 718.00

• 283.

  Shelton Earp; Lisa Carey; Jonathan Serody; Karen McKinnon

  A New and Improved Anti-HER2 Breast Cancer Vaccine Asssessment of Genomic I

  10/1/2008 - 9/30/2010

  Sponsor: Breast Cancer Research Foundation

  Funding: $ 250,000.00

• 284.

  Rich Goldberg

  Phase IB Study of Sorafenib for Patients with Locally Advanced or Metastatic Hep

  10/1/2008 - 9/30/2009

  Sponsor: Canadian Association of Medical Oncologists

  Funding: $ 57,898.00

• 285.

  Shelton Earp; Shu-Mang Feng

  A New and Improved Anti-HER2 Breast Cancer Vaccine Asssessment of Genomic I

  10/1/2008 - 9/30/2010

  Sponsor: Breast Cancer Research Foundation

  Funding: $ 200,000.00

• 286.

  Rich Goldberg

  M10-300 An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination Wit

  9/30/2008 - 9/29/2010

  Sponsor: Industry Sponsor

  Funding: $ 12,112.00

• 287.

  Rich Goldberg

  M10-300 An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination Wit

  9/30/2008 - 9/29/2010

  Sponsor: Industry Sponsor

  Funding: $ 2,534.00

• 288.

  Rich Goldberg

  M10-300 An Open-Label, Randomized Phase 2 Study of ABT-869 in Combination Wit

  9/30/2008 - 9/29/2010

  Sponsor: Industry Sponsor

  Funding: $ 679.00

• 289.

  Cary Moody; Nancy Raab-Traub

  The Role of Caspase Activation in the Differentiation-Dependent Life Cycle of HP

  9/20/2008 - 8/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 249,000.00

• 290.

  Yue Xiong

  Controlling Mammary Luminal and Basal Progenitor Cell Proliferation, Differentia

  9/15/2008 - 9/14/2011

  Sponsor: Susan G Komen for the Cure

  Funding: $ 600,000.00

• 291.

  Andrew Olshan; George Retsch-Bogart; Anna Maria Siega-Riz; Fei Zou

  Genetic Susceptibility Factors in the Etiology of Neuroblastoma

  9/15/2008 - 7/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 540,786.00

• 292.

  Andrew Olshan; Anna Maria Siega-Riz; Fei Zou

  Genetic Susceptibility Factors in the Etiology of Neuroblastoma

  9/15/2008 - 7/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 565,278.00

• 293.

  Andrew Olshan; Anna Maria Siega-Riz; Fei Zou

  Genetic Susceptibility Factors in the Etiology of Neuroblastoma

  9/15/2008 - 7/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 587,352.00

• 294.

  Andrew Olshan; Anna Maria Siega-Riz; Fei Zou

  Genetic Susceptibility Factors in the Etiology of Neuroblastoma

  9/15/2008 - 7/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 555,943.00

• 295.

  Andrew Olshan; Fei Zou

  Genetic Susceptibility Factors in the Etiology of Neuroblastoma

  9/15/2008 - 7/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 551,019.00

• 296.

  Peggy Leatt; Richard Goldberg; Bryan Weiner; Joanne Marshall; Jeffrey Peppercorn

  Cancer Care Quality Research Training Program

  9/5/2008 - 8/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 308,688.00

• 297.

  Peggy Leatt; Richard Goldberg; Bryan Weiner; Jeffrey Peppercorn; Morris Weinberger

  Cancer Care Quality Research Training Program

  9/5/2008 - 8/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 360,132.00

• 298.

  Peggy Leatt; Richard Goldberg; Joanne Marshall; Morris Weinberger; Bryan Weiner

  Cancer Care Quality Research Training Program

  9/5/2008 - 8/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 411,039.00

• 299.

  Lisa Carey

  A Phase II, Randomized, Open Label Trial of Pre-Operative (Neoadjuvant) Letrozol

  9/2/2008 - 4/30/2009

  Sponsor: University of Alabama at Birmingham

  Funding: $ 12,884.00

• 300.

  Lisa Carey

  A Phase II, Randomized, Open Label Trial of Pre-Operative (Neoadjuvant) Letrozol

  9/2/2008 - 4/30/2009

  Sponsor: University of Alabama at Birmingham

  Funding: $ 6,442.00

• 301.

  Lisa Carey; Richard Goldberg; H Shelton Earp; Paul Godley

  Academic Training in Oncology at The University of North Carolina at Chapel Hill

  9/1/2008 - 8/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 128,532.00

• 302.

  Lisa Carey; H Shelton Earp; Richard Goldberg; Paul Godley

  Academic Training in Oncology at The University of North Carolina at Chapel Hill

  9/1/2008 - 8/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 259,137.00

• 303.

  Lisa Carey; Richard Goldberg; H Shelton Earp; Paul Godley

  Academic Training in Oncology at The University of North Carolina at Chapel Hill

  9/1/2008 - 8/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 246,254.00

• 304.

  Lisa Carey; Richard Goldberg

  Academic Training in Oncology at The University of North Carolina at Chapel Hill

  9/1/2008 - 8/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 220,020.00

• 305.

  Lisa Carey

  Academic Training in Oncology at The University of North Carolina at Chapel Hill

  9/1/2008 - 8/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 255,067.00

• 306.

  Thomas Shea; Robert Irons; Julia Whitley

  Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell T

  8/6/2008 - 9/30/2012

  Sponsor: National Marrow Donor Program

  Funding: $ 3,594.00

• 307.

  Thomas Shea; Robert Irons; Julia Whitley

  Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell T

  8/6/2008 - 9/30/2012

  Sponsor: National Marrow Donor Program

  Funding: $ 2,330.00

• 308.

  Thomas Shea; Robert Irons; Julia Whitley

  Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell T

  8/6/2008 - 9/30/2012

  Sponsor: National Marrow Donor Program

  Funding: $ 1,165.00

• 309.

  Thomas Shea; Robert Irons; Julia Whitley

  Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell T

  8/6/2008 - 9/30/2012

  Sponsor: National Marrow Donor Program

  Funding: $ 1,165.00

• 310.

  Thomas Shea; Robert Irons; Julia Whitley

  Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell T

  8/6/2008 - 9/30/2012

  Sponsor: National Marrow Donor Program

  Funding: $ 1,518.00

• 311.

  Thomas Shea; Robert Irons; Julia Whitley

  Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell T

  8/6/2008 - 9/30/2012

  Sponsor: National Marrow Donor Program

  Funding: $ 5,704.00

• 312.

  Thomas Shea; Robert Irons; Julia Whitley

  Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell T

  8/6/2008 - 9/30/2012

  Sponsor: National Marrow Donor Program

  Funding: $ 7,222.00

• 313.

  Thomas Shea; Robert Irons; Julia Whitley

  Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell T

  8/6/2008 - 9/30/2012

  Sponsor: National Marrow Donor Program

  Funding: $ 2,199.00

• 314.

  Thomas Shea; Robert Irons; Julia Whitley

  Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell T

  8/6/2008 - 9/30/2012

  Sponsor: National Marrow Donor Program

  Funding: $ 5,704.00

• 315.

  Thomas Shea; Robert Irons; Julia Whitley

  Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell T

  8/6/2008 - 9/30/2012

  Sponsor: National Marrow Donor Program

  Funding: $ 11,408.00

• 316.

  Thomas Shea

  MM018029 An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inh

  7/2/2008 - 7/1/2011

  Sponsor: Industry Sponsor

  Funding: $ 11,164.00

• 317.

  Thomas Shea

  MM018029 An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inh

  7/2/2008 - 7/1/2011

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 318.

  Thomas Shea

  MM018029 An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inh

  7/2/2008 - 7/1/2011

  Sponsor: Industry Sponsor

  Funding: $ 763.00

• 319.

  Thomas Shea

  MM018029 An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inh

  7/2/2008 - 7/1/2011

  Sponsor: Industry Sponsor

  Funding: $ 5,970.00

• 320.

  Thomas Shea

  MM018029 An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inh

  7/2/2008 - 7/1/2011

  Sponsor: Industry Sponsor

  Funding: $ 13,836.00

• 321.

  Thomas Shea

  MM018029 An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inh

  7/2/2008 - 7/1/2011

  Sponsor: Industry Sponsor

  Funding: $ 6,237.00

• 322.

  Thomas Shea

  MM018029 An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inh

  7/2/2008 - 7/1/2011

  Sponsor: Industry Sponsor

  Funding: $ 2,492.00

• 323.

  Thomas Shea

  MM018029 An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inh

  7/2/2008 - 7/1/2011

  Sponsor: Industry Sponsor

  Funding: $ 4,871.00

• 324.

  Thomas Shea

  MM018029 An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inh

  7/2/2008 - 7/1/2011

  Sponsor: Industry Sponsor

  Funding: $ 6,706.00

• 325.

  Thomas Shea

  MM018029 An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inh

  7/2/2008 - 7/1/2011

  Sponsor: Industry Sponsor

  Funding: $ 27,013.00

• 326.

  Thomas Shea

  MM018029 An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inh

  7/2/2008 - 7/1/2011

  Sponsor: Industry Sponsor

  Funding: $ 7,509.00

• 327.

  Thomas Shea

  MM018029 An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inh

  7/2/2008 - 7/1/2011

  Sponsor: Industry Sponsor

  Funding: $ 1,458.00

• 328.

  Thomas Shea

  MM018029 An Open-label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inh

  7/2/2008 - 7/1/2011

  Sponsor: Industry Sponsor

  Funding: $ 18,693.00

• 329.

  Jonathan Serody

  Blockade of NF-kB for prevention/treatment of GVHD

  7/1/2008 - 6/30/2010

  Sponsor: Industry Sponsor

  Funding: $ 351,946.00

• 330.

  Jonathan Serody

  Blockade of NF-kB for prevention/treatment of GVHD

  7/1/2008 - 6/30/2010

  Sponsor: Industry Sponsor

  Funding: $ 70,800.00

• 331.

  Jenny Ting

  The role of plexin-A1 mediated T cell activation in atherosclerosis

  7/1/2008 - 6/30/2010

  Sponsor: American Heart Association (AHA)

  Funding: $ 80,000.00

• 332.

  Norman Sharpless

  Role of p16INK4a in islet regeneration with aging

  7/1/2008 - 6/30/2009

  Sponsor: Ellison Medical Foundation

  Funding: $ 53,350.00

• 333.

  Andrew Olshan

  Merck Quantitative Sciences Graduate Fellowship in Epidemiology

  6/30/2008 - 12/31/2011

  Sponsor: Merck Company Foundation

  Funding: $ 120,000.00

• 334.

  Lisa Carey

  H42090s Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive B

  6/24/2008 - 6/30/2012

  Sponsor: Industry Sponsor

  Funding: $ 6,500.00

• 335.

  Lisa Carey

  H42090s Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive B

  6/24/2008 - 6/30/2012

  Sponsor: Industry Sponsor

  Funding: $ 6,500.00

• 336.

  Lisa Carey

  H42090s Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive B

  6/24/2008 - 6/30/2012

  Sponsor: Industry Sponsor

  Funding: $ 6,500.00

• 337.

  Lisa Carey

  H42090s Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive B

  6/24/2008 - 6/30/2012

  Sponsor: Industry Sponsor

  Funding: $ 6,500.00

• 338.

  Lisa Carey

  H42090s Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive B

  6/24/2008 - 6/30/2012

  Sponsor: Industry Sponsor

  Funding: $ 19,500.00

• 339.

  Lisa Carey

  H42090s Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive B

  6/24/2008 - 6/30/2012

  Sponsor: Industry Sponsor

  Funding: $ 6,500.00

• 340.

  Lisa Carey

  H42090s Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive B

  6/24/2008 - 6/30/2012

  Sponsor: Industry Sponsor

  Funding: $ 6,500.00

• 341.

  Lisa Carey

  H42090s Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive B

  6/24/2008 - 6/30/2012

  Sponsor: Industry Sponsor

  Funding: $ 6,500.00

• 342.

  Jacqueline Gibson; Michael Aitken; Richard Andrews; Noel Brewer; Gregory Characklis; Jiu-Chiuan Chen; Carl Ernst; Jonathan Kotch; David Leith; Leena Nylander-French; Andrew Olshan; Ivan Rusyn; Marc Serre; Uma Shankar; Katherine Shea; Mark Sobsey; William Sollecito; James Swenberg; William Vizuete; Jason West; Dale Whittington

  National Strategy for Environment and Health for the United Arab Emirates

  6/1/2008 - 5/31/2012

  Sponsor: United Arab Emirates University

  Funding: $ 7,785,989.00

• 343.

  Jacqueline Gibson; Michael Aitken; Richard Andrews; Noel Brewer; Gregory Characklis; Jiu-Chiuan Chen; Carl Ernst; Jonathan Kotch; David Leith; Leena Nylander-French; Andrew Olshan; Ivan Rusyn; Marc Serre; Uma Shankar; Katherine Shea; Mark Sobsey; William Sollecito; James Swenberg; William Vizuete; Jason West; Dale Whittington

  National Strategy for Environment and Health for the United Arab Emirates

  6/1/2008 - 5/31/2012

  Sponsor: United Arab Emirates University

  Funding: $ 4,322,754.00

• 344.

  Jacqueline Gibson; Michael Aitken; Richard Andrews; Noel Brewer; Gregory Characklis; Jiu-Chiuan Chen; Carl Ernst; Jonathan Kotch; David Leith; Leena Nylander-French; Andrew Olshan; Ivan Rusyn; Marc Serre; Uma Shankar; Katherine Shea; Mark Sobsey; William Sollecito; James Swenberg; William Vizuete; Jason West; Dale Whittington

  National Strategy for Environment and Health for the United Arab Emirates

  6/1/2008 - 5/31/2012

  Sponsor: United Arab Emirates University

  Funding: $ 734,232.00

• 345.

  Jacqueline Gibson; Michael Aitken; Richard Andrews; Noel Brewer; Gregory Characklis; Jiu-Chiuan Chen; Carl Ernst; Jonathan Kotch; David Leith; Leena Nylander-French; Andrew Olshan; Ivan Rusyn; Marc Serre; Uma Shankar; Katherine Shea; Mark Sobsey; William Sollecito; James Swenberg; William Vizuete; Jason West; Dale Whittington

  National Strategy for Environment and Health for the United Arab Emirates

  6/1/2008 - 5/31/2012

  Sponsor: United Arab Emirates University

  Funding: $ 51,100.00

• 346.

  Lisa Carey

  AVON PRIME: TO#1/TBCRC-007, JHU PO#2000426773

  5/30/2008 - 6/30/2012

  Sponsor: Johns Hopkins University

  Funding: $ 8,450.00

• 347.

  Marschall Runge; Etta Pisano; Adaora Adimora; Alice Ammerman; Victoria Bae-Jump; Patricia Basta; James Beck; Alan Blatecky; Charlotte Boettiger Cooney; Richard Boucher; Kim Brouwer; Hope Bryan; Marjorie Busby; John Buse; Patricia Byrns; Jianwen Cai; Timothy Carey; Giselle Corbie-Smith; David Couper; Samuel Cykert; Margaret Dardess; Arlene Davis; Evan Dellon; Peggye Dilworth-Anderson; Rosalie Dominik; Joseph Eron; Denise Esserman; Donna Evon; Ronald Falk; Jason Fine; Michael Fried; William Funkhouser; Joanne Garrett; Bradley Gaynes; John Gilmore; Debbie Gipson; Paul Godley; Jose-Marie Griffiths; Margaret Gulley; Jacquie Halladay; Laura Hanson; Kristen Hassmiller; Gail Henderson; Susan Henning; Mei Huang; Joseph Ibrahim; Gary Johnson; Joanne Jordan; Jonathan Juliano; Rudolph Juliano; Michael Kappelman; Michael Kosorok; Lisa Lavange; Clara Lee; Margaret Leigh; Thomas Linden; William Maixner; William Marzluff; Elizabeth Mayer-Davis; Howard McLeod; Cathy Melvin; Steven Meshnick; William Miller; Javed Mostafa; Brenda Motsinger; Steven Offenbacher; Eugene Orringer; Cam Patterson; David Peden; Charles Perou; Susan Pusek; Ralph Raasch; David Ransohoff; Marie Rape; Kristin Reiter; George Retsch-Bogart; Catherine Rohweder; Malika Roman Isler; Janet Rubin; Margarete Sandelowski; Hanna Sanoff; Christopher Sims; Philip Sloane; Paul Stewart; Theresa Swift-Scanlan; Leigh Thorne; Sue Tolleson-Rinehart; Michael Topal; Anthony Viera; Michael Wagner; Rebecca Walker; David Weber; Karen Weck-Taylor; Morris Weinberger; Bryan Weiner; Crystal Wiley Cene; Kirk Wilhelmsen; Fred Wright; Erika Hanami; Tania Mendoza; Trevor Presler

  Clinical and Translational Science Award (CTSA) - TL Awards

  5/19/2008 - 4/30/2013

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 168,726.00

• 348.

  Marschall Runge; Etta Pisano; Adaora Adimora; Alice Ammerman; Victoria Bae-Jump; Patricia Basta; James Beck; Alan Blatecky; Charlotte Boettiger Cooney; Richard Boucher; Kim Brouwer; Hope Bryan; Marjorie Busby; John Buse; Patricia Byrns; Jianwen Cai; Timothy Carey; Giselle Corbie-Smith; David Couper; Samuel Cykert; Margaret Dardess; Arlene Davis; Evan Dellon; Peggye Dilworth-Anderson; Rosalie Dominik; Joseph Eron; Denise Esserman; Donna Evon; Ronald Falk; Jason Fine; Michael Fried; William Funkhouser; Joanne Garrett; Bradley Gaynes; John Gilmore; Debbie Gipson; Paul Godley; Jose-Marie Griffiths; Margaret Gulley; Jacquie Halladay; Laura Hanson; Kristen Hassmiller; Gail Henderson; Susan Henning; Mei Huang; Joseph Ibrahim; Gary Johnson; Joanne Jordan; Jonathan Juliano; Rudolph Juliano; Michael Kappelman; Michael Kosorok; Lisa Lavange; Clara Lee; Margaret Leigh; Thomas Linden; William Maixner; William Marzluff; Elizabeth Mayer-Davis; Howard McLeod; Cathy Melvin; Steven Meshnick; William Miller; Javed Mostafa; Brenda Motsinger; Steven Offenbacher; Eugene Orringer; Cam Patterson; David Peden; Charles Perou; Susan Pusek; Ralph Raasch; David Ransohoff; Marie Rape; Kristin Reiter; George Retsch-Bogart; Catherine Rohweder; Malika Roman Isler; Janet Rubin; Margarete Sandelowski; Hanna Sanoff; Christopher Sims; Philip Sloane; Paul Stewart; Theresa Swift-Scanlan; Leigh Thorne; Sue Tolleson-Rinehart; Michael Topal; Anthony Viera; Michael Wagner; Rebecca Walker; David Weber; Karen Weck-Taylor; Morris Weinberger; Bryan Weiner; Crystal Wiley Cene; Kirk Wilhelmsen; Fred Wright; Erika Hanami; Tania Mendoza; Trevor Presler

  Clinical and Translational Science Award (CTSA) - KL Awards

  5/19/2008 - 4/30/2013

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 2,256,133.00

• 349.

  Marschall Runge; Etta Pisano; Adaora Adimora; Alice Ammerman; Victoria Bae-Jump; Patricia Basta; James Beck; Alan Blatecky; Charlotte Boettiger Cooney; Richard Boucher; Kim Brouwer; Hope Bryan; Marjorie Busby; John Buse; Patricia Byrns; Jianwen Cai; Timothy Carey; Giselle Corbie-Smith; David Couper; Samuel Cykert; Margaret Dardess; Arlene Davis; Evan Dellon; Peggye Dilworth-Anderson; Rosalie Dominik; Joseph Eron; Denise Esserman; Donna Evon; Ronald Falk; Jason Fine; Michael Fried; William Funkhouser; Joanne Garrett; Bradley Gaynes; John Gilmore; Debbie Gipson; Paul Godley; Jose-Marie Griffiths; Margaret Gulley; Jacquie Halladay; Laura Hanson; Kristen Hassmiller; Gail Henderson; Susan Henning; Mei Huang; Joseph Ibrahim; Gary Johnson; Joanne Jordan; Jonathan Juliano; Rudolph Juliano; Michael Kappelman; Michael Kosorok; Lisa Lavange; Clara Lee; Margaret Leigh; Thomas Linden; William Maixner; William Marzluff; Elizabeth Mayer-Davis; Howard McLeod; Cathy Melvin; Steven Meshnick; William Miller; Javed Mostafa; Brenda Motsinger; Steven Offenbacher; Eugene Orringer; Cam Patterson; David Peden; Charles Perou; Susan Pusek; Ralph Raasch; David Ransohoff; Marie Rape; Kristin Reiter; George Retsch-Bogart; Catherine Rohweder; Malika Roman Isler; Janet Rubin; Margarete Sandelowski; Hanna Sanoff; Christopher Sims; Philip Sloane; Paul Stewart; Theresa Swift-Scanlan; Leigh Thorne; Sue Tolleson-Rinehart; Michael Topal; Anthony Viera; Michael Wagner; Rebecca Walker; David Weber; Karen Weck-Taylor; Morris Weinberger; Bryan Weiner; Crystal Wiley Cene; Kirk Wilhelmsen; Fred Wright; Erika Hanami; Tania Mendoza; Trevor Presler

  Clinical and Translational Science Award (CTSA) - UL Awards

  5/19/2008 - 4/30/2013

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 10,150,567.00

• 350.

  Marschall Runge; Etta Pisano; Adaora Adimora; Alice Ammerman; James Anderson; Paul Armistead; Patricia Basta; James Beck; Charlotte Boettiger Cooney; Richard Boucher; Kim Brouwer; John Buse; Patricia Byrns; Jianwen Cai; Leigh Callahan; Timothy Carey; Sai Chavala; Ronald Chen; Giselle Corbie-Smith; Tamera Coyne-Beasley; Arlene Davis; Evan Dellon; Peggye Dilworth-Anderson; John Edwards; Lloyd Edwards; Joseph Eron; Denise Esserman; Donna Evon; Ronald Falk; Jason Fine; Michael Fried; William Funkhouser; Joanne Garrett; Bradley Gaynes; John Gilmore; Jose-Marie Griffiths; Ajay Gulati; Margaret Gulley; Jacquie Halladay; Laura Hanson; Kristen Hassmiller; Gail Henderson; Susan Henning; Michelle Hernandez; Mei Huang; Wanda Hunter; Gary Johnson; Joanne Jordan; Jonathan Juliano; Rudolph Juliano; Michael Kosorok; Lisa Lavange; Margaret Leigh; Alexandra Lightfoot; Weili Lin; Thomas Linden; James Lindsey; William Maixner; William Marzluff; Elizabeth Mayer-Davis; Howard McLeod; Steven Meshnick; William Miller; Javed Mostafa; Brenda Motsinger; Matthew Nielsen; Steven Offenbacher; Eugene Orringer; Cam Patterson; David Peden; Bahjat Qaqish; Ralph Raasch; David Ransohoff; George Retsch-Bogart; Janet Rubin; Margarete Sandelowski; Pranab Sen; Christopher Sims; Betsy Sleath; Philip Sloane; Paul Stewart; Theresa Swift-Scanlan; Leigh Thorne; Michael Topal; Kinh Truong; Michael Wagner; Rebecca Walker; David Weber; Karen Weck-Taylor; Morris Weinberger; Bryan Weiner; Crystal Wiley Cene; Kirk Wilhelmsen; Fred Wright; Hongtu Zhu

  Clinical and Translational Science Award (CTSA) - TL Awards

  5/19/2008 - 4/30/2013

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 169,608.00

• 351.

  Marschall Runge; Adaora Adimora; Robert Agans; Stanley Ahalt; Alice Ammerman; Paul Armistead; Gary Asher; Shrikant Bangdiwala; Patricia Basta; James Beck; Richard Boucher; Kim Brouwer; John Buse; Jianwen Cai; Leigh Callahan; Tim Carey; Ronald Chen; Cindy Clark; Giselle Corbie-Smith; Tamera Coyne-Beasley; Arlene Davis; Peggye Dilworth-Anderson; Rosalie Dominik; Joseph Duncan; John Edwards; Lloyd Edwards; Joseph Eron; Denise Esserman; Ronald Falk; Jason Fine; Michael Fried; William Funkhouser; Joanne Garrett; Bradley Gaynes; John Gilmore; Ajay Gulati; Margaret Gulley; Jacquie Halladay; Laura Hanson; Gail Henderson; Susan Henning; Michelle Hernandez; Christopher Hurt; Gary Johnson; Joanne Jordan; Eric Juengst; Rudolph Juliano; Nigel Key; Michael Kosorok; Lisa LaVange; Margaret Leigh; Alexandra Lightfoot; Weili Lin; Thomas Linden; James Lindsey; Terry Magnuson; William Maixner; William Marzluff; Elizabeth Mayer-Davis; Howard McLeod; William Miller; Javed Mostafa; Brenda Motsinger; Matthew Nielsen; Steven Offenbacher; Eugene Orringer; Steven Park; Cam Patterson; David Peden; Timothy Plattsmills; Bahjat Qaqish; Ralph Raasch; David Ransohoff; George Retsch-Bogart; Janet Rubin; Margarete Sandelowski; Pranab Sen; Christopher Sims; Betsy Sleath; Philip Sloane; Paul Stewart; Leigh Thorne; Michael Topal; Kinh Truong; John Van Aalst; Anthony Viera; Michael Wagner; Rebecca Walker; David Weber; Karen Weck-Taylor; Morris Weinberger; Bryan Weiner; Kirk Wilhelmsen; Fred Wright; Michael Wu; Hongtu Zhu

  Clinical and Translational Science Award (CTSA) - TL Awards

  5/19/2008 - 4/30/2013

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 169,608.00

• 352.

  Marschall Runge; Adaora Adimora; Robert Agans; Stanley Ahalt; Alice Ammerman; Paul Armistead; Gary Asher; Shrikant Bangdiwala; Patricia Basta; James Beck; Richard Boucher; Kim Brouwer; John Buse; Jianwen Cai; Leigh Callahan; Tim Carey; Ronald Chen; Cindy Clark; Giselle Corbie-Smith; Tamera Coyne-Beasley; Arlene Davis; Peggye Dilworth-Anderson; Rosalie Dominik; Joseph Duncan; John Edwards; Lloyd Edwards; Joseph Eron; Denise Esserman; Ronald Falk; Jason Fine; Michael Fried; William Funkhouser; Joanne Garrett; Bradley Gaynes; John Gilmore; Ajay Gulati; Margaret Gulley; Jacquie Halladay; Laura Hanson; Gail Henderson; Susan Henning; Michelle Hernandez; Christopher Hurt; Gary Johnson; Joanne Jordan; Eric Juengst; Rudolph Juliano; Nigel Key; Michael Kosorok; Lisa LaVange; Margaret Leigh; Alexandra Lightfoot; Weili Lin; Thomas Linden; James Lindsey; Terry Magnuson; William Maixner; William Marzluff; Elizabeth Mayer-Davis; Howard McLeod; William Miller; Javed Mostafa; Brenda Motsinger; Matthew Nielsen; Steven Offenbacher; Eugene Orringer; Steven Park; Cam Patterson; David Peden; Timothy Plattsmills; Bahjat Qaqish; Ralph Raasch; David Ransohoff; George Retsch-Bogart; Janet Rubin; Margarete Sandelowski; Pranab Sen; Christopher Sims; Betsy Sleath; Philip Sloane; Paul Stewart; Leigh Thorne; Michael Topal; Kinh Truong; John Van Aalst; Anthony Viera; Michael Wagner; Rebecca Walker; David Weber; Karen Weck-Taylor; Morris Weinberger; Bryan Weiner; Kirk Wilhelmsen; Fred Wright; Michael Wu; Hongtu Zhu

  Clinical and Translational Science Award (CTSA) - TL Awards

  5/19/2008 - 4/30/2013

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 1,814.00

• 353.

  Marschall Runge; Etta Pisano; Adaora Adimora; Alice Ammerman; James Anderson; Paul Armistead; Patricia Basta; James Beck; Charlotte Boettiger Cooney; Richard Boucher; Kim Brouwer; John Buse; Patricia Byrns; Jianwen Cai; Leigh Callahan; Timothy Carey; Sai Chavala; Ronald Chen; Giselle Corbie-Smith; Tamera Coyne-Beasley; Arlene Davis; Evan Dellon; Peggye Dilworth-Anderson; John Edwards; Lloyd Edwards; Joseph Eron; Denise Esserman; Donna Evon; Ronald Falk; Jason Fine; Michael Fried; William Funkhouser; Joanne Garrett; Bradley Gaynes; John Gilmore; Jose-Marie Griffiths; Ajay Gulati; Margaret Gulley; Jacquie Halladay; Laura Hanson; Kristen Hassmiller; Gail Henderson; Susan Henning; Michelle Hernandez; Mei Huang; Wanda Hunter; Gary Johnson; Joanne Jordan; Jonathan Juliano; Rudolph Juliano; Michael Kosorok; Lisa Lavange; Margaret Leigh; Alexandra Lightfoot; Weili Lin; Thomas Linden; James Lindsey; William Maixner; William Marzluff; Elizabeth Mayer-Davis; Howard McLeod; Steven Meshnick; William Miller; Javed Mostafa; Brenda Motsinger; Matthew Nielsen; Steven Offenbacher; Eugene Orringer; Cam Patterson; David Peden; Bahjat Qaqish; Ralph Raasch; David Ransohoff; George Retsch-Bogart; Janet Rubin; Margarete Sandelowski; Pranab Sen; Christopher Sims; Betsy Sleath; Philip Sloane; Paul Stewart; Theresa Swift-Scanlan; Leigh Thorne; Michael Topal; Kinh Truong; Michael Wagner; Rebecca Walker; David Weber; Karen Weck-Taylor; Morris Weinberger; Bryan Weiner; Crystal Wiley Cene; Kirk Wilhelmsen; Fred Wright; Hongtu Zhu

  Clinical and Translational Science Award (CTSA) - KL Awards

  5/19/2008 - 4/30/2013

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 2,256,133.00

• 354.

  Marschall Runge; Adaora Adimora; Robert Agans; Stanley Ahalt; Alice Ammerman; Paul Armistead; Gary Asher; Shrikant Bangdiwala; Patricia Basta; James Beck; Richard Boucher; Kim Brouwer; John Buse; Jianwen Cai; Leigh Callahan; Tim Carey; Ronald Chen; Cindy Clark; Giselle Corbie-Smith; Tamera Coyne-Beasley; Arlene Davis; Peggye Dilworth-Anderson; Rosalie Dominik; Joseph Duncan; John Edwards; Lloyd Edwards; Joseph Eron; Denise Esserman; Ronald Falk; Jason Fine; Michael Fried; William Funkhouser; Joanne Garrett; Bradley Gaynes; John Gilmore; Ajay Gulati; Margaret Gulley; Jacquie Halladay; Laura Hanson; Gail Henderson; Susan Henning; Michelle Hernandez; Christopher Hurt; Gary Johnson; Joanne Jordan; Eric Juengst; Rudolph Juliano; Nigel Key; Michael Kosorok; Lisa LaVange; Margaret Leigh; Alexandra Lightfoot; Weili Lin; Thomas Linden; James Lindsey; Terry Magnuson; William Maixner; William Marzluff; Elizabeth Mayer-Davis; Howard McLeod; William Miller; Javed Mostafa; Brenda Motsinger; Matthew Nielsen; Steven Offenbacher; Eugene Orringer; Steven Park; Cam Patterson; David Peden; Timothy Plattsmills; Bahjat Qaqish; Ralph Raasch; David Ransohoff; George Retsch-Bogart; Janet Rubin; Margarete Sandelowski; Pranab Sen; Christopher Sims; Betsy Sleath; Philip Sloane; Paul Stewart; Leigh Thorne; Michael Topal; Kinh Truong; John Van Aalst; Anthony Viera; Michael Wagner; Rebecca Walker; David Weber; Karen Weck-Taylor; Morris Weinberger; Bryan Weiner; Kirk Wilhelmsen; Fred Wright; Michael Wu; Hongtu Zhu

  Clinical and Translational Science Award (CTSA) - KL Awards

  5/19/2008 - 4/30/2013

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 2,256,133.00

• 355.

  Marschall Runge; Etta Pisano; Adaora Adimora; Alice Ammerman; James Anderson; Paul Armistead; Patricia Basta; James Beck; Charlotte Boettiger Cooney; Richard Boucher; Kim Brouwer; John Buse; Patricia Byrns; Jianwen Cai; Leigh Callahan; Timothy Carey; Sai Chavala; Ronald Chen; Giselle Corbie-Smith; Tamera Coyne-Beasley; Arlene Davis; Evan Dellon; Peggye Dilworth-Anderson; John Edwards; Lloyd Edwards; Joseph Eron; Denise Esserman; Donna Evon; Ronald Falk; Jason Fine; Michael Fried; William Funkhouser; Joanne Garrett; Bradley Gaynes; John Gilmore; Jose-Marie Griffiths; Ajay Gulati; Margaret Gulley; Jacquie Halladay; Laura Hanson; Kristen Hassmiller; Gail Henderson; Susan Henning; Michelle Hernandez; Mei Huang; Wanda Hunter; Gary Johnson; Joanne Jordan; Jonathan Juliano; Rudolph Juliano; Michael Kosorok; Lisa Lavange; Margaret Leigh; Alexandra Lightfoot; Weili Lin; Thomas Linden; James Lindsey; William Maixner; William Marzluff; Elizabeth Mayer-Davis; Howard McLeod; Steven Meshnick; William Miller; Javed Mostafa; Brenda Motsinger; Matthew Nielsen; Steven Offenbacher; Eugene Orringer; Cam Patterson; David Peden; Bahjat Qaqish; Ralph Raasch; David Ransohoff; George Retsch-Bogart; Janet Rubin; Margarete Sandelowski; Pranab Sen; Christopher Sims; Betsy Sleath; Philip Sloane; Paul Stewart; Theresa Swift-Scanlan; Leigh Thorne; Michael Topal; Kinh Truong; Michael Wagner; Rebecca Walker; David Weber; Karen Weck-Taylor; Morris Weinberger; Bryan Weiner; Crystal Wiley Cene; Kirk Wilhelmsen; Fred Wright; Hongtu Zhu

  Clinical and Translational Science Award (CTSA) - UL Awards

  5/19/2008 - 4/30/2013

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 10,198,216.00

• 356.

  Marschall Runge; Adaora Adimora; Robert Agans; Stanley Ahalt; Alice Ammerman; Paul Armistead; Gary Asher; Shrikant Bangdiwala; Patricia Basta; James Beck; Richard Boucher; Kim Brouwer; John Buse; Jianwen Cai; Leigh Callahan; Tim Carey; Ronald Chen; Cindy Clark; Giselle Corbie-Smith; Tamera Coyne-Beasley; Arlene Davis; Peggye Dilworth-Anderson; Rosalie Dominik; Joseph Duncan; John Edwards; Lloyd Edwards; Joseph Eron; Denise Esserman; Ronald Falk; Jason Fine; Michael Fried; William Funkhouser; Joanne Garrett; Bradley Gaynes; John Gilmore; Ajay Gulati; Margaret Gulley; Jacquie Halladay; Laura Hanson; Gail Henderson; Susan Henning; Michelle Hernandez; Christopher Hurt; Gary Johnson; Joanne Jordan; Eric Juengst; Rudolph Juliano; Nigel Key; Michael Kosorok; Lisa LaVange; Margaret Leigh; Alexandra Lightfoot; Weili Lin; Thomas Linden; James Lindsey; Terry Magnuson; William Maixner; William Marzluff; Elizabeth Mayer-Davis; Howard McLeod; William Miller; Javed Mostafa; Brenda Motsinger; Matthew Nielsen; Steven Offenbacher; Eugene Orringer; Steven Park; Cam Patterson; David Peden; Timothy Plattsmills; Bahjat Qaqish; Ralph Raasch; David Ransohoff; George Retsch-Bogart; Janet Rubin; Margarete Sandelowski; Pranab Sen; Christopher Sims; Betsy Sleath; Philip Sloane; Paul Stewart; Leigh Thorne; Michael Topal; Kinh Truong; John Van Aalst; Anthony Viera; Michael Wagner; Rebecca Walker; David Weber; Karen Weck-Taylor; Morris Weinberger; Bryan Weiner; Kirk Wilhelmsen; Fred Wright; Michael Wu; Hongtu Zhu

  Clinical and Translational Science Award (CTSA) - UL Awards

  5/19/2008 - 4/30/2013

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 9,178,095.00

• 357.

  Marschall Runge; Adaora Adimora; Robert Agans; Stanley Ahalt; Alice Ammerman; Paul Armistead; Gary Asher; Shrikant Bangdiwala; Patricia Basta; James Beck; Richard Boucher; Kim Brouwer; John Buse; Jianwen Cai; Leigh Callahan; Tim Carey; Ronald Chen; Cindy Clark; Giselle Corbie-Smith; Tamera Coyne-Beasley; Arlene Davis; Peggye Dilworth-Anderson; Rosalie Dominik; Joseph Duncan; John Edwards; Lloyd Edwards; Joseph Eron; Denise Esserman; Ronald Falk; Jason Fine; Michael Fried; William Funkhouser; Joanne Garrett; Bradley Gaynes; John Gilmore; Ajay Gulati; Margaret Gulley; Jacquie Halladay; Laura Hanson; Gail Henderson; Susan Henning; Michelle Hernandez; Christopher Hurt; Gary Johnson; Joanne Jordan; Eric Juengst; Rudolph Juliano; Nigel Key; Michael Kosorok; Lisa LaVange; Margaret Leigh; Alexandra Lightfoot; Weili Lin; Thomas Linden; James Lindsey; Terry Magnuson; William Maixner; William Marzluff; Elizabeth Mayer-Davis; Howard McLeod; William Miller; Javed Mostafa; Brenda Motsinger; Matthew Nielsen; Steven Offenbacher; Eugene Orringer; Steven Park; Cam Patterson; David Peden; Timothy Plattsmills; Bahjat Qaqish; Ralph Raasch; David Ransohoff; George Retsch-Bogart; Janet Rubin; Margarete Sandelowski; Pranab Sen; Christopher Sims; Betsy Sleath; Philip Sloane; Paul Stewart; Leigh Thorne; Michael Topal; Kinh Truong; John Van Aalst; Anthony Viera; Michael Wagner; Rebecca Walker; David Weber; Karen Weck-Taylor; Morris Weinberger; Bryan Weiner; Kirk Wilhelmsen; Fred Wright; Michael Wu; Hongtu Zhu

  Clinical and Translational Science Award (CTSA) - UL Awards

  5/19/2008 - 4/30/2013

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 721,245.00

• 358.

  Marschall Runge; Adaora Adimora; Robert Agans; Stanley Ahalt; Alice Ammerman; Paul Armistead; Gary Asher; Shrikant Bangdiwala; Patricia Basta; James Beck; Richard Boucher; Kim Brouwer; John Buse; Jianwen Cai; Leigh Callahan; Tim Carey; Ronald Chen; Cindy Clark; Giselle Corbie-Smith; Tamera Coyne-Beasley; Arlene Davis; Peggye Dilworth-Anderson; Rosalie Dominik; Joseph Duncan; John Edwards; Lloyd Edwards; Joseph Eron; Denise Esserman; Ronald Falk; Jason Fine; Michael Fried; William Funkhouser; Joanne Garrett; Bradley Gaynes; John Gilmore; Ajay Gulati; Margaret Gulley; Jacquie Halladay; Laura Hanson; Gail Henderson; Susan Henning; Michelle Hernandez; Christopher Hurt; Gary Johnson; Joanne Jordan; Eric Juengst; Rudolph Juliano; Nigel Key; Michael Kosorok; Lisa LaVange; Margaret Leigh; Alexandra Lightfoot; Weili Lin; Thomas Linden; James Lindsey; Terry Magnuson; William Maixner; William Marzluff; Elizabeth Mayer-Davis; Howard McLeod; William Miller; Javed Mostafa; Brenda Motsinger; Matthew Nielsen; Steven Offenbacher; Eugene Orringer; Steven Park; Cam Patterson; David Peden; Timothy Plattsmills; Bahjat Qaqish; Ralph Raasch; David Ransohoff; George Retsch-Bogart; Janet Rubin; Margarete Sandelowski; Pranab Sen; Christopher Sims; Betsy Sleath; Philip Sloane; Paul Stewart; Leigh Thorne; Michael Topal; Kinh Truong; John Van Aalst; Anthony Viera; Michael Wagner; Rebecca Walker; David Weber; Karen Weck-Taylor; Morris Weinberger; Bryan Weiner; Kirk Wilhelmsen; Fred Wright; Michael Wu; Hongtu Zhu

  Clinical and Translational Science Award (CTSA) - UL Awards

  5/19/2008 - 4/30/2013

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 196,894.00

• 359.

  Marschall Runge; Adaora Adimora; Robert Agans; Alice Ammerman; Eric Bair; Shrikant Bangdiwala; Vytas Bankaitis; Christopher Barker; Patricia Basta; James Beck; Richard Boucher; Kim Brouwer; John Buse; Jianwen Cai; Tim Carey; Giselle Corbie-Smith; Tamera Coyne-Beasley; Arlene Davis; Robert Devellis; Peggye Dilworth-Anderson; Rosalie Dominik; Katrina Donahue; Lloyd Edwards; Joseph Eron; Denise Esserman; Ronald Falk; Jason Fine; Bill Funkhouser; Joanne Garrett; Bradley Gaynes; John Gilmore; Margaret Gulley; Jacquie Halladay; Jennifer Hayden; Gail Henderson; Susan Henning; Mei Huang; Gary Johnson; Joanne Jordan; Eric Juengst; Nigel Key; Mimi Kim; Michael Kosorok; Margaret Leigh; Chenxi Li; Alexandra Lightfoot; Feng-Chang Lin; Weili Lin; Thomas Linden; Nigel Mackman; Terry Magnuson; Bill Marzluff; Elizabeth Mayer-Davis; Howard McLeod; William Miller; Rita O'Sullivan; Steven Offenbacher; Eugene Orringer; David Peden; Eliana Perrin; Bahjat Qaqish; Ralph Raasch; David Ransohoff; George Retsch-Bogart; Dan Reuland; Malika Roman Isler; Janet Rubin; Margarete Sandelowski; Pranab Sen; Christopher Sims; Betsy Sleath; Philip Sloane; Paul Stewart; Leigh Thorne; Michael Topal; Kinh Truong; Anthony Viera; Michael Wagner; Rebecca Walker; Mark Weaver; David Weber; Karen Weck-Taylor; Morris Weinberger; Bryan Weiner; Fred Wright; Michael Wu; Donglin Zeng; Hongtu Zhu

  CTSA Non-Competing Renewal 4/30/2012

  5/19/2008 - 4/30/2014

  Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)

  Funding: $ 2,256,133.00

• 360.

  Marschall Runge; Adaora Adimora; Robert Agans; Alice Ammerman; Eric Bair; Shrikant Bangdiwala; Vytas Bankaitis; Christopher Barker; Patricia Basta; James Beck; Richard Boucher; Kim Brouwer; John Buse; Jianwen Cai; Tim Carey; Giselle Corbie-Smith; Tamera Coyne-Beasley; Arlene Davis; Robert Devellis; Peggye Dilworth-Anderson; Rosalie Dominik; Katrina Donahue; Lloyd Edwards; Joseph Eron; Denise Esserman; Ronald Falk; Jason Fine; Bill Funkhouser; Joanne Garrett; Bradley Gaynes; John Gilmore; Margaret Gulley; Jacquie Halladay; Jennifer Hayden; Gail Henderson; Susan Henning; Mei Huang; Gary Johnson; Joanne Jordan; Eric Juengst; Nigel Key; Mimi Kim; Michael Kosorok; Margaret Leigh; Chenxi Li; Alexandra Lightfoot; Feng-Chang Lin; Weili Lin; Thomas Linden; Nigel Mackman; Terry Magnuson; Bill Marzluff; Elizabeth Mayer-Davis; Howard McLeod; William Miller; Rita O'Sullivan; Steven Offenbacher; Eugene Orringer; David Peden; Eliana Perrin; Bahjat Qaqish; Ralph Raasch; David Ransohoff; George Retsch-Bogart; Dan Reuland; Malika Roman Isler; Janet Rubin; Margarete Sandelowski; Pranab Sen; Christopher Sims; Betsy Sleath; Philip Sloane; Paul Stewart; Leigh Thorne; Michael Topal; Kinh Truong; Anthony Viera; Michael Wagner; Rebecca Walker; Mark Weaver; David Weber; Karen Weck-Taylor; Morris Weinberger; Bryan Weiner; Fred Wright; Michael Wu; Donglin Zeng; Hongtu Zhu

  CTSA Non-Competing Renewal 4/30/2012

  5/19/2008 - 4/30/2014

  Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)

  Funding: $ 171,422.00

• 361.

  Marschall Runge; Adaora Adimora; Robert Agans; Alice Ammerman; Eric Bair; Shrikant Bangdiwala; Vytas Bankaitis; Christopher Barker; Patricia Basta; James Beck; Richard Boucher; Kim Brouwer; John Buse; Jianwen Cai; Tim Carey; Giselle Corbie-Smith; Tamera Coyne-Beasley; Arlene Davis; Robert Devellis; Peggye Dilworth-Anderson; Rosalie Dominik; Katrina Donahue; Lloyd Edwards; Joseph Eron; Denise Esserman; Ronald Falk; Jason Fine; Bill Funkhouser; Joanne Garrett; Bradley Gaynes; John Gilmore; Margaret Gulley; Jacquie Halladay; Jennifer Hayden; Gail Henderson; Susan Henning; Mei Huang; Gary Johnson; Joanne Jordan; Eric Juengst; Nigel Key; Mimi Kim; Michael Kosorok; Margaret Leigh; Chenxi Li; Alexandra Lightfoot; Feng-Chang Lin; Weili Lin; Thomas Linden; Nigel Mackman; Terry Magnuson; Bill Marzluff; Elizabeth Mayer-Davis; Howard McLeod; William Miller; Rita O'Sullivan; Steven Offenbacher; Eugene Orringer; David Peden; Eliana Perrin; Bahjat Qaqish; Ralph Raasch; David Ransohoff; George Retsch-Bogart; Dan Reuland; Malika Roman Isler; Janet Rubin; Margarete Sandelowski; Pranab Sen; Christopher Sims; Betsy Sleath; Philip Sloane; Paul Stewart; Leigh Thorne; Michael Topal; Kinh Truong; Anthony Viera; Michael Wagner; Rebecca Walker; Mark Weaver; David Weber; Karen Weck-Taylor; Morris Weinberger; Bryan Weiner; Fred Wright; Michael Wu; Donglin Zeng; Hongtu Zhu

  CTSA Non-Competing Renewal 4/30/2012

  5/19/2008 - 4/30/2014

  Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)

  Funding: $ 10,119,351.00

• 362.

  Jenny Ting; Albert Baldwin; Manzoor Bhat; Silva Markovic-Plese; Glenn Matsushima

  Novel Immune Pathways in Multiple Sclerosis Pathogenesis and Therapy

  4/1/2008 - 3/31/2013

  Sponsor: National Multiple Sclerosis Society (NMSS)

  Funding: $ 825,000.00

• 363.

  David Peden; Neil Alexis; William Bennett; Willie Brickey; Philip Bromberg; Beverly Koller; John Lay; Terry Noah; Stephen Tilley; Jenny Ting; Haibo Zhou

  Immunobiology of Acute Environmental Asthma - ARRA

  3/1/2008 - 2/28/2013

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 1,504,121.00

• 364.

  Gary Johnson

  Defining Signaling Network Plasticity

  3/1/2008 - 11/15/2008

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 73,150.00

• 365.

  David Peden; Neil Alexis; William Bennett; Willie Brickey; Philip Bromberg; Beverly Koller; John Lay; Terry Noah; Stephen Tilley; Jenny Ting; Haibo Zhou

  Immunobiology of Acute Environmental Asthma - ARRA

  3/1/2008 - 2/28/2013

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 1,398,276.00

• 366.

  David Peden; Neil Alexis; William Bennett; Willie Brickey; Philip Bromberg; Beverly Koller; John Lay; Terry Noah; Stephen Tilley; Jenny Ting; Haibo Zhou

  Immunobiology of Acute Environmental Asthma - ARRA

  3/1/2008 - 2/28/2013

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 155,365.00

• 367.

  David Peden; Neil Alexis; William Bennett; Willie Brickey; Philip Bromberg; Xiaoyang Hua; Beverly Koller; Martina Kovarova; John Lay; Terry Noah; Stephen Tilley; Jenny Ting; Haibo Zhou

  Immunobiology of Acute Environmental Asthma - ARRA

  3/1/2008 - 2/28/2013

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 1,565,263.00

• 368.

  David Peden; Beverly Koller; Stephen Tilley; Jenny Ting

  Immunobiology of Acute Environmental Asthma - ARRA

  3/1/2008 - 2/28/2013

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 852,000.00

• 369.

  David Peden; Ilona Jaspers; Terry Noah; Jenny Ting; Sally Ivins

  Immunobiology of Acute Environmental Asthma - ARRA

  3/1/2008 - 2/28/2013

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 218,863.00

• 370.

  David Peden; Beverly Koller; Stephen Tilley; Jenny Ting; Neil Alexis; William Bennett; Willie Brickey; Philip Bromberg; John Lay; Terry Noah; Haibo Zhou

  Immunobiology of Acute Environmental Asthma - ARRA

  3/1/2008 - 2/28/2013

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 1,429,329.00

• 371.

  David Peden; Beverly Koller; Stephen Tilley; Jenny Ting; Neil Alexis; William Bennett; Willie Brickey; Philip Bromberg; John Lay; Terry Noah; Haibo Zhou

  Immunobiology of Acute Environmental Asthma - ARRA

  3/1/2008 - 2/28/2013

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 118,150.00

• 372.

  David Peden; Beverly Koller; Stephen Tilley; Jenny Ting; Neil Alexis; William Bennett; Willie Brickey; Philip Bromberg; John Lay; Terry Noah; Haibo Zhou; Carole Robinette; Margaret Sanders

  Immunobiology of Acute Environmental Asthma - ARRA

  3/1/2008 - 2/28/2013

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 1,539,754.00

• 373.

  Young Whang; H Shelton Earp; Nupam Mahajan; Carol Parker

  Regulation of androgen receptor by HER-2 and Ack1 tyrosine kinases - ARRA

  2/1/2008 - 12/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 246,375.00

• 374.

  Young Whang; H Shelton Earp; Nupam Mahajan; Carol Parker

  Regulation of androgen receptor by HER-2 and Ack1 tyrosine kinases - ARRA

  2/1/2008 - 12/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 26,280.00

• 375.

  Young Whang; H Shelton Earp

  Regulation of androgen receptor by HER-2 and Ack1 tyrosine kinases - ARRA

  2/1/2008 - 12/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 245,390.00

• 376.

  Young Whang; H Shelton Earp

  Regulation of androgen receptor by HER-2 and Ack1 tyrosine kinases - ARRA

  2/1/2008 - 12/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 27,265.00

• 377.

  Bill Marzluff

  A Novel Factor Involved in Translation of Histone mRNA and Subsets of PolyA mRNA

  2/1/2008 - 6/14/2009

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 49,646.00

• 378.

  Jonathan Serody

  The role of the chemokine receptor CCR4 and CCR7 in graft-versus-host disease

  2/1/2008 - 6/30/2009

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 58,886.00

• 379.

  Jonathan Serody

  The role of the chemokine receptor CCR4 and CCR7 in graft-versus-host disease

  2/1/2008 - 6/30/2009

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 25,190.00

• 380.

  Jonathan Serody

  The role of the chemokine receptor CCR4 and CCR7 in graft-versus-host disease

  2/1/2008 - 6/30/2009

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 215.00

• 381.

  Bill Marzluff

  A Novel Factor Involved in Translation of Histone mRNA and Subsets of PolyA mRNA

  2/1/2008 - 6/14/2009

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 14,782.00

• 382.

  Bill Marzluff

  A Novel Factor Involved in Translation of Histone mRNA and Subsets of PolyA mRNA

  2/1/2008 - 6/14/2009

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 108.00

• 383.

  Young Whang; Shelton Earp

  Regulation of androgen receptor by HER-2 and Ack1 tyrosine kinases - ARRA

  2/1/2008 - 12/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 245,390.00

• 384.

  Young Whang; Shelton Earp

  Regulation of androgen receptor by HER-2 and Ack1 tyrosine kinases - ARRA

  2/1/2008 - 12/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 19,086.00

• 385.

  Young Whang; Shelton Earp

  Regulation of androgen receptor by HER-2 and Ack1 tyrosine kinases - ARRA

  2/1/2008 - 12/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 238,028.00

• 386.

  Young Whang; Shelton Earp

  Regulation of androgen receptor by HER-2 and Ack1 tyrosine kinases - ARRA

  2/1/2008 - 12/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 26,448.00

• 387.

  Jonathan Serody

  GlycoMimetics Inc Service Agreement

  1/1/2008 - 8/31/2008

  Sponsor: Industry Sponsor

  Funding: $ 111,744.00

• 388.

  Thomas Shea; Julia Whitley

  265 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evalua

  12/28/2007 - 12/27/2010

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 389.

  Thomas Shea; Julia Whitley

  265 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evalua

  12/28/2007 - 12/27/2010

  Sponsor: Industry Sponsor

  Funding: $ 3,000.00

• 390.

  Thomas Shea; Julia Whitley

  265 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evalua

  12/28/2007 - 12/27/2010

  Sponsor: Industry Sponsor

  Funding: $ 15,748.00

• 391.

  Thomas Shea; Julia Whitley

  265 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evalua

  12/28/2007 - 12/27/2010

  Sponsor: Industry Sponsor

  Funding: $ 11,811.00

• 392.

  Thomas Shea; Julia Whitley

  265 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evalua

  12/28/2007 - 12/27/2010

  Sponsor: Industry Sponsor

  Funding: $ 15,748.00

• 393.

  Thomas Shea; Julia Whitley

  265 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evalua

  12/28/2007 - 12/27/2010

  Sponsor: Industry Sponsor

  Funding: $ 3,937.00

• 394.

  Thomas Shea; Julia Whitley

  265 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evalua

  12/28/2007 - 12/27/2010

  Sponsor: Industry Sponsor

  Funding: $ 11,817.00

• 395.

  Thomas Shea

  EM-1421-105 Phase I Study of Terameprocol (EM-1421), a Survivin and Cyclin-Dep

  12/11/2007 - 12/10/2010

  Sponsor: Industry Sponsor

  Funding: $ 12,112.00

• 396.

  Thomas Shea

  EM-1421-105 Phase I Study of Terameprocol (EM-1421), a Survivin and Cyclin-Dep

  12/11/2007 - 12/10/2010

  Sponsor: Industry Sponsor

  Funding: $ 948.00

• 397.

  Thomas Shea

  EM-1421-105 Phase I Study of Terameprocol (EM-1421), a Survivin and Cyclin-Dep

  12/11/2007 - 12/10/2010

  Sponsor: Industry Sponsor

  Funding: $ 16,149.00

• 398.

  Thomas Shea

  EM-1421-105 Phase I Study of Terameprocol (EM-1421), a Survivin and Cyclin-Dep

  12/11/2007 - 12/10/2010

  Sponsor: Industry Sponsor

  Funding: $ 25,285.00

• 399.

  Thomas Shea

  iCLO086 A Non-randomized Dose Escalation Study of Clofarabine in Combination w

  10/10/2007 - 10/9/2010

  Sponsor: Industry Sponsor

  Funding: $ 12,112.00

• 400.

  Thomas Shea

  iCLO086 A Non-randomized Dose Escalation Study of Clofarabine in Combination w

  10/10/2007 - 10/9/2010

  Sponsor: Industry Sponsor

  Funding: $ 21,083.00

• 401.

  Thomas Shea

  iCLO086 A Non-randomized Dose Escalation Study of Clofarabine in Combination w

  10/10/2007 - 10/9/2010

  Sponsor: Industry Sponsor

  Funding: $ 21,083.00

• 402.

  Thomas Shea

  iCLO086 A Non-randomized Dose Escalation Study of Clofarabine in Combination w

  10/10/2007 - 10/9/2010

  Sponsor: Industry Sponsor

  Funding: $ 46,383.00

• 403.

  Rich Goldberg

  ETAB-1 Longitudinal Evaluation of Cancer-related Symptoms and Quality of Life:

  10/3/2007 - 10/2/2010

  Sponsor: Duke University Medical Center

  Funding: $ 8,958.00

• 404.

  William Marston; Joseph Fulton; Robert Mendes; Thomas Shea; Nicolle Lemire

  UABI-55-0610-1 Use of TRC Autologous Bone Marrow Cells in Patients with Perip

  10/2/2007 - 10/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 11,164.00

• 405.

  William Marston; Joseph Fulton; Robert Mendes; Thomas Shea; Nicolle Lemire

  UABI-55-0610-1 Use of TRC Autologous Bone Marrow Cells in Patients with Perip

  10/2/2007 - 10/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 1,896.00

• 406.

  William Marston; Joseph Fulton; Robert Mendes; Thomas Shea; Nicolle Lemire

  UABI-55-0610-1 Use of TRC Autologous Bone Marrow Cells in Patients with Perip

  10/2/2007 - 10/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 2,022.00

• 407.

  William Marston; Joseph Fulton; Robert Mendes; Thomas Shea; Nicolle Lemire

  UABI-55-0610-1 Use of TRC Autologous Bone Marrow Cells in Patients with Perip

  10/2/2007 - 10/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 19,147.00

• 408.

  William Marston; Joseph Fulton; Robert Mendes; Thomas Shea; Nicolle Lemire

  UABI-55-0610-1 Use of TRC Autologous Bone Marrow Cells in Patients with Perip

  10/2/2007 - 10/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 12,311.00

• 409.

  William Marston; Joseph Fulton; Robert Mendes; Thomas Shea; Nicolle Lemire

  UABI-55-0610-1 Use of TRC Autologous Bone Marrow Cells in Patients with Perip

  10/2/2007 - 10/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 10,421.00

• 410.

  William Marston; Joseph Fulton; Robert Mendes; Thomas Shea; Nicolle Lemire

  UABI-55-0610-1 Use of TRC Autologous Bone Marrow Cells in Patients with Perip

  10/2/2007 - 10/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 6,455.00

• 411.

  William Marston; Joseph Fulton; Robert Mendes; Thomas Shea; Nicolle Lemire

  UABI-55-0610-1 Use of TRC Autologous Bone Marrow Cells in Patients with Perip

  10/2/2007 - 10/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 1,346.00

• 412.

  William Marston; Joseph Fulton; Robert Mendes; Thomas Shea; Nicolle Lemire

  UABI-55-0610-1 Use of TRC Autologous Bone Marrow Cells in Patients with Perip

  10/2/2007 - 10/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 1,282.00

• 413.

  William Marston; Joseph Fulton; Robert Mendes; Thomas Shea; Nicolle Lemire

  UABI-55-0610-1 Use of TRC Autologous Bone Marrow Cells in Patients with Perip

  10/2/2007 - 10/1/2010

  Sponsor: Industry Sponsor

  Funding: $ 2,472.00

• 414.

  Frank Church; William Kim; Dougald Monroe; Norman Sharpless; Herbert Whinna

  p16INK4a, Senescence and Aging in Venous Thromboembolism

  9/30/2007 - 8/31/2010

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 196,249.00

• 415.

  Frank Church; William Kim; Dougald Monroe; Norman Sharpless; Herbert Whinna

  p16INK4a, Senescence and Aging in Venous Thromboembolism

  9/30/2007 - 8/31/2010

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 160,105.00

• 416.

  Barbara Entwisle; Nancy Dole; Anna Maria Siega-Riz; Jane Brown; Giselle Corbie-Smith; Amy Herring; Andrew Olshan; Lisa Pearce; David Peden; John Thorp

  Study Centers for the National Childrens Study

  9/28/2007 - 9/27/2012

  Sponsor: NIH National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDKD)

  Funding: $ 1,246,137.00

• 417.

  Barbara Entwisle; Nancy Dole; Anna Maria Siega-Riz; Jane Brown; Giselle Corbie-Smith; Amy Herring; Andrew Olshan; Lisa Pearce; David Peden; John Thorp

  Study Centers for the National Children’s Study

  9/28/2007 - 9/27/2012

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 1,246,137.00

• 418.

  Barbara Entwisle; Nancy Dole; Anna Maria Siega-Riz; Jane Brown; Giselle Corbie-Smith; Amy Herring; Andrew Olshan; Lisa Pearce; David Peden; John Thorp

  Study Centers for the National Children’s Study

  9/28/2007 - 9/27/2012

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 462,503.00

• 419.

  Barbara Entwisle; Nancy Dole; Anna Maria Siega-Riz; Jane Brown; Giselle Corbie-Smith; Amy Herring; Andrew Olshan; Lisa Pearce; David Peden; John Thorp

  Study Centers for the National Children’s Study

  9/28/2007 - 9/27/2012

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 2,431,038.00

• 420.

  Barbara Entwisle; Nancy Dole; Anna Maria Siega-Riz; Jane Brown; Giselle Corbie-Smith; Amy Herring; Andrew Olshan; Lisa Pearce; David Peden; John Thorp

  Study Centers for the National Children’s Study

  9/28/2007 - 9/27/2012

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 2,122,082.00

• 421.

  Barbara Entwisle; Nancy Dole; Anna Maria Siega-Riz; Jane Brown; Giselle Corbie-Smith; Amy Herring; Andrew Olshan; Lisa Pearce; David Peden; John Thorp

  Study Centers for the National Children’s Study

  9/28/2007 - 9/27/2012

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 2,408,204.00

• 422.

  Gail Henderson; Jonathan Berg; Jean Cadigan; John Conley; Giselle Corbie-Smith; Arlene Davis; Lynn Dressler; James Evans; Eric Juengst; Daniel Nelson; Cynthia Powell; Christine Rini; Myra Roche; Malika Roman Isler; Debra Skinner; Marcia Van Riper; Rebecca Walker

  Center for Genomics and Society

  9/27/2007 - 4/30/2013

  Sponsor: NIH National Human Genome Research Institute (NHGRI)

  Funding: $ 878,079.00

• 423.

  Norman Sharpless; Richard Goldberg; Paul Godley

  UNC Oncology Clinical Translational Research Training Program

  9/17/2007 - 8/31/2017

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 214,609.00

• 424.

  Norman Sharpless; Richard Goldberg; Kristy Richards

  UNC Oncology Clinical Translational Research Training Program

  9/17/2007 - 8/31/2017

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 443,266.00

• 425.

  Norman Sharpless; Richard Goldberg; Carey Anders; Kristy Richards

  UNC Oncology Clinical Translational Research Training Program

  9/17/2007 - 8/31/2017

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 376,271.00

• 426.

  Thomas Shea

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 9,922.00

• 427.

  Thomas Shea; Paula McIver

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 12,581.00

• 428.

  Thomas Shea

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 16,020.00

• 429.

  Thomas Shea

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 3,950.00

• 430.

  Thomas Shea

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 13,078.00

• 431.

  Thomas Shea

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 7,240.00

• 432.

  Thomas Shea

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 6,456.00

• 433.

  Thomas Shea

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 8,498.00

• 434.

  Thomas Shea

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 435.

  Thomas Shea

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 6,880.00

• 436.

  Thomas Shea

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 2,029.00

• 437.

  Thomas Shea

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 6,569.00

• 438.

  Thomas Shea

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 2,502.00

• 439.

  Thomas Shea

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 4,769.00

• 440.

  Thomas Shea

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 4,645.00

• 441.

  Thomas Shea

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 3,601.00

• 442.

  Thomas Shea

  CAMN107A2303 A phase III multi-center, open-label, randomized study of imatin

  9/17/2007 - 10/1/2014

  Sponsor: Industry Sponsor

  Funding: $ 565.00

• 443.

  Norman Sharpless; Richard Goldberg; Kristy Richards

  UNC Oncology Clinical Translational Research Training Program

  9/17/2007 - 8/31/2017

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 443,266.00

• 444.

  Norman Sharpless; Richard Goldberg; Carey Anders; James Coghill

  UNC Oncology Clinical Translational Research Training Program

  9/17/2007 - 8/31/2017

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 449,324.00

• 445.

  Norman Sharpless; Richard Goldberg

  UNC Oncology Clinical Translational Research Training Program

  9/17/2007 - 8/31/2017

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 268,027.00

• 446.

  Norman Sharpless

  UNC Oncology Clinical Translational Research Training Program

  9/17/2007 - 8/31/2017

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 574,664.00

• 447.

  William Kaufmann; James Bear; Marila Cordeiro-Stone; Allison Deal; Timothy Elston; Pamela Groben; Xiaojun Guan; Joseph Ibrahim; Clark Jeffries; Zhi Liu; David Ollila; Aziz Sancar; Norman Sharpless; Dennis Simpson; Nancy Thomas

  The System of Response to DNA Damage Suppresses Environmental Melanomagenesis

  9/10/2007 - 4/30/2013

  Sponsor: NIH National Institute of Environmental Health Sciences (NIEHS)

  Funding: $ 1,318,947.00

• 448.

  William Kaufmann; James Bear; Haitao Chu; Marila Cordeiro-Stone; Timothy Elston; Pamela Groben; Joseph Ibrahim; Clark Jeffries; David Ollila; Aziz Sancar; Norman Sharpless; Janiel Shields; Dennis Simpson; Nancy Thomas

  The System of Response to DNA Damage Suppresses Environmental Melanomagenesis

  9/10/2007 - 4/30/2013

  Sponsor: NIH National Institute of Environmental Health Sciences (NIEHS)

  Funding: $ 1,359,917.00

• 449.

  William Kaufmann; James Bear; Haitao Chu; Marila Cordeiro-Stone; Timothy Elston; Pamela Groben; Joseph Ibrahim; Clark Jeffries; Pei-Fen Kuan; David Ollila; Aziz Sancar; Norman Sharpless; Janiel Shields; Dennis Simpson; Nancy Thomas

  The System of Response to DNA Damage Suppresses Environmental Melanomagenesis

  9/10/2007 - 4/30/2013

  Sponsor: NIH National Institute of Environmental Health Sciences (NIEHS)

  Funding: $ 1,373,029.00

• 450.

  Bill Marzluff; Eric Wagner

  Eric J. Wagner/Fellow Characterizing Novel Components Involved in 3' edn Process

  9/3/2007 - 7/31/2008

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 89,177.00

• 451.

  Bryan Weiner; Lisa Carey; William Carpenter; Marisa Domino; Paul Godley; Richard Goldberg; Shoou-Yih Lee; George Pink; Kristin Reiter; Mark Socinski

  Implementing Systemic Interventions to Close the Discovery-Delivery Gap

  8/15/2007 - 5/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 490,318.00

• 452.

  Bryan Weiner; Lisa Carey; William Carpenter; Paul Godley

  Implementing Systemic Interventions to Close the Discovery-Delivery Gap

  8/15/2007 - 5/31/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 530,568.00

• 453.

  Nancy Raab-Traub

  The role of EBV encoded miRNAs in lymphoproliferative disorders

  7/1/2007 - 6/30/2010

  Sponsor: Leukemia and Lymphoma Society (LLS)

  Funding: $ 50,000.00

• 454.

  Nancy Raab-Traub

  The role of EBV encoded miRNAs in lymphoproliferative disorders

  7/1/2007 - 6/30/2010

  Sponsor: Leukemia and Lymphoma Society (LLS)

  Funding: $ 100,000.00

• 455.

  Gary Johnson

  Regulation and Function of the Cerebral Cavernous Malformation 2 Protein

  7/1/2007 - 4/30/2009

  Sponsor: AHA Mid-Atlantic Affiliate (DC, MD, NC, SC, VA)

  Funding: $ 40,000.00

• 456.

  Norman Sharpless; Hanna Sanoff

  The p16INK4a tumor suppressor in stem cell aging

  7/1/2007 - 6/30/2013

  Sponsor: Burroughs Wellcome Fund

  Funding: $ 750,000.00

• 457.

  Bill Marzluff

  FELLOW:STEINIGER, MINDY-Histone pre-mRNA processing in Drosophila Melanogaster

  7/1/2007 - 12/14/2008

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 52,898.00

• 458.

  David Peden; Neil Alexis; William Bennett; Ilona Jaspers; Terry Noah; Jenny Ting; Weidong Wu; Haibo Zhou; Willie Brickey; Philip Bromberg; Johnny Carson; Bradford Harris; Milan Hazucha; Alan Hinderliter; John Lay; William Reed; Robert Roubey; William Sanders; Mirek Styblo; Stephen Tilley; Margaret Sanders

  Human Health Effects of Environmental Pollutants

  7/1/2007 - 1/31/2015

  Sponsor: United States Environmental Protection Agency (EPA)

  Funding: $ 537,035.00

• 459.

  David Peden; Neil Alexis; William Bennett; Ilona Jaspers; Terry Noah; Jenny Ting; Weidong Wu; Haibo Zhou; Willie Brickey; Philip Bromberg; Johnny Carson; Bradford Harris; Milan Hazucha; Alan Hinderliter; John Lay; William Reed; Robert Roubey; William Sanders; Mirek Styblo; Stephen Tilley; Margaret Sanders

  Human Health Effects of Environmental Pollutants

  7/1/2007 - 1/31/2015

  Sponsor: United States Environmental Protection Agency (EPA)

  Funding: $ 676,650.00

• 460.

  David Peden; Neil Alexis; William Bennett; Ilona Jaspers; Terry Noah; Jenny Ting; Weidong Wu; Haibo Zhou; Willie Brickey; Philip Bromberg; Johnny Carson; Bradford Harris; Milan Hazucha; Alan Hinderliter; John Lay; William Reed; Robert Roubey; William Sanders; Mirek Styblo; Stephen Tilley; Margaret Sanders

  Human Health Effects of Environmental Pollutants

  7/1/2007 - 1/31/2015

  Sponsor: United States Environmental Protection Agency (EPA)

  Funding: $ 1,096,064.00

• 461.

  David Peden; Neil Alexis; William Bennett; Ilona Jaspers; Terry Noah; Jenny Ting; Weidong Wu; Haibo Zhou; Willie Brickey; Philip Bromberg; Johnny Carson; Bradford Harris; Milan Hazucha; Alan Hinderliter; John Lay; William Reed; Robert Roubey; William Sanders; Mirek Styblo; Stephen Tilley; Margaret Sanders

  Human Health Effects of Environmental Pollutants

  7/1/2007 - 1/31/2015

  Sponsor: United States Environmental Protection Agency (EPA)

  Funding: $ 565,256.00

• 462.

  David Peden; Neil Alexis; William Bennett; Ilona Jaspers; Terry Noah; Jenny Ting; Weidong Wu; Haibo Zhou; Willie Brickey; Philip Bromberg; Johnny Carson; Bradford Harris; Milan Hazucha; Alan Hinderliter; John Lay; William Reed; Robert Roubey; William Sanders; Mirek Styblo; Stephen Tilley; Margaret Sanders

  Human Health Effects of Environmental Pollutants

  7/1/2007 - 1/31/2015

  Sponsor: United States Environmental Protection Agency (EPA)

  Funding: $ 220,319.00

• 463.

  David Peden; Neil Alexis; William Bennett; Ilona Jaspers; Terry Noah; Jenny Ting; Weidong Wu; Haibo Zhou; Willie Brickey; Philip Bromberg; Johnny Carson; Bradford Harris; Milan Hazucha; Alan Hinderliter; John Lay; William Reed; Robert Roubey; William Sanders; Mirek Styblo; Stephen Tilley; Margaret Sanders

  Human Health Effects of Environmental Pollutants

  7/1/2007 - 1/31/2015

  Sponsor: United States Environmental Protection Agency (EPA)

  Funding: $ 60,000.00

• 464.

  David Peden; Neil Alexis; William Bennett; Ilona Jaspers; Terry Noah; Jenny Ting; Weidong Wu; Haibo Zhou; Willie Brickey; Philip Bromberg; Johnny Carson; Bradford Harris; Milan Hazucha; Alan Hinderliter; John Lay; William Reed; Robert Roubey; William Sanders; Mirek Styblo; Stephen Tilley; Margaret Sanders

  Human Health Effects of Environmental Pollutants

  7/1/2007 - 1/31/2015

  Sponsor: United States Environmental Protection Agency (EPA)

  Funding: $ 260,878.00

• 465.

  David Peden; Neil Alexis; William Bennett; Ilona Jaspers; Terry Noah; Jenny Ting; Weidong Wu; Haibo Zhou; Willie Brickey; Philip Bromberg; Johnny Carson; Bradford Harris; Milan Hazucha; Alan Hinderliter; John Lay; William Reed; Robert Roubey; William Sanders; Mirek Styblo; Stephen Tilley; Margaret Sanders

  Human Health Effects of Environmental Pollutants

  7/1/2007 - 1/31/2015

  Sponsor: United States Environmental Protection Agency (EPA)

  Funding: $ 700,000.00

• 466.

  David Peden; Neil Alexis; William Bennett; Ilona Jaspers; Terry Noah; Jenny Ting; Weidong Wu; Haibo Zhou; Willie Brickey; Philip Bromberg; Johnny Carson; Bradford Harris; Milan Hazucha; Alan Hinderliter; John Lay; William Reed; Robert Roubey; William Sanders; Mirek Styblo; Stephen Tilley; Margaret Sanders

  Human Health Effects of Environmental Pollutants

  7/1/2007 - 1/31/2015

  Sponsor: United States Environmental Protection Agency (EPA)

  Funding: $ 693,186.00

• 467.

  David Peden; Neil Alexis; William Bennett; Ilona Jaspers; Terry Noah; Jenny Ting; Weidong Wu; Haibo Zhou; Willie Brickey; Philip Bromberg; Johnny Carson; Bradford Harris; Milan Hazucha; Alan Hinderliter; John Lay; William Reed; Robert Roubey; William Sanders; Mirek Styblo; Stephen Tilley; Margaret Sanders

  Human Health Effects of Environmental Pollutants

  7/1/2007 - 1/31/2015

  Sponsor: United States Environmental Protection Agency (EPA)

  Funding: $ 460,000.00

• 468.

  David Peden; Neil Alexis; William Bennett; Ilona Jaspers; Terry Noah; Jenny Ting; Weidong Wu; Haibo Zhou; Willie Brickey; Philip Bromberg; Johnny Carson; Bradford Harris; Milan Hazucha; Alan Hinderliter; John Lay; William Reed; Robert Roubey; William Sanders; Mirek Styblo; Stephen Tilley; Margaret Sanders

  Human Health Effects of Environmental Pollutants

  7/1/2007 - 1/31/2015

  Sponsor: United States Environmental Protection Agency (EPA)

  Funding: $ 418,000.00

• 469.

  David Peden; Neil Alexis; William Bennett; Ilona Jaspers; Terry Noah; Jenny Ting; Weidong Wu; Haibo Zhou; Willie Brickey; Philip Bromberg; Johnny Carson; Bradford Harris; Milan Hazucha; Alan Hinderliter; John Lay; William Reed; Robert Roubey; William Sanders; Mirek Styblo; Stephen Tilley; Margaret Sanders

  Human Health Effects of Environmental Pollutants

  7/1/2007 - 1/31/2015

  Sponsor: United States Environmental Protection Agency (EPA)

  Funding: $ 584,623.00

• 470.

  Marion Couch; Michael Hudgens; Jonathan Serody; Michael Stadler; Xiaoying Yin

  Effects of TLRs 4 and 9 on Allogeneic Whole Cell GM-CSF-Secreting Tumor Vaccine

  7/1/2007 - 6/30/2009

  Sponsor: American Academy of Otolaryngic Allergy (AAOA)

  Funding: $ 11,000.00

• 471.

  Bill Marzluff

  FELLOW:STEINIGER, MINDY-Histone pre-mRNA processing in Drosophila Melanogaster

  7/1/2007 - 12/14/2008

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 25,332.00

• 472.

  Thomas Shea

  CPTK787AUS39 Phase II Open Label Study PTK787/ZK222584 in Adult Patients with

  6/28/2007 - 6/27/2010

  Sponsor: Duke University Medical Center

  Funding: $ 9,562.00

• 473.

  Blossom Damania; Dirk Dittmer; Jenny Ting

  Innate Immunity and KSHV

  6/1/2007 - 5/31/2017

  Sponsor: NIH National Institute of Dental and Craniofacial Research (NIDCR)

  Funding: $ 335,090.00

• 474.

  Blossom Damania; Dirk Dittmer; Jenny Ting

  Innate Immunity and KSHV

  6/1/2007 - 5/31/2017

  Sponsor: NIH National Institute of Dental and Craniofacial Research (NIDCR)

  Funding: $ 328,089.00

• 475.

  Blossom Damania; Jenny Ting

  Innate Immunity and KSHV

  6/1/2007 - 5/31/2017

  Sponsor: NIH National Institute of Dental and Craniofacial Research (NIDCR)

  Funding: $ 365,968.00

• 476.

  Norman Sharpless

  The Role of Somatic Inactivation of p16 INK4a in Ras-driven Melanoma

  6/1/2007 - 5/31/2009

  Sponsor: National Cancer Center

  Funding: $ 25,000.00

• 477.

  Norman Sharpless

  The Role of Somatic Inactivation of p16 INK4a in Ras-driven Melanoma

  6/1/2007 - 5/31/2009

  Sponsor: National Cancer Center

  Funding: $ 25,000.00

• 478.

  Gary Johnson

  PHERAstar Multiple Reader for HTS Development

  6/1/2007 - 5/31/2008

  Sponsor: North Carolina Biotechnology Center (NCBC)

  Funding: $ 66,960.00

• 479.

  Terry Magnuson

  FELLOW:NICHOLAS OSBORNE- Role of PBAF-specific subunit BAF200 in blood vessel

  5/18/2007 - 5/17/2010

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 58,886.00

• 480.

  Terry Magnuson

  The Role of the PBAF-Specific subunit BAF200 in blood vessel formation

  5/18/2007 - 5/17/2010

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 49,646.00

• 481.

  Terry Magnuson

  The role of the PBAF-specific subunit BAF200 in blood vessel formation

  5/18/2007 - 5/17/2010

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 51,710.00

• 482.

  Rich Goldberg

  CRAD001C2242 An open-label, multicenter Phase 1 study investigating the combin

  5/15/2007 - 6/30/2009

  Sponsor: Industry Sponsor

  Funding: $ 9,584.00

• 483.

  Sundeep Kalantry; Terry Magnuson

  Epigenetic Mechanism of X-chromosome Inactivation

  4/12/2007 - 3/31/2010

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 82,101.00

• 484.

  Mark Heise; Jonathan Serody; Laura White

  Arbovirus Evasion of Type I Interferon Induction

  4/1/2007 - 3/31/2009

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 177,589.00

• 485.

  Andrew Olshan; Jianwen Cai

  Quality of Life Among African-American Head and Neck Cancer Survivors

  4/1/2007 - 3/31/2011

  Sponsor: Lance Armstrong Foundation

  Funding: $ 81,837.00

• 486.

  Andrew Olshan; Jianwen Cai

  Quality of Life Among African-American Head and Neck Cancer Survivors

  4/1/2007 - 3/31/2011

  Sponsor: Lance Armstrong Foundation

  Funding: $ 82,435.00

• 487.

  Andrew Olshan; Jianwen Cai

  Quality of Life Among African-American Head and Neck Cancer Survivors

  4/1/2007 - 3/31/2011

  Sponsor: Lance Armstrong Foundation

  Funding: $ 82,488.00

• 488.

  Thomas Shea; Julia Whitley

  Weekly Subcutaneous Efalizumab for the Treatment of Steroid Refractory Graft-Ver

  3/30/2007 - 3/15/2008

  Sponsor: Industry Sponsor

  Funding: $ 11,592.00

• 489.

  Jenny Ting; Willie Brickey

  YopM and protective innate defenses against plague

  3/16/2007 - 2/28/2011

  Sponsor: University of Kentucky (UK)

  Funding: $ 30,000.00

• 490.

  Jenny Ting; Willie Brickey

  YopM and protective innate defenses against plague

  3/16/2007 - 2/28/2011

  Sponsor: University of Kentucky (UK)

  Funding: $ 30,178.00

• 491.

  Jenny Ting; Willie Brickey

  YopM and protective innate defenses against plague

  3/16/2007 - 2/28/2011

  Sponsor: University of Kentucky (UK)

  Funding: $ 31,913.00

• 492.

  Lisa Carey

  Ph II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Recept

  2/5/2007 - 10/24/2009

  Sponsor: Industry Sponsor

  Funding: $ 5,056.00

• 493.

  Lisa Carey

  Ph II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Recept

  2/5/2007 - 10/24/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 494.

  Lisa Carey

  Ph II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Recept

  2/5/2007 - 10/24/2009

  Sponsor: Industry Sponsor

  Funding: $ 1,912.00

• 495.

  Lisa Carey

  Ph II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Recept

  2/5/2007 - 10/24/2009

  Sponsor: Industry Sponsor

  Funding: $ 3,406.00

• 496.

  Lisa Carey

  Ph II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Recept

  2/5/2007 - 10/24/2009

  Sponsor: Industry Sponsor

  Funding: $ 3,825.00

• 497.

  Lisa Carey

  Ph II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Recept

  2/5/2007 - 10/24/2009

  Sponsor: Industry Sponsor

  Funding: $ 10,066.00

• 498.

  Lisa Carey

  Ph II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Recept

  2/5/2007 - 10/24/2009

  Sponsor: Industry Sponsor

  Funding: $ 7,056.00

• 499.

  Lisa Carey

  Ph II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Recept

  2/5/2007 - 10/24/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,247.00

• 500.

  Lisa Carey

  Ph II Study of Dasatinib (BMS-354825) for Advanced Estrogen/Progesterone Recept

  2/5/2007 - 10/24/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,384.00

• 501.

  Thomas Shea

  PRI-104 R,Blinded,MC Stdy of Proteinase 3 PR1 Peptide Mixed w/Montanide ISA-51

  1/30/2007 - 1/29/2010

  Sponsor: Industry Sponsor

  Funding: $ 9,625.00

• 502.

  Thomas Shea

  PRI-104 R,Blinded,MC Stdy of Proteinase 3 PR1 Peptide Mixed w/Montanide ISA-51

  1/30/2007 - 1/29/2010

  Sponsor: Industry Sponsor

  Funding: $ 12,112.00

• 503.

  Marci Campbell; Marilie Gammon; Paul Godley; Merle Mishel; Thomas Shea

  Deductive Qualitative Study of the Lance Armstrong Foundation Centers of Excelle

  1/1/2007 - 12/31/2011

  Sponsor: Lance Armstrong Foundation

  Funding: $ 400,000.00

• 504.

  Marci Campbell; Marilie Gammon; Paul Godley; Merle Mishel; Thomas Shea

  Deductive Qualitative Study of the Lance Armstrong Foundation Centers of Excelle

  1/1/2007 - 12/31/2011

  Sponsor: Lance Armstrong Foundation

  Funding: $ 249,932.00

• 505.

  Amy Herring; Andrew Olshan

  Consequences and Course of Uterine Fibroids in Pregnancy

  1/1/2007 - 12/31/2008

  Sponsor: Vanderbilt University Medical Center

  Funding: $ 224,113.00

• 506.

  Amy Herring; Andrew Olshan

  Consequences and Course of Uterine Fibroids in Pregnancy

  1/1/2007 - 12/31/2008

  Sponsor: Vanderbilt University Medical Center

  Funding: $ 10,448.00

• 507.

  Andrew Olshan; Amy Herring; Michele Jonsson-Funk

  Non-steroidal Anti-Inflammatory Use and Miscarriage

  1/1/2007 - 2/28/2009

  Sponsor: Vanderbilt University Medical Center

  Funding: $ 47,571.00

• 508.

  Andrew Olshan; Amy Herring; Michele Jonsson-Funk

  Non-steroidal Anti-Inflammatory Use and Miscarriage

  1/1/2007 - 2/28/2009

  Sponsor: Vanderbilt University Medical Center

  Funding: $ 312,700.00

• 509.

  Andrew Olshan; Amy Herring; Michele Jonsson-Funk

  Non-steroidal Anti-Inflammatory Use and Miscarriage

  1/1/2007 - 2/28/2009

  Sponsor: Vanderbilt University Medical Center

  Funding: $ 51,925.00

• 510.

  Donald Rosenstein; Marilie Gammon; Paul Godley; Merle Mishel; Thomas Shea

  NC STRONG Center for Healthy Survivorships: Lineberger Lance Armstrong Center of Excellence and Community Partnerships

  1/1/2007 - 12/31/2012

  Sponsor: Lance Armstrong Foundation

  Funding: $ 220,000.00

• 511.

  Courtney Griffin; Terry Magnuson

  ATP-Dependent Chromatin-remodeling complexes and vascular development

  12/1/2006 - 9/24/2008

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 82,101.00

• 512.

  Thomas Shea

  CLBH589B2211 A phase II, multicentre study of oral LBH589 in patients with ac

  11/15/2006 - 1/31/2009

  Sponsor: Industry Sponsor

  Funding: $ 9,584.00

• 513.

  Lisa Carey

  Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast can

  11/1/2006 - 10/29/2009

  Sponsor: Industry Sponsor

  Funding: $ 5,000.00

• 514.

  Lisa Carey

  Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast can

  11/1/2006 - 10/29/2009

  Sponsor: Industry Sponsor

  Funding: $ 23,442.00

• 515.

  Lisa Carey

  Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast can

  11/1/2006 - 10/29/2009

  Sponsor: Industry Sponsor

  Funding: $ 4,741.00

• 516.

  Lisa Carey

  Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast can

  11/1/2006 - 10/29/2009

  Sponsor: Industry Sponsor

  Funding: $ 11,775.00

• 517.

  Lisa Carey

  Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast can

  11/1/2006 - 10/29/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,292.00

• 518.

  Lisa Carey

  Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast can

  11/1/2006 - 10/29/2009

  Sponsor: Industry Sponsor

  Funding: $ 10,629.00

• 519.

  Lisa Carey

  Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast can

  11/1/2006 - 10/29/2009

  Sponsor: Industry Sponsor

  Funding: $ 4,159.00

• 520.

  Lisa Carey

  Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast can

  11/1/2006 - 10/29/2009

  Sponsor: Industry Sponsor

  Funding: $ 720.00

• 521.

  Lisa Carey

  Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast can

  11/1/2006 - 10/29/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,489.00

• 522.

  Lisa Carey

  Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast can

  11/1/2006 - 10/29/2009

  Sponsor: Industry Sponsor

  Funding: $ 322.00

• 523.

  Lisa Carey

  Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast can

  11/1/2006 - 10/29/2009

  Sponsor: Industry Sponsor

  Funding: $ 3,001.00

• 524.

  Lisa Carey

  Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast can

  11/1/2006 - 10/29/2009

  Sponsor: Industry Sponsor

  Funding: $ 4,776.00

• 525.

  Lisa Carey; Emily Burrows

  AVON PRIME for Breast Cancer Research Consortium Activities

  10/1/2006 - 6/30/2012

  Sponsor: Johns Hopkins University

  Funding: $ 100,000.00

• 526.

  Lisa Carey; Emily Burrows

  AVON PRIME for Breast Cancer Research Consortium Activities

  10/1/2006 - 6/30/2012

  Sponsor: Johns Hopkins University

  Funding: $ 100,000.00

• 527.

  Bill Marzluff

  UNC-Chapel Hill Integrated Biomedical Research Training Program

  9/30/2006 - 7/31/2011

  Sponsor: NIH National Institute on Drug Abuse (NIDA)

  Funding: $ 73,956.00

• 528.

  Bill Marzluff

  UNC-Chapel Hill Integrated Biomedical Research Training Program

  9/30/2006 - 7/31/2011

  Sponsor: NIH National Institute on Drug Abuse (NIDA)

  Funding: $ 133,167.00

• 529.

  Bill Marzluff

  UNC-Chapel Hill Integrated Biomedical Research Training Program

  9/30/2006 - 7/31/2011

  Sponsor: NIH National Institute on Drug Abuse (NIDA)

  Funding: $ 151,751.00

• 530.

  Bill Marzluff

  UNC-Chapel Hill Integrated Biomedical Research Training Program

  9/30/2006 - 7/31/2011

  Sponsor: NIH National Institute on Drug Abuse (NIDA)

  Funding: $ 195,193.00

• 531.

  Bill Marzluff

  UNC-Chapel Hill Integrated Biomedical Research Training Program

  9/30/2006 - 7/31/2011

  Sponsor: NIH National Institute on Drug Abuse (NIDA)

  Funding: $ 151,751.00

• 532.

  Bill Marzluff

  UNC-Chapel Hill Integrated Biomedical Research Training Program

  9/30/2006 - 7/31/2011

  Sponsor: NIH National Institute on Drug Abuse (NIDA)

  Funding: $ 39,807.00

• 533.

  Bill Marzluff; Robert Dennis

  UNC-Chapel Hill Integrated Biomedical Research Training Program

  9/30/2006 - 7/31/2011

  Sponsor: NIH National Institute on Drug Abuse (NIDA)

  Funding: $ 192,359.00

• 534.

  Bill Marzluff; Robert Dennis; Timothy Elston

  UNC-Chapel Hill Integrated Biomedical Research Training Program

  9/30/2006 - 7/31/2011

  Sponsor: NIH National Institute on Drug Abuse (NIDA)

  Funding: $ 124,388.00

• 535.

  Andrew Olshan

  Control Selection Methods for Childhood Cancer Studies

  9/11/2006 - 7/31/2009

  Sponsor: Childrens Hospital of Philadelphia

  Funding: $ 5,805.00

• 536.

  Andrew Olshan

  Control Selection Methods for Childhood Cancer Studies

  9/11/2006 - 7/31/2009

  Sponsor: Childrens Hospital of Philadelphia

  Funding: $ 6,020.00

• 537.

  Andrew Olshan

  Control Selection Methods for Childhood Cancer Studies

  9/11/2006 - 7/31/2009

  Sponsor: Childrens Hospital of Philadelphia

  Funding: $ 6,256.00

• 538.

  Barbara Entwisle; Nancy Dole; Andrew Olshan

  Incorporating a Biomedical Perspective in Population-Based Research

  9/1/2006 - 8/31/2009

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 160,718.00

• 539.

  Jenny Ting

  Fellow:Iocca,Heather-Effects of cytokines of the TNF family on CNS remyelination

  8/1/2006 - 7/31/2009

  Sponsor: National Multiple Sclerosis Society (NMSS)

  Funding: $ 156,515.00

• 540.

  Lorraine Alexander; Andrew Olshan; Jane Schroeder

  Durham Epidemiologic Research & Information Center ERIC Notebook Writing, Produc

  8/1/2006 - 9/30/2008

  Sponsor: Durham Veterans Affairs Medical Center

  Funding: $ 61,808.00

• 541.

  Andrew Olshan

  Children's Cancer Research Network (CCRN)

  7/31/2006 - 7/30/2007

  Sponsor: National Childhood Cancer Foundation

  Funding: $ 19,237.00

• 542.

  Xiao Sha Chang; Adrienne Cox; Gary Johnson; Eric Schreiber; Otto Zhou

  Carbon Nanotube Field Emission Microbeam Array for Single Cell Irradiation

  7/14/2006 - 4/30/2009

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 133,519.00

• 543.

  Gary Johnson; Kazuhiro Nakamura

  Inhibitor Screens for Five MAPK Kinase Kinases Important in Human Disease

  7/1/2006 - 6/30/2008

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 182,500.00

• 544.

  Bill Marzluff; Stephen Rogers

  Screen for molecules inhibiting histone pre-mRNA processing

  7/1/2006 - 6/30/2007

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 73,000.00

• 545.

  Gary Johnson; Thomas Hilder

  Thomas L. Hilder/Fellow Proteomic Analysis of the Cerebral Cavernous Malformation Signaling Complex (Postdoctoral Fellowship)

  7/1/2006 - 6/30/2008

  Sponsor: AHA Mid-Atlantic Affiliate (DC, MD, NC, SC, VA)

  Funding: $ 70,000.00

• 546.

  Yue Xiong

  Animal Model For Human Small Cell Lung Cancer

  7/1/2006 - 6/30/2008

  Sponsor: American Lung Association

  Funding: $ 75,000.00

• 547.

  Yue Xiong

  Animal Model For Human Small Cell Lung Cancer

  7/1/2006 - 6/30/2008

  Sponsor: American Lung Association

  Funding: $ 75,000.00

• 548.

  Andrew Olshan

  Meningioma: Risk Factors and Quality of Life

  6/26/2006 - 3/31/2010

  Sponsor: Duke University Clinical Research Institute

  Funding: $ 46,755.00

• 549.

  Andrew Olshan

  Meningioma: Risk Factors and Quality of Life

  6/26/2006 - 3/31/2010

  Sponsor: Duke University Clinical Research Institute

  Funding: $ 97,757.00

• 550.

  Andrew Olshan

  Meningioma: Risk Factors and Quality of Life

  6/26/2006 - 3/31/2010

  Sponsor: Duke University Clinical Research Institute

  Funding: $ 51,090.00

• 551.

  Lisa Carey

  Novel Biomarkers for Aromatase Inhibitor Therapy

  6/1/2006 - 12/31/2006

  Sponsor: Washington University in Saint Louis

  Funding: $ 4,635.00

• 552.

  Thomas Shea

  Ph II random dbl blind placebo controlled trial of Velafermin for prevention of

  5/18/2006 - 5/17/2009

  Sponsor: Industry Sponsor

  Funding: $ 30,456.00

• 553.

  Thomas Shea

  Ph II random dbl blind placebo controlled trial of Velafermin for prevention of

  5/18/2006 - 5/17/2009

  Sponsor: Industry Sponsor

  Funding: $ 14,000.00

• 554.

  Thomas Shea

  Ph II random dbl blind placebo controlled trial of Velafermin for prevention of

  5/18/2006 - 5/17/2009

  Sponsor: Industry Sponsor

  Funding: $ 39,292.00

• 555.

  Thomas Shea

  Ph II random dbl blind placebo controlled trial of Velafermin for prevention of

  5/18/2006 - 5/17/2009

  Sponsor: Industry Sponsor

  Funding: $ 6,061.00

• 556.

  Thomas Shea

  Ph II random dbl blind placebo controlled trial of Velafermin for prevention of

  5/18/2006 - 5/17/2009

  Sponsor: Industry Sponsor

  Funding: $ 1,500.00

• 557.

  Thomas Shea

  Ph II random dbl blind placebo controlled trial of Velafermin for prevention of

  5/18/2006 - 5/17/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,030.00

• 558.

  Gary Johnson; Michael Malone

  Michael H. Malone/Fellow CCM proteins and vascular MAPK signal transduction

  5/15/2006 - 5/14/2009

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 43,996.00

• 559.

  Gary Johnson

  CCM proteins and vascular MAPK signal transduction

  5/15/2006 - 2/15/2008

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 45,976.00

• 560.

  Lisa Carey

  PH I IStudy of Lapatinib for Brain Metastases in Subjects w/ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and

  5/9/2006 - 5/8/2009

  Sponsor: Industry Sponsor

  Funding: $ 8,000.00

• 561.

  Lisa Carey

  PH I IStudy of Lapatinib for Brain Metastases in Subjects w/ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and

  5/9/2006 - 5/8/2009

  Sponsor: Industry Sponsor

  Funding: $ 2,000.00

• 562.

  Lisa Carey

  PH I IStudy of Lapatinib for Brain Metastases in Subjects w/ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and

  5/9/2006 - 5/8/2009

  Sponsor: Industry Sponsor

  Funding: $ 44,133.00

• 563.

  Lisa Carey

  PH I IStudy of Lapatinib for Brain Metastases in Subjects w/ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and

  5/9/2006 - 5/8/2009

  Sponsor: Industry Sponsor

  Funding: $ 3,635.00

• 564.

  Lisa Carey

  PH I IStudy of Lapatinib for Brain Metastases in Subjects w/ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and

  5/9/2006 - 5/8/2009

  Sponsor: Industry Sponsor

  Funding: $ 4,318.00

• 565.

  Lisa Carey

  PH I IStudy of Lapatinib for Brain Metastases in Subjects w/ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and

  5/9/2006 - 5/8/2009

  Sponsor: Industry Sponsor

  Funding: $ 4,469.00

• 566.

  Lisa Carey

  PH I IStudy of Lapatinib for Brain Metastases in Subjects w/ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and

  5/9/2006 - 5/8/2009

  Sponsor: Industry Sponsor

  Funding: $ 17,298.00

• 567.

  Jonathan Serody

  STTR--Blockade of NF-kB for prevention/treatment of GVHD

  5/1/2006 - 4/30/2007

  Sponsor: Industry Sponsor

  Funding: $ 112,046.00

• 568.

  Thomas Shea

  PH III, Dbl-Blind Trial of FavID (Id/KLH) & GM-CSF Following CHOP/Rituximab as First-Line Therapy in Subjs w/Hight-intermediate & High-risk

  4/28/2006 - 12/31/2010

  Sponsor: Industry Sponsor

  Funding: $ 605.00

• 569.

  Shelton Earp; Rebecca Cook

  An Anti-proliferative Role for HER4 in Breast Cancer

  4/7/2006 - 2/28/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 259,150.00

• 570.

  Shelton Earp

  An Anti-proliferative Role for HER4 in Breast Cancer

  4/7/2006 - 2/28/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 207,320.00

• 571.

  Shelton Earp

  An Anti-proliferative Role for HER4 in Breast Cancer

  4/7/2006 - 2/28/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 44,315.00

• 572.

  Shelton Earp

  An Anti-proliferative Role for HER4 in Breast Cancer

  4/7/2006 - 2/28/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 251,635.00

• 573.

  Shelton Earp

  An Anti-proliferative Role for HER4 in Breast Cancer

  4/7/2006 - 2/28/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 226,472.00

• 574.

  Shelton Earp

  An Anti-proliferative Role for HER4 in Breast Cancer

  4/7/2006 - 2/28/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 25,163.00

• 575.

  Shelton Earp

  An Anti-proliferative Role for HER4 in Breast Cancer

  4/7/2006 - 2/28/2013

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 251,635.00

• 576.

  Jenny Ting; Brian O'Connor

  Fellow:Brian O'Connor--CIITA regulation of plexin-A1 in dendritic cells

  4/1/2006 - 8/31/2008

  Sponsor: Cancer Research Institute

  Funding: $ 137,000.00

• 577.

  Terry Magnuson; Andrew Fedoriw

  Fellow:Andrew Fedoriw--Stem cell self-renewal in the mouse germline

  4/1/2006 - 3/31/2009

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 45,976.00

• 578.

  James Anderson; Albert Baldwin; William Coleman; Terry Magnuson; Sharon Milgram; Cam Patterson; Ryan Sartor; Jonathan Serody; Patricia Tidwell; Jenny Ting; Paul Watkins

  UNC-Chapel Hill Program in Translational Medicine

  4/1/2006 - 3/31/2011

  Sponsor: Howard Hughes Medical Institute

  Funding: $ 800,000.00

• 579.

  Terry Magnuson

  FELLOW:ANDREW FEDORIW-Stem Cell self-renewal in the mouse germline

  4/1/2006 - 3/31/2009

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 48,796.00

• 580.

  Terry Magnuson

  Fellow:Andrew Fedoriw--Stem cell self-renewal in the mouse germline

  4/1/2006 - 3/31/2009

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 51,278.00

• 581.

  Jenny Ting

  UNC SERCEB

  3/1/2006 - 2/29/2008

  Sponsor: Duke University

  Funding: $ 706,307.00

• 582.

  Jenny Ting

  UNC SERCEB

  3/1/2006 - 2/29/2008

  Sponsor: Duke University

  Funding: $ 292,000.00

• 583.

  Jenny Ting

  UNC SERCEB

  3/1/2006 - 2/29/2008

  Sponsor: Duke University

  Funding: $ 241,136.00

• 584.

  Jenny Ting

  UNC SERCEB

  3/1/2006 - 2/29/2008

  Sponsor: Duke University

  Funding: $ 73,953.00

• 585.

  Jenny Ting; Ralph Baric; Christoph Borchers; Jeffrey Frelinger; Robert Johnston; Robert Roubey; Lishan Su

  UNC SERCEB

  3/1/2006 - 2/29/2008

  Sponsor: Duke University

  Funding: $ 1,318,031.00

• 586.

  Jenny Ting; Aravinda Desilva

  UNC SERCEB

  3/1/2006 - 2/29/2008

  Sponsor: Duke University

  Funding: $ 57,726.00

• 587.

  Jenny Ting

  UNC SERCEB

  3/1/2006 - 2/29/2008

  Sponsor: Duke University

  Funding: $ 51,576.00

• 588.

  Jenny Ting

  UNC SERCEB

  3/1/2006 - 2/29/2008

  Sponsor: Duke University

  Funding: $ 1,850.00

• 589.

  Jenny Ting

  UNC SERCEB

  3/1/2006 - 2/29/2008

  Sponsor: Duke University

  Funding: $ 71,962.00

• 590.

  Rich Goldberg

  Open-Lbl, Multi-Center, PH II Trial of Neoadjuvant Irinotecan in Combination w/Infusional 5-FU, Leucovorin (Folfiri) Plus Bevacizumag in Pts w/Unres

  2/15/2006 - 2/14/2009

  Sponsor: Industry Sponsor

  Funding: $ 10,000.00

• 591.

  Thomas Shea

  PH I Study Eval Combined Zevalin (Ibritumomab Tiuxetan) & Velcde (bortezomib) in Relapsed/Refractory Low-grade or Follicular B-Cell and Mantl

  2/8/2006 - 2/7/2009

  Sponsor: Industry Sponsor

  Funding: $ 42,509.00

• 592.

  Thomas Shea

  PH I Study Eval Combined Zevalin (Ibritumomab Tiuxetan) & Velcde (bortezomib) in Relapsed/Refractory Low-grade or Follicular B-Cell and Mantl

  2/8/2006 - 2/7/2009

  Sponsor: Industry Sponsor

  Funding: $ 42,509.00

• 593.

  Thomas Shea

  PH I Study Eval Combined Zevalin (Ibritumomab Tiuxetan) & Velcde (bortezomib) in Relapsed/Refractory Low-grade or Follicular B-Cell and Mantl

  2/8/2006 - 2/7/2009

  Sponsor: Industry Sponsor

  Funding: $ 33,173.00

• 594.

  Gary Johnson; Ann Winter-Vann

  Ann M. Winter-Vann /Fellow Impact of the interaction between MEKK1 and Rho proteins on metastasis (Postdoctoral Fellowship)

  1/1/2006 - 10/19/2007

  Sponsor: American Cancer Society (ACS)

  Funding: $ 138,000.00

• 595.

  Bill Marzluff

  Phosphorylation Dependent Recognition of a Histone mRNA Hairpin by SLBP

  1/1/2006 - 12/31/2010

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 263,610.00

• 596.

  Bill Marzluff

  Phosphorylation Dependent Recognition of a Histone mRNA Hairpin by SLBP

  1/1/2006 - 12/31/2010

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 198,091.00

• 597.

  Bill Marzluff

  Phosphorylation Dependent Recognition of a Histone mRNA Hairpin by SLBP

  1/1/2006 - 12/31/2010

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 42,342.00

• 598.

  Bill Marzluff; Roopa Thapar

  Phosphorylation Dependent Recognition of a Histone mRNA Hairpin by SLBP

  1/1/2006 - 12/31/2010

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 192,346.00

• 599.

  Bill Marzluff; Roopa Thapar

  Phosphorylation Dependent Recognition of a Histone mRNA Hairpin by SLBP

  1/1/2006 - 12/31/2010

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 48,087.00

• 600.

  Bill Marzluff; Roopa Thapar

  Phosphorylation Dependent Recognition of a Histone mRNA Hairpin by SLBP

  1/1/2006 - 12/31/2010

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 216,390.00

• 601.

  Bill Marzluff; Roopa Thapar

  Phosphorylation Dependent Recognition of a Histone mRNA Hairpin by SLBP

  1/1/2006 - 12/31/2010

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 24,043.00

• 602.

  Lisa Carey

  Master Subcontract Agreement (Global Agreement) HHSN261200622008C

  1/1/2006 - 9/30/2011

  Sponsor: H Lee Moffitt Cancer and Research Institute

  Funding: $ 4,678.00

• 603.

  Lisa Carey

  Master Subcontract Agreement (Global Agreement) HHSN261200622008C

  1/1/2006 - 9/30/2011

  Sponsor: H Lee Moffitt Cancer and Research Institute

  Funding: $ 9,356.00

• 604.

  Lisa Carey

  Master Subcontract Agreement (Global Agreement) HHSN261200622008C

  1/1/2006 - 9/30/2011

  Sponsor: H Lee Moffitt Cancer and Research Institute

  Funding: $ 18,712.00

• 605.

  Lisa Carey

  Master Subcontract Agreement (Global Agreement) HHSN261200622008C

  1/1/2006 - 9/30/2011

  Sponsor: H Lee Moffitt Cancer and Research Institute

  Funding: $ 4,678.00

• 606.

  Lisa Carey

  Master Subcontract Agreement (Global Agreement) HHSN261200622008C

  1/1/2006 - 9/30/2011

  Sponsor: H Lee Moffitt Cancer and Research Institute

  Funding: $ 4,678.00

• 607.

  Lisa Carey

  Master Subcontract Agreement (Global Agreement) HHSN261200622008C

  1/1/2006 - 9/30/2011

  Sponsor: H Lee Moffitt Cancer and Research Institute

  Funding: $ 9,356.00

• 608.

  Lisa Carey

  Master Subcontract Agreement (Global Agreement) HHSN261200622008C

  1/1/2006 - 9/30/2011

  Sponsor: H Lee Moffitt Cancer and Research Institute

  Funding: $ 4,592.00

• 609.

  Lisa Carey

  Master Subcontract Agreement (Global Agreement) HHSN261200622008C

  1/1/2006 - 9/30/2011

  Sponsor: H Lee Moffitt Cancer and Research Institute

  Funding: $ 4,678.00

• 610.

  Lisa Carey

  Master Subcontract Agreement (Global Agreement) HHSN261200622008C

  1/1/2006 - 9/30/2011

  Sponsor: H Lee Moffitt Cancer and Research Institute

  Funding: $ 32,746.00

• 611.

  Lisa Carey

  Master Subcontract Agreement (Global Agreement) HHSN261200622008C

  1/1/2006 - 9/30/2011

  Sponsor: H Lee Moffitt Cancer and Research Institute

  Funding: $ 23,390.00

• 612.

  Lisa Carey

  Master Subcontract Agreement (Global Agreement) HHSN261200622008C

  1/1/2006 - 9/30/2011

  Sponsor: H Lee Moffitt Cancer and Research Institute

  Funding: $ 4,678.00

• 613.

  Lisa Carey

  Master Subcontract Agreement (Global Agreement) HHSN261200622008C

  1/1/2006 - 9/30/2011

  Sponsor: H Lee Moffitt Cancer and Research Institute

  Funding: $ 5,500.00

• 614.

  Lisa Carey

  Master Subcontract Agreement (Global Agreement) HHSN261200622008C

  1/1/2006 - 9/22/2013

  Sponsor: H Lee Moffitt Cancer and Research Institute

  Funding: $ 16,500.00

• 615.

  Lisa Carey

  Phase II Trial of Cetuximab Alone & in Combination with Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic BC

  12/6/2005 - 12/6/2008

  Sponsor: Industry Sponsor

  Funding: $ 48,000.00

• 616.

  Lisa Carey

  Phase II Trial of Cetuximab Alone & in Combination with Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic BC

  12/6/2005 - 12/6/2008

  Sponsor: Industry Sponsor

  Funding: $ 95,000.00

• 617.

  Lisa Carey

  Phase II Trial of Cetuximab Alone & in Combination with Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic BC

  12/6/2005 - 12/6/2008

  Sponsor: Industry Sponsor

  Funding: $ 109,000.00

• 618.

  Lisa Carey

  Phase II Trial of Cetuximab Alone & in Combination with Carboplatin in ER-Negative, PR-Negative, HER-2 Nonoverexpressing Metastatic BC

  12/6/2005 - 12/6/2008

  Sponsor: Industry Sponsor

  Funding: $ 42,348.00

• 619.

  Lisa Carey

  The Breast Cancer Clinical Trials Consortium

  10/1/2005 - 9/30/2007

  Sponsor: Johns Hopkins University

  Funding: $ 30,000.00

• 620.

  Lisa Carey

  BREAST CANCER RESEARCH FOUNDATION PRIME for Consortium Activities

  10/1/2005 - 9/30/2012

  Sponsor: Johns Hopkins University

  Funding: $ 100,000.00

• 621.

  Lisa Carey; Emily Burrows

  BREAST CANCER RESEARCH FOUNDATION PRIME for Consortium Activities

  10/1/2005 - 9/30/2012

  Sponsor: Johns Hopkins University

  Funding: $ 100,000.00

• 622.

  Lisa Carey

  BREAST CANCER RESEARCH FOUNDATION PRIME for Consortium Activities

  10/1/2005 - 9/30/2012

  Sponsor: Johns Hopkins University

  Funding: $ 28,500.00

• 623.

  Lisa Carey

  BREAST CANCER RESEARCH FOUNDATION PRIME for Consortium Activities

  10/1/2005 - 9/30/2012

  Sponsor: Johns Hopkins University

  Funding: $ 37,500.00

• 624.

  Lisa Carey; Amy Garrett

  BREAST CANCER RESEARCH FOUNDATION PRIME for Consortium Activities

  10/1/2005 - 9/30/2012

  Sponsor: Johns Hopkins University

  Funding: $ 37,500.00

• 625.

  Lisa Carey

  The Breast Cancer Clinical Trials Consortium

  10/1/2005 - 9/30/2007

  Sponsor: Johns Hopkins University

  Funding: $ 30,000.00

• 626.

  Myron Cohen; Nicholas Shaheen; Thomas Shea

  Center for HIV/AIDS Vaccine Immunology (CHAVI) - UNC Subawards

  10/1/2005 - 6/30/2013

  Sponsor: Duke University

  Funding: $ 582,928.00

• 627.

  Rudolph Juliano; Hongyu An; Xiao Sha Chang; Moo Cho; Joseph Desimone; H Shelton Earp; Valeri Gorbounov; Klaus Hahn; Gary Johnson; Ryszard Kole; David Lalush; Weili Lin; Wenbin Lin; Rihe Liu; Jianping Lu; Pauline Lund; Etta Pisano; M Ramsey; Eric Schreiber; Jonathan Serody; Norman Sharpless; Martin Styner; Susan Sunnarborg; Richard Superfine; Terry Van Dyke; Glenn Walker; Yue Xiong; Muhammad Yousaf; Otto Zhou

  Carolina Center of Cancer Nanotechnology Excellence - ARRA

  9/30/2005 - 8/31/2012

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 3,373,755.00

• 628.

  Rudolph Juliano; Nancy Allbritton; Hongyu An; James Bear; Xiao Sha Chang; Joseph Desimone; H Shelton Earp; Klaus Hahn; Gary Johnson; Ryszard Kole; David Lalush; Weili Lin; Wenbin Lin; Rihe Liu; Jianping Lu; Pauline Lund; Etta Pisano; John Ramsey; Eric Schreiber; Norman Sharpless; Richard Superfine; Terry Van Dyke; Glenn Walker; Young Whang; Yue Xiong; Muhammad Yousaf; Otto Zhou

  Carolina Center of Cancer Nanotechnology Excellence - ARRA

  9/30/2005 - 8/31/2012

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 3,430,039.00

• 629.

  Rudolph Juliano; Jean Alarie; Nancy Allbritton; Hongyu An; James Bear; Xiao Sha Chang; Joseph Desimone; H Shelton Earp; Greg Forest; Klaus Hahn; Gary Johnson; David Lalush; Weili Lin; Wenbin Lin; Rihe Liu; Jianping Lu; James Luft; Pauline Lund; Mary Napier; Etta Pisano; Abby Pulsipher; John Ramsey; Eric Schreiber; Norman Sharpless; Susan Sunnarborg; Richard Superfine; Joel Tepper; Shaomin Tian; Terry Van Dyke; Glenn Walker; Young Whang; Yue Xiong; Jen Jen Yeh; Muhammad Yousaf; Hong Yuan; Otto Zhou

  Carolina Center of Cancer Nanotechnology Excellence - ARRA

  9/30/2005 - 8/31/2012

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 3,507,500.00

• 630.

  Til Stürmer; Michael Murray; William Carpenter; Richard Goldberg; Robert Sandler; Hanna Sanoff

  MASTER AGREEMENT--Developing Evidence to Inform Decisions about Effectiveness: The DEcIDE Network

  9/16/2005 - 7/14/2013

  Sponsor: Agency for Healthcare Research and Quality (AHRQ)

  Funding: $ 20,000.00

• 631.

  Til Stürmer; William Carpenter; Richard Goldberg; Michael Murray; Robert Sandler; Hanna Sanoff

  MASTER AGREEMENT--Developing Evidence to Inform Decisions about Effectiveness: The DEcIDE Network

  9/16/2005 - 7/14/2013

  Sponsor: Agency for Healthcare Research and Quality (AHRQ)

  Funding: $ 440,000.00

• 632.

  Til Stürmer; William Carpenter; Michael Murray; Richard Goldberg; Amir Khandani; Bert O'Neil; Wendy Rathmell

  MASTER AGREEMENT--Developing Evidence to Inform Decisions about Effectiveness: The DEcIDE Network

  9/16/2005 - 7/14/2013

  Sponsor: Agency for Healthcare Research and Quality (AHRQ)

  Funding: $ 35,000.00

• 633.

  Jenny Ting

  Innate Immune Genes and Transplant Rejection

  9/15/2005 - 1/31/2011

  Sponsor: Duke University

  Funding: $ 239,428.00

• 634.

  Jenny Ting

  Innate Immune Genes and Transplant Rejection

  9/15/2005 - 1/31/2011

  Sponsor: Duke University

  Funding: $ 233,801.00

• 635.

  Jenny Ting; Willie Brickey

  Innate Immune Genes and Transplant Rejection

  9/15/2005 - 1/31/2011

  Sponsor: Duke University

  Funding: $ 227,021.00

• 636.

  Jenny Ting; Willie Brickey

  Innate Immune Genes and Transplant Rejection

  9/15/2005 - 1/31/2011

  Sponsor: Duke University

  Funding: $ 225,073.00

• 637.

  Jenny Ting; Willie Brickey

  Innate Immune Genes and Transplant Rejection

  9/15/2005 - 1/31/2011

  Sponsor: Duke University

  Funding: $ 225,073.00

• 638.

  Karen Mohlke; Norman Sharpless

  Targeted Genetic Analysis of T2D and Quantitative Traits

  9/1/2005 - 5/31/2015

  Sponsor: NIH National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDKD)

  Funding: $ 732,121.00

• 639.

  Karen Mohlke; Norman Sharpless

  Targeted Genetic Analysis of T2D and Quantitative Traits

  9/1/2005 - 5/31/2015

  Sponsor: NIH National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDKD)

  Funding: $ 627,665.00

• 640.

  Jenny Ting

  Inflammation and Radiation-Induced Lung Injury

  8/31/2005 - 7/31/2010

  Sponsor: Duke University

  Funding: $ 218,857.00

• 641.

  Jenny Ting

  Inflammation and Radiation-Induced Lung Injury

  8/31/2005 - 7/31/2010

  Sponsor: Duke University

  Funding: $ 220,647.00

• 642.

  Jenny Ting

  Inflammation and Radiation-Induced Lung Injury

  8/31/2005 - 7/31/2010

  Sponsor: Duke University

  Funding: $ 207,000.00

• 643.

  Jenny Ting; Willie Brickey; Joseph Duncan

  Inflammation and Radiation-Induced Lung Injury

  8/31/2005 - 7/31/2010

  Sponsor: Duke University

  Funding: $ 202,860.00

• 644.

  Jenny Ting; Willie Brickey

  Inflammation and Radiation-Induced Lung Injury

  8/31/2005 - 7/31/2010

  Sponsor: Duke University

  Funding: $ 202,860.00

• 645.

  Norman Sharpless

  Ink4a/Arf Expression in Aging

  8/15/2005 - 8/14/2009

  Sponsor: Ellison Medical Foundation

  Funding: $ 200,000.00

• 646.

  Norman Sharpless

  Ink4a/Arf Expression in Aging

  8/15/2005 - 8/14/2009

  Sponsor: Ellison Medical Foundation

  Funding: $ 150,000.00

• 647.

  Norman Sharpless

  Ink4a/Arf Expression in Aging

  8/15/2005 - 8/14/2009

  Sponsor: Ellison Medical Foundation

  Funding: $ 100,000.00

• 648.

  Jenny Ting

  Research Agreement with Biogen, Inc.

  8/12/2005 - 8/11/2006

  Sponsor: Industry Sponsor

  Funding: $ 32,850.00

• 649.

  Norman Sharpless; Shannon Penland

  Fellow:Shannon Penland/RNA Expression Profiles from FFPE Colorectal Carcinoma Specimens and Correlation to Clinical Outcome

  8/1/2005 - 7/30/2006

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 27,500.00

• 650.

  Jenny Ting; Martin Costello; Patrick Flood

  Innate Immune Response Genes and P. Gingivalis

  8/1/2005 - 4/30/2012

  Sponsor: NIH National Institute of Dental and Craniofacial Research (NIDCR)

  Funding: $ 386,965.00

• 651.

  Jenny Ting; Martin Costello; Patrick Flood

  Innate Immune Response Genes and P. Gingivalis

  8/1/2005 - 4/30/2012

  Sponsor: NIH National Institute of Dental and Craniofacial Research (NIDCR)

  Funding: $ 388,313.00

• 652.

  Jenny Ting; Patrick Flood

  Innate Immune Response Genes and P. Gingivalis

  8/1/2005 - 4/30/2012

  Sponsor: NIH National Institute of Dental and Craniofacial Research (NIDCR)

  Funding: $ 387,492.00

• 653.

  Jenny Ting; Patrick Flood

  Innate Immune Response Genes and P. Gingivalis

  8/1/2005 - 4/30/2012

  Sponsor: NIH National Institute of Dental and Craniofacial Research (NIDCR)

  Funding: $ 393,871.00

• 654.

  Jenny Ting; Patrick Flood

  Innate Immune Response Genes and P. Gingivalis

  8/1/2005 - 4/30/2012

  Sponsor: NIH National Institute of Dental and Craniofacial Research (NIDCR)

  Funding: $ 404,829.00

• 655.

  Jonathan Serody; Marion Couch

  Fellow:Marion Couch/Allogeneic Vaccine with Immunomodulation for Oral Cancer

  7/1/2005 - 12/31/2006

  Sponsor: American Academy of Otolaryngic Allergy (AAOA)

  Funding: $ 50,000.00

• 656.

  Andrew Olshan

  Chidren's Cancer Research Network (CCRN)

  7/1/2005 - 6/30/2006

  Sponsor: National Childhood Cancer Foundation

  Funding: $ 13,033.00

• 657.

  Jenny Ting; Brian O Connor

  Brian P. O'Connor/Fellow CIITA Regulation of Plexin-A1 in Dendritic Cells

  7/1/2005 - 3/31/2006

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 43,976.00

• 658.

  Terry Magnuson; Courtney Griffin

  A Role for Mammalian SWI/SNF-Related Chromatin-Remodeling Complexes in Vascular Dev (Postdoc Fellowship)

  7/1/2005 - 11/30/2006

  Sponsor: AHA Mid-Atlantic Affiliate (DC, MD, NC, SC, VA)

  Funding: $ 70,000.00

• 659.

  Jenny Ting

  Innate Immune Gene and Asthma

  7/1/2005 - 6/30/2009

  Sponsor: Sandler Family Supporting Foundation

  Funding: $ 250,000.00

• 660.

  Jenny Ting; Kristi Williams

  Monarch-1: A Pyrin/NBD/LRR Protein As A Regulator of TLR Activation

  7/1/2005 - 6/30/2007

  Sponsor: American Cancer Society (ACS)

  Funding: $ 85,000.00

• 661.

  Bill Marzluff

  Support for UNC Shared Bioinformatics Resource

  7/1/2005 - 6/30/2007

  Sponsor: University of North Carolina General Administration (UNC GA)

  Funding: $ 130,000.00

• 662.

  Bill Marzluff

  Support for UNC Shared Bioinformatics Resource

  7/1/2005 - 6/30/2007

  Sponsor: University of North Carolina General Administration (UNC GA)

  Funding: $ 10,000.00

• 663.

  Bill Marzluff

  Support for UNC Shared Bioinformatics Resource

  7/1/2005 - 6/30/2007

  Sponsor: University of North Carolina General Administration (UNC GA)

  Funding: $ 137,000.00

• 664.

  Jenny Ting; Beckley Davis

  Novel CATERPILLER Gene Involved in Mucosal Inflammation

  7/1/2005 - 6/30/2007

  Sponsor: NIH National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDKD)

  Funding: $ 43,976.00

• 665.

  Jenny Ting; Beckley Davis

  Novel CATERPILLER Gene Involved in Mucosal Inflammation

  7/1/2005 - 6/30/2007

  Sponsor: NIH National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDKD)

  Funding: $ 4,320.00

• 666.

  Jenny Ting; Beckley Davis

  Novel CATERPILLER Gene Involved in Mucosal Inflammation

  7/1/2005 - 6/30/2007

  Sponsor: NIH National Institute of Diabetes, Digestive, and Kidney Diseases (NIDDKD)

  Funding: $ 50,428.00

• 667.

  Jenny Ting

  Innate Immune Gene and Asthma

  7/1/2005 - 6/30/2009

  Sponsor: Sandler Family Supporting Foundation

  Funding: $ 250,000.00

• 668.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 70,908.00

• 669.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 12,000.00

• 670.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 32,000.00

• 671.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 7,200.00

• 672.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 24,000.00

• 673.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 22,000.00

• 674.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 76,970.00

• 675.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 60,000.00

• 676.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 1,000.00

• 677.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 35,384.00

• 678.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 1,000.00

• 679.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 5,850.00

• 680.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 22,600.00

• 681.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 12,812.00

• 682.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 102,000.00

• 683.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 5,000.00

• 684.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 8,350.00

• 685.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 8,200.00

• 686.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 50,900.00

• 687.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 3,100.00

• 688.

  Thomas Shea

  CALGB - CASE STUDY SERVICES

  7/1/2005 - 6/30/2011

  Sponsor: University of Chicago Cancer and Leukemia Group B (CALGB)

  Funding: $ 44,350.00

• 689.

  Jenny Ting

  Innate Immune Gene and Asthma

  7/1/2005 - 6/30/2009

  Sponsor: Sandler Family Supporting Foundation

  Funding: $ 250,000.00

• 690.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 6,000.00

• 691.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 386.00

• 692.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 193.00

• 693.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 193.00

• 694.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 716.00

• 695.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 193.00

• 696.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 903.00

• 697.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 716.00

• 698.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 8,301.00

• 699.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 12,376.00

• 700.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 17,708.00

• 701.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 9,342.00

• 702.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 5,251.00

• 703.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 4,488.00

• 704.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 5,643.00

• 705.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 2,684.00

• 706.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 1,411.00

• 707.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 2,684.00

• 708.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 1,966.00

• 709.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 8,713.00

• 710.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 3,713.00

• 711.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 1,236.00

• 712.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 544.00

• 713.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 7,785.00

• 714.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 1,488.00

• 715.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 654.00

• 716.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 3,713.00

• 717.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 327.00

• 718.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 1,460.00

• 719.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 1,460.00

• 720.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 711.00

• 721.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 150.00

• 722.

  Thomas Shea

  Random, ... Stdy of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjs w/Chronic Phase Philadelphia Chromosome-Positive Chronic Myelo

  6/15/2005 - 6/14/2008

  Sponsor: Industry Sponsor

  Funding: $ 1,565.00

• 723.

  Jenny Ting; Miriam Braunstein

  M. Tuberculosis and Host-Defense Mechanisms

  6/1/2005 - 2/28/2011

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 308,938.00

• 724.

  Jenny Ting; Miriam Braunstein

  M. Tuberculosis and Host-Defense Mechanisms

  6/1/2005 - 2/28/2011

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 354,915.00

• 725.

  Jenny Ting

  M. Tuberculosis and Host-Defense Mechanisms

  6/1/2005 - 2/28/2011

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 344,622.00

• 726.

  Jenny Ting; Miriam Braunstein

  M. Tuberculosis and Host-Defense Mechanisms

  6/1/2005 - 2/28/2011

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 338,074.00

• 727.

  Jenny Ting; Miriam Braunstein

  M. Tuberculosis and Host-Defense Mechanisms

  6/1/2005 - 2/28/2011

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 304,267.00

• 728.

  Jenny Ting; Miriam Braunstein

  M. Tuberculosis and Host-Defense Mechanisms

  6/1/2005 - 2/28/2011

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 33,807.00

• 729.

  Jonathan Serody; Elizabeth Dees; Karen McKinnon

  Multimodality Therapy for Metastatic Breast Cancer

  4/15/2005 - 3/31/2008

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 288,350.00

• 730.

  Jonathan Serody; Elizabeth Dees; Karen McKinnon

  Multimodality Therapy for Metastatic Breast Cancer

  4/15/2005 - 3/31/2008

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 281,574.00

• 731.

  Thomas Shea

  Ph II Clinical Trial of Oral Suberoylanilide Hydroxamix Acid (L-0010793038) in Pts w/ Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

  4/14/2005 - 5/14/2007

  Sponsor: Industry Sponsor

  Funding: $ 9,500.00

• 732.

  Thomas Shea

  Ph II Clinical Trial of Oral Suberoylanilide Hydroxamix Acid (L-0010793038) in Pts w/ Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)

  4/14/2005 - 5/14/2007

  Sponsor: Industry Sponsor

  Funding: $ 14,015.00

• 733.

  Jonathan Serody

  Treg Migration in GVHD (ARRA)

  4/1/2005 - 7/31/2010

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 340,845.00

• 734.

  Jonathan Serody

  Treg Migration in GVHD (ARRA)

  4/1/2005 - 7/31/2010

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 316,559.00

• 735.

  Jonathan Serody

  Treg Migration in GVHD (ARRA)

  4/1/2005 - 7/31/2010

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 66,852.00

• 736.

  Jonathan Serody

  Treg Migration in GVHD (ARRA)

  4/1/2005 - 7/31/2010

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 315,929.00

• 737.

  Jonathan Serody

  Treg Migration in GVHD (ARRA)

  4/1/2005 - 7/31/2010

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 67,528.00

• 738.

  Jonathan Serody

  Treg Migration in GVHD (ARRA)

  4/1/2005 - 7/31/2010

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 315,699.00

• 739.

  Jonathan Serody

  Treg Migration in GVHD (ARRA)

  4/1/2005 - 7/31/2010

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 71,427.00

• 740.

  Jonathan Serody

  Treg Migration in GVHD (ARRA)

  4/1/2005 - 7/31/2010

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 357,263.00

• 741.

  Jonathan Serody

  Treg Migration in GVHD (ARRA)

  4/1/2005 - 7/31/2010

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 39,696.00

• 742.

  Jonathan Serody

  Treg Migration in GVHD (ARRA)

  4/1/2005 - 7/31/2010

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 136,719.00

• 743.

  Jonathan Serody; Stephen Clarke

  Treg Migration in GVHD

  4/1/2005 - 7/31/2012

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 420,446.00

• 744.

  Thomas Shea; Terrance Comeau; Don Gabriel; Robert Irons; Celeste Lindley; Jonathan Serody; Christine Walko

  Allogeneic Hematopoietic Cell Transplantation for Patients w/Hematologic Disorders Who Are Undergoing Dose-Adjusted Trtmt w/Maximally Intensive

  2/21/2005 - 8/1/2011

  Sponsor: Industry Sponsor

  Funding: $ 32,000.00

• 745.

  Thomas Shea; Terrance Comeau; Don Gabriel; Robert Irons; Celeste Lindley; Jonathan Serody; Christine Walko

  Allogeneic Hematopoietic Cell Transplantation for Patients w/Hematologic Disorders Who Are Undergoing Dose-Adjusted Trtmt w/Maximally Intensive

  2/21/2005 - 8/1/2011

  Sponsor: Industry Sponsor

  Funding: $ 32,000.00

• 746.

  Terry Magnuson; Stormy Chamberlain

  Stormy J. Chamberlain/Fellow SUZ12 Function in Heterochromatin and mouse development (Postdoctoral Fellowship)

  12/13/2004 - 12/12/2007

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 47,296.00

• 747.

  Terry Magnuson; Stormy Chamberlain

  SUZ12 Function in Heterochromatin & Muse Development/FELLOW:STORMY CHAMBERLAIN

  12/13/2004 - 12/12/2007

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 42,976.00

• 748.

  Terry Magnuson

  SUZ12 function in heterochromatin and mouse development

  12/13/2004 - 12/12/2007

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 50,428.00

• 749.

  Yue Xiong

  Suppression Of Prostate Tumor By INK4c And PTEN

  11/15/2004 - 11/14/2007

  Sponsor: Army Medical Research and Material Command

  Funding: $ 546,632.00

• 750.

  Jonathan Serody

  Genetic susceptibility to F. tularensis

  9/30/2004 - 8/31/2006

  Sponsor: Duke University Medical Center

  Funding: $ 84,595.00

• 751.

  Jonathan Serody

  Genetic susceptibility to F. tularensis

  9/30/2004 - 8/31/2006

  Sponsor: Duke University Medical Center

  Funding: $ 84,595.00

• 752.

  Gary Johnson

  UNC Center for Nanosensing the Stressome

  9/30/2004 - 7/12/2005

  Sponsor: NIH National Eye Institue

  Funding: $ 73,000.00

• 753.

  Morgan Giddings; William Marzluff

  Software to Identify Post-translational Modifications From Proteomic Data Sets (

  9/24/2004 - 1/31/2011

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 294,746.00

• 754.

  Morgan Giddings; William Marzluff

  Software to Identify Post-translational Modifications From Proteomic Data Sets (

  9/24/2004 - 1/31/2011

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 32,749.00

• 755.

  Morgan Giddings; William Marzluff

  Software to Identify Post-translational Modifications From Proteomic Data Sets (

  9/24/2004 - 1/31/2011

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 294,746.00

• 756.

  Morgan Giddings; William Marzluff

  Software to Identify Post-translational Modifications From Proteomic Data Sets (

  9/24/2004 - 1/31/2011

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 29,474.00

• 757.

  Morgan Giddings; William Marzluff

  Software to Identify Post-translational Modifications From Proteomic Data Sets (

  9/24/2004 - 1/31/2011

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 291,798.00

• 758.

  Kirk Wilhelmsen; Daniel Reed; James Evans; Bradley Hemminger; Ethan Lange; Terry Magnuson; Karen Mohlke; Kari North; Jan Prins; Patrick Sullivan; Alexander Tropsha; Wei Wang; Fred Wright

  THE CAROLINA CETER FOR EXPLORATORY GENETIC ANALYSIS

  9/22/2004 - 7/31/2009

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 563,799.00

• 759.

  Kirk Wilhelmsen; Daniel Reed; James Evans; Bradley Hemminger; Ethan Lange; Terry Magnuson; Karen Mohlke; Kari North; Jan Prins; Patrick Sullivan; Alexander Tropsha; Wei Wang; Fred Wright

  THE CAROLINA CETER FOR EXPLORATORY GENETIC ANALYSIS

  9/22/2004 - 7/31/2009

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 559,433.00

• 760.

  Terry Magnuson; Jennifer Brennan

  The Role of Atrx in Development and Chromatin Remodeling Fellow: Brennan, J

  9/1/2004 - 8/31/2006

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 48,296.00

• 761.

  Terry Magnuson; Jennifer Brennan

  Fellow:Jennifer Brennan--The Role of Atrx in Development and Chromatin Remodeling

  9/1/2004 - 8/31/2006

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 42,976.00

• 762.

  Norman Sharpless

  The Role of p16INK4a in Mammalian Aging

  8/15/2004 - 7/31/2014

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 290,836.00

• 763.

  Norman Sharpless

  The Role of p16INK4a in Mammalian Aging

  8/15/2004 - 7/31/2014

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 290,836.00

• 764.

  Norman Sharpless

  The Role of p16INK4a in Mammalian Aging

  8/15/2004 - 7/31/2014

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 284,001.00

• 765.

  Norman Sharpless

  The Role of p16INK4a in Mammalian Aging

  8/15/2004 - 7/31/2014

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 275,765.00

• 766.

  Norman Sharpless

  The Role of p16INK4a in Mammalian Aging

  8/15/2004 - 7/31/2014

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 270,249.00

• 767.

  Norman Sharpless; Lisa Carey

  The Role of p16INK4a in Mammalian Aging

  8/15/2004 - 7/31/2014

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 303,400.00

• 768.

  Norman Sharpless; Lisa Carey

  The Role of p16INK4a in Mammalian Aging

  8/15/2004 - 7/31/2014

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 300,366.00

• 769.

  Norman Sharpless; Lisa Carey; Hyman Muss

  The Role of p16INK4a in Mammalian Aging

  8/15/2004 - 7/31/2014

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 288,712.00

• 770.

  Norman Sharpless; Lisa Carey; Hyman Muss

  The Role of p16INK4a in Mammalian Aging

  8/15/2004 - 7/31/2014

  Sponsor: NIH National Institute on Aging (NIA)

  Funding: $ 288,712.00

• 771.

  Nancy Raab-Traub

  Epstein-Barr Virus: activation of WNT/Wingless Signaling

  8/11/2004 - 5/31/2010

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 324,806.00

• 772.

  Nancy Raab-Traub

  Epstein-Barr Virus: activation of WNT/Wingless Signaling

  8/11/2004 - 5/31/2010

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 324,806.00

• 773.

  Nancy Raab-Traub

  Epstein-Barr Virus: activation of WNT/Wingless Signaling

  8/11/2004 - 5/31/2010

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 317,174.00

• 774.

  Nancy Raab-Traub

  Epstein-Barr Virus: activation of WNT/Wingless Signaling

  8/11/2004 - 5/31/2010

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 307,976.00

• 775.

  Nancy Raab-Traub

  Epstein-Barr Virus: activation of WNT/Wingless Signaling

  8/11/2004 - 5/31/2010

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 307,976.00

• 776.

  Joel Tepper; Albert Baldwin; Benjamin Calvo; Channing Der; Richard Goldberg; Tope Keku; Hong Jin Kim; Howard McLeod; Michael Meyers; Natalia Mitin; Bert O'Neil; Robert Sandler; Carolyn Sartor; Yan Shi; David Threadgill; Michael Topal

  SPORE in Gastrointestional Cancer/NON-WORKING PRIME

  8/9/2004 - 7/31/2011

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 2,149,769.00

• 777.

  Joel Tepper; Albert Baldwin; Channing Der; Howard McLeod; Robert Sandler; David Threadgill; Benjamin Calvo; Richard Goldberg; Tope Keku; Michael Meyers; Natalia Mitin; Bert O'Neil; Carolyn Sartor; Jen Jen Yeh

  SPORE in Gastrointestional Cancer/NON-WORKING PRIME

  8/9/2004 - 7/31/2011

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 2,149,769.00

• 778.

  Joel Tepper; Albert Baldwin; Channing Der; Tope Keku; Howard McLeod; David Threadgill; James Auman; William Funkhouser; Richard Goldberg; Joseph Ibrahim; Hong Jin Kim; James Marron; Michael Meyers; Ryan Miller; Bert O'Neil; Robert Sandler; Leigh Thorne; Fred Wright; Jen Jen Yeh

  SPORE in Gastrointestional Cancer/NON-WORKING PRIME

  8/9/2004 - 7/31/2011

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 1,074,664.00

• 779.

  Bill Marzluff; Eric Wagner

  Eric J. Wagner/Fellow Elucidation of the Histone 3' End Formation Mechanism (Postdoctoral Fellowship)

  8/1/2004 - 7/31/2007

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 48,296.00

• 780.

  Bill Marzluff; Eric Wagner

  Elucidation of the Histone 3' End Formation Mechanism--Fellow:Eric Wagner

  8/1/2004 - 7/31/2007

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 42,976.00

• 781.

  Bill Marzluff

  Eric J. Wagner/Fellow Elucidation of the Histone 3' End Formation Mechanism (Postdoctoral Fellowship)

  8/1/2004 - 7/31/2007

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 50,428.00

• 782.

  James Marron; H Shelton Earp; Ivan Rusyn; Leigh Thorne

  MASTER AGREEMENT---CABIG Subcontract

  7/16/2004 - 3/7/2007

  Sponsor: Industry Sponsor

  Funding: $ 339,796.00

• 783.

  James Marron; H Shelton Earp; Ivan Rusyn; Leigh Thorne

  MASTER AGREEMENT---CABIG Subcontract

  7/16/2004 - 3/7/2007

  Sponsor: Industry Sponsor

  Funding: $ 36,500.00

• 784.

  James Marron; H Shelton Earp; Ivan Rusyn; Leigh Thorne

  MASTER AGREEMENT---CABIG Subcontract

  7/16/2004 - 3/7/2007

  Sponsor: Industry Sponsor

  Funding: $ 36,500.00

• 785.

  James Marron; H Shelton Earp; Ivan Rusyn; Leigh Thorne

  MASTER AGREEMENT---CABIG Subcontract

  7/16/2004 - 3/7/2007

  Sponsor: Industry Sponsor

  Funding: $ 36,500.00

• 786.

  Jenny Ting; Kristi Williams

  Monarch-1 an Antagonist of TLR-Induced Allergic Inflammatn/FELLOW:KRISTI WILLIAMS

  7/1/2004 - 6/30/2006

  Sponsor: Federation of Clinical Immunology Societies (FOCIS)

  Funding: $ 75,000.00

• 787.

  Terry Magnuson; Caterina Gallippi

  Joint Biomedical Engineering Program In Functional Genomics

  7/1/2004 - 12/31/2006

  Sponsor: Whitaker Foundation

  Funding: $ 491,041.00

• 788.

  Terry Magnuson; Caterina Gallippi

  Joint Biomedical Engineering Program In Functional Genomics

  7/1/2004 - 12/31/2006

  Sponsor: Whitaker Foundation

  Funding: $ 353,286.00

• 789.

  Terry Magnuson; Caterina Gallippi

  Joint Biomedical Engineering Program In Functional Genomics

  7/1/2004 - 12/31/2006

  Sponsor: Whitaker Foundation

  Funding: $ 38,317.00

• 790.

  Jenny Ting; Beckley Davis

  A Novel Caterpiller Gene Involved In Mucosal Inflammation/fellow:Beckley Davis

  7/1/2004 - 6/30/2005

  Sponsor: Crohns and Colitis Foundation of America (CCFA)

  Funding: $ 102,300.00

• 791.

  Jenny Ting; Joseph Duncan

  Biochem Characterization of Monarch-1, A Regular of Signaling within the Innate Immune Sys

  7/1/2004 - 6/30/2007

  Sponsor: Industry Sponsor

  Funding: $ 65,000.00

• 792.

  Jenny Ting; Joseph Duncan

  Biochem Characterization of Monarch-1, A Regular of Signaling within the Innate Immune Sys

  7/1/2004 - 6/30/2007

  Sponsor: Industry Sponsor

  Funding: $ 130,000.00

• 793.

  Donald Baucom; Lisa Carey; Elizabeth Dees; Michael Schell

  A Couples Approach to Enhance Breast Cancer Survivorship

  7/1/2004 - 4/30/2010

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 535,823.00

• 794.

  Donald Baucom; Lisa Carey; Elizabeth Dees; Michael Schell

  A Couples Approach to Enhance Breast Cancer Survivorship

  7/1/2004 - 4/30/2010

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 514,488.00

• 795.

  Donald Baucom; Lisa Carey; Elizabeth Dees; Michael Schell

  A Couples Approach to Enhance Breast Cancer Survivorship

  7/1/2004 - 4/30/2010

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 516,548.00

• 796.

  Donald Baucom; Lisa Carey; Elizabeth Dees; Jeffrey Peppercorn

  A Couples Approach to Enhance Breast Cancer Survivorship

  7/1/2004 - 4/30/2010

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 499,894.00

• 797.

  Donald Baucom; Lisa Carey; Elizabeth Dees

  A Couples Approach to Enhance Breast Cancer Survivorship

  7/1/2004 - 4/30/2010

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 441,305.00

• 798.

  Jenny Ting; Christopher Moore

  Cell & molecular function of CD4+CD25+T regulatory cells in autoimmune diabetes-Fellow: C Moore

  5/1/2004 - 4/30/2005

  Sponsor: Juvenile Diabetes Research Foundation

  Funding: $ 44,212.00

• 799.

  Jenny Ting; Christopher Moore

  Cell & molecular function of CD4+CD25+T regulatory cells in autoimmune diabetes-Fellow: C Moore

  5/1/2004 - 4/30/2005

  Sponsor: Juvenile Diabetes Research Foundation

  Funding: $ 48,928.00

• 800.

  Yue Xiong; Chad McCall

  Function and Mechanism of Cullin 4A in Breast Cancer Development-Fellow:McCall

  2/27/2004 - 2/26/2007

  Sponsor: Army Medical Research and Material Command

  Funding: $ 90,000.00

• 801.

  Nancy Raab-Traub; ro shauna s rothwell

  NIGMS MARC Predoctoral Fellowship/FELLOW: ROSHAUNA S ROTHWELL

  2/1/2004 - 10/31/2009

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 28,796.00

• 802.

  Fred Sparling; Mark Heise; Robert Johnston; Tom Kawula; Jenny Ting

  Regional Centers of Excellence for Biodefense and Emerging Infectious Disease Research (RCE)

  9/4/2003 - 2/29/2008

  Sponsor: Duke University

  Funding: $ 317,184.00

• 803.

  Fred Sparling; Mark Heise; Robert Johnston; Tom Kawula; Jenny Ting

  Regional Centers of Excellence for Biodefense and Emerging Infectious Disease Research (RCE)

  9/4/2003 - 2/29/2008

  Sponsor: Duke University

  Funding: $ 120,453.00

• 804.

  Fred Sparling; Ralph Baric; Jeffrey Frelinger; Matthew Redinbo; Jenny Ting; Laura White

  SERCEB Southeast Regional Centers of Excellence for Biodefense and Emerging Infe

  9/4/2003 - 2/28/2014

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 1.00

• 805.

  Fred Sparling; Ralph Baric; Jeffrey Frelinger; Matthew Redinbo; Jenny Ting; Laura White

  SERCEB Southeast Regional Centers of Excellence for Biodefense and Emerging Infe

  9/4/2003 - 2/28/2014

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 10,189,682.00

• 806.

  Fred Sparling; Ralph Baric; Jeffrey Frelinger; Matthew Redinbo; Jenny Ting; Laura White

  SERCEB Southeast Regional Centers of Excellence for Biodefense and Emerging Infe

  9/4/2003 - 2/28/2014

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 4,495,015.00

• 807.

  Fred Sparling; Ralph Baric; Jeffrey Frelinger; Matthew Redinbo; Jenny Ting; Laura White

  SERCEB Southeast Regional Centers of Excellence for Biodefense and Emerging Infe

  9/4/2003 - 2/28/2014

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 327,772.00

• 808.

  Fred Sparling; Ralph Baric; Jeffrey Frelinger; Matthew Redinbo; Jenny Ting; Laura White

  SERCEB Southeast Regional Centers of Excellence for Biodefense and Emerging Infe

  9/4/2003 - 2/28/2014

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 4,063.00

• 809.

  Fred Sparling; Ralph Baric; Aravinda Desilva; Jeffrey Frelinger; William Goldman; Beverly Koller; Virginia Miller; Jenny Ting; Nancy Davis; Mark Heise; Robert Johnston; Tom Kawula; Raymond Pickles; Matthew Redinbo; Lishan Su

  SERCEB Southeast Regional Centers of Excellence for Biodefense and Emerging Infe

  9/4/2003 - 2/28/2014

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 3,506,633.00

• 810.

  Fred Sparling; Ralph Baric; Aravinda Desilva; Jeffrey Frelinger; William Goldman; Beverly Koller; Virginia Miller; Jenny Ting; Nancy Davis; Mark Heise; Robert Johnston; Tom Kawula; Raymond Pickles; Matthew Redinbo; Lishan Su

  SERCEB Southeast Regional Centers of Excellence for Biodefense and Emerging Infe

  9/4/2003 - 2/28/2014

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 480,000.00

• 811.

  Fred Sparling; Ralph Baric; Aravinda Desilva; Jeffrey Frelinger; William Goldman; Mark Heise; Virginia Miller; Jenny Ting; Tom Kawula; Raymond Pickles; Matthew Redinbo; Lishan Su

  SERCEB Southeast Regional Centers of Excellence for Biodefense and Emerging Infe

  9/4/2003 - 2/28/2014

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 7,065,687.00

• 812.

  Fred Sparling; Ralph Baric; Aravinda Desilva; William Goldman; Mark Heise; Tom Kawula; Virginia Miller; Raymond Pickles; Lishan Su; Jenny Ting

  SERCEB Southeast Regional Centers of Excellence for Biodefense and Emerging Infe

  9/4/2003 - 2/28/2014

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 6,495,290.00

• 813.

  Fred Sparling; Ralph Baric; Aravinda Desilva; William Goldman; Mark Heise; Tom Kawula; Virginia Miller; Raymond Pickles; Lishan Su; Jenny Ting

  SERCEB Southeast Regional Centers of Excellence for Biodefense and Emerging Infe

  9/4/2003 - 2/28/2014

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 649,530.00

• 814.

  Fred Sparling; Ralph Baric; Aravinda Desilva; William Goldman; Mark Heise; Tom Kawula; Virginia Miller; Raymond Pickles; Lishan Su; Jenny Ting

  SERCEB Southeast Regional Centers of Excellence for Biodefense and Emerging Infe

  9/4/2003 - 2/28/2014

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 7,154,750.00

• 815.

  Fred Sparling; Ralph Baric; Aravinda Desilva; William Goldman; Mark Heise; Tom Kawula; Virginia Miller; Raymond Pickles; Lishan Su; Jenny Ting

  SERCEB Southeast Regional Centers of Excellence for Biodefense and Emerging Infe

  9/4/2003 - 2/28/2014

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 230,937.00

• 816.

  Rich Goldberg

  Consortium Agreement Between Mayo Clinic Rochester Acting As The Administrative Center For North Central Cancer Treatment Group and The University of

  9/1/2003 - 12/31/2005

  Sponsor: Mayo Clinic

  Funding: $ 34,351.00

• 817.

  Rich Goldberg

  Consortium Agreement Between Mayo Clinic Rochester Acting As The Administrative Center For North Central Cancer Treatment Group and The University of

  9/1/2003 - 12/31/2005

  Sponsor: Mayo Clinic

  Funding: $ 13,705.00

• 818.

  Gary Johnson

  MEKK2 Regulation of Mast Cell/TCell Cytokine Production

  9/1/2003 - 8/31/2004

  Sponsor: National Jewish Health

  Funding: $ 137,500.00

• 819.

  Rich Goldberg

  Pharmacogenetics Advanced Colorectal Cancer

  8/1/2003 - 7/31/2005

  Sponsor: University of Washington

  Funding: $ 8,367.00

• 820.

  Rich Goldberg

  Pharmacogenetics Advanced Colorectal Cancer

  8/1/2003 - 7/31/2005

  Sponsor: University of Washington

  Funding: $ 8,367.00

• 821.

  Jenny Ting; Susanna Greer

  Ubiquitination Regulates CIITA Activity and MHC II Expression on Microglia

  8/1/2003 - 7/31/2008

  Sponsor: National Multiple Sclerosis Society (NMSS)

  Funding: $ 559,189.00

• 822.

  Jonathan Serody

  Mechanisms Involved in T Cell Trafficking in GVHD

  8/1/2003 - 5/31/2010

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 323,632.00

• 823.

  Jonathan Serody

  Mechanisms Involved in T Cell Trafficking in GVHD

  8/1/2003 - 5/31/2010

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 323,632.00

• 824.

  Jonathan Serody

  Mechanisms Involved in T Cell Trafficking in GVHD

  8/1/2003 - 5/31/2010

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 323,632.00

• 825.

  Jonathan Serody

  Mechanisms Involved in T Cell Trafficking in GVHD

  8/1/2003 - 5/31/2010

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 316,027.00

• 826.

  Jonathan Serody

  Mechanisms Involved in T Cell Trafficking in GVHD

  8/1/2003 - 5/31/2010

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 306,862.00

• 827.

  Gary Johnson

  Function of MEKK3 and its osmosensing scaffold protein AARA

  8/1/2003 - 7/31/2016

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 292,000.00

• 828.

  Gary Johnson

  Function of MEKK3 and its osmosensing scaffold protein AARA

  8/1/2003 - 7/31/2016

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 292,000.00

• 829.

  Gary Johnson

  Function of MEKK3 and its osmosensing scaffold protein AARA

  8/1/2003 - 7/31/2016

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 292,000.00

• 830.

  Gary Johnson

  Function of MEKK3 and its osmosensing scaffold protein AARA

  8/1/2003 - 7/31/2016

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 285,138.00

• 831.

  Gary Johnson; Nancy Johnson; Kazuhiro Nakamura

  Function of MEKK3 and its osmosensing scaffold protein AARA

  8/1/2003 - 7/31/2016

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 95,046.00

• 832.

  Gary Johnson; Kazuhiro Nakamura

  Function of MEKK3 and its osmosensing scaffold protein AARA

  8/1/2003 - 7/31/2016

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 316,714.00

• 833.

  Gary Johnson; Amy Abell

  Function of MEKK3 and its osmosensing scaffold protein AARA

  8/1/2003 - 7/31/2016

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 110,656.00

• 834.

  Gary Johnson; Kazuhiro Nakamura

  Function of MEKK3 and its osmosensing scaffold protein AARA

  8/1/2003 - 7/31/2016

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 317,694.00

• 835.

  Gary Johnson

  Function of MEKK3 and its osmosensing scaffold protein AARA

  8/1/2003 - 7/31/2016

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 103,812.00

• 836.

  Gary Johnson; Kazuhiro Nakamura

  Function of MEKK3 and its osmosensing scaffold protein AARA

  8/1/2003 - 7/31/2016

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 314,517.00

• 837.

  Gary Johnson; Kazuhiro Nakamura

  Function of MEKK3 and its osmosensing scaffold protein AARA

  8/1/2003 - 7/31/2016

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 311,372.00

• 838.

  Gary Johnson; Matt Ewend; Ryan Miller

  Function of MEKK3 and its osmosensing scaffold protein AARA

  8/1/2003 - 7/31/2016

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 391,740.00

• 839.

  Norman Sharpless

  The Regulation of the Tumor Suppressor p16INK4a in Cancer and Aging

  7/1/2003 - 6/30/2006

  Sponsor: Sidney Kimmel Foundation

  Funding: $ 200,000.00

• 840.

  Kari North; Gerardo Heiss; Andrew Olshan

  Gene-by-Smoking Interaction and Risk of Atherosclerosis

  7/1/2003 - 6/30/2008

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 380,538.00

• 841.

  Kari North; Gerardo Heiss; Andrew Olshan

  Gene-by-Smoking Interaction and Risk of Atherosclerosis

  7/1/2003 - 6/30/2008

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 426,147.00

• 842.

  Kari North; Gerardo Heiss; Andrew Olshan

  Gene-by-Smoking Interaction and Risk of Atherosclerosis

  7/1/2003 - 6/30/2008

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 284,958.00

• 843.

  Norman Sharpless

  The Role of the Tumor Suppressor p16INK4a in Mammalian Aging

  7/1/2003 - 6/30/2008

  Sponsor: American Federation for Aging Research (AFAR)

  Funding: $ 426,647.00

• 844.

  Terry Magnuson; Sundeep Kalantry

  Fellow:Sundeel Kalantry--Mechanisms of Imprinted X-Inactivation

  7/1/2003 - 6/30/2006

  Sponsor: American Cancer Society (ACS)

  Funding: $ 124,000.00

• 845.

  Yue Xiong; Stuart Shumway

  Fellow:S Shumway--TSC1 and TSC2 Bridge Cell Cycle and Cell Growth Regulation

  7/1/2003 - 1/31/2007

  Sponsor: American Cancer Society (ACS)

  Funding: $ 124,000.00

• 846.

  Andrew Olshan

  Biological Basis for Chemoprevention of Ovarian Cancer

  5/1/2003 - 9/30/2006

  Sponsor: Duke University

  Funding: $ 32,620.00

• 847.

  Andrew Olshan

  Biological Basis for Chemoprevention of Ovarian Cancer

  5/1/2003 - 9/30/2006

  Sponsor: Duke University

  Funding: $ 70,293.00

• 848.

  Terry Magnuson

  SpectruMedix 9610 Mutation Discovery System

  5/1/2003 - 4/30/2004

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 272,757.00

• 849.

  Andrew Olshan

  Estrogen Bioactivation & risk of ovarian cancer

  4/1/2003 - 3/31/2004

  Sponsor: Duke University Medical Center

  Funding: $ 23,765.00

• 850.

  Andrew Olshan

  Estrogen Bioactivation & risk of ovarian cancer

  4/1/2003 - 3/31/2004

  Sponsor: Duke University Medical Center

  Funding: $ 24,716.00

• 851.

  Andrew Olshan

  Estrogen Bioactivation & risk of ovarian cancer

  4/1/2003 - 3/31/2004

  Sponsor: Duke University Medical Center

  Funding: $ 4,284.00

• 852.

  Yue Xiong; Paul Andrews; Feng Bai

  The Cullin-ROC Family of E3 Ubiquitin Ligases

  2/1/2003 - 3/31/2015

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 257,494.00

• 853.

  Yue Xiong; Paul Andrews; Feng Bai

  The Cullin-ROC Family of E3 Ubiquitin Ligases

  2/1/2003 - 3/31/2015

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 259,951.00

• 854.

  Yue Xiong; Paul Andrews; Feng Bai

  The Cullin-ROC Family of E3 Ubiquitin Ligases

  2/1/2003 - 3/31/2015

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 259,951.00

• 855.

  Yue Xiong; Paul Andrews; Feng Bai

  The Cullin-ROC Family of E3 Ubiquitin Ligases

  2/1/2003 - 3/31/2015

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 253,842.00

• 856.

  Yue Xiong

  The Cullin-ROC Family of E3 Ubiquitin Ligases

  2/1/2003 - 3/31/2015

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 307,331.00

• 857.

  Yue Xiong

  The Cullin-ROC Family of E3 Ubiquitin Ligases

  2/1/2003 - 3/31/2015

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 307,357.00

• 858.

  Yue Xiong

  The Cullin-ROC Family of E3 Ubiquitin Ligases

  2/1/2003 - 3/31/2015

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 284,911.00

• 859.

  Yue Xiong

  The Cullin-ROC Family of E3 Ubiquitin Ligases

  2/1/2003 - 3/31/2015

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 31,656.00

• 860.

  Yue Xiong; Xin Hai Pei

  The Cullin-ROC Family of E3 Ubiquitin Ligases

  2/1/2003 - 3/31/2015

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 322,788.00

• 861.

  Yue Xiong

  The Cullin-ROC Family of E3 Ubiquitin Ligases

  2/1/2003 - 3/31/2015

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 91,024.00

• 862.

  Yue Xiong

  The Cullin-ROC Family of E3 Ubiquitin Ligases

  2/1/2003 - 3/31/2015

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 358,079.00

• 863.

  Yue Xiong

  The Cullin-ROC Family of E3 Ubiquitin Ligases

  2/1/2003 - 3/31/2015

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 358,142.00

• 864.

  Yue Xiong

  The Cullin-ROC Family of E3 Ubiquitin Ligases

  2/1/2003 - 3/31/2015

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 322,386.00

• 865.

  Don Gabriel; Jonathan Serody; Thomas Shea

  Roche ML16420 The pharmacokinetics of ganciclovir following a dose of valganciclovir versus ganciclovir IV in bone marrow transplant/human stem cell t

  1/13/2003 - 12/31/2004

  Sponsor: Industry Sponsor

  Funding: $ 35,225.00

• 866.

  Don Gabriel; Jonathan Serody; Thomas Shea

  Roche ML16420 The pharmacokinetics of ganciclovir following a dose of valganciclovir versus ganciclovir IV in bone marrow transplant/human stem cell t

  1/13/2003 - 12/31/2004

  Sponsor: Industry Sponsor

  Funding: $ 1,000.00

• 867.

  Yue Xiong; Chad McCall

  Control of p53 Cytoplasmic Degradation by a Novel Roc-Cullin Ubiquitin Ligase; Fellow-Chad McCall

  1/2/2003 - 1/1/2004

  Sponsor: Triangle Community Foundation

  Funding: $ 6,250.00

• 868.

  Lisa Carey

  p53 Mutation Analysis to Predict Tumor Response in Patients Undergoing Neoadjuvant Treatment for Locally Advanced Breast Cancer

  10/1/2002 - 9/30/2007

  Sponsor: Army Medical Research and Material Command

  Funding: $ 433,289.00

• 869.

  Joseph Piven; Grace Baranek; Margaret Burchinal; Guido Gerig; Jean Lauder; Terry Magnuson; Steve Reznick; Fei Zou

  Nonworking Prime---Gene-Brain-Behavior Relationships in Autism

  9/15/2002 - 8/31/2007

  Sponsor: NIH National Institute of Mental Health (NIMH)

  Funding: $ 1,720,520.00

• 870.

  Andrew Olshan

  North Carolina Center for Birth Defects Research and Prevention

  9/1/2002 - 11/30/2008

  Sponsor: Centers for Disease Control and Prevention (CDC)

  Funding: $ 939,950.00

• 871.

  Andrew Olshan

  North Carolina Center for Birth Defects Research and Prevention

  9/1/2002 - 11/30/2008

  Sponsor: Centers for Disease Control and Prevention (CDC)

  Funding: $ 825,000.00

• 872.

  Andrew Olshan

  North Carolina Center for Birth Defects Research and Prevention

  9/1/2002 - 11/30/2008

  Sponsor: Centers for Disease Control and Prevention (CDC)

  Funding: $ 727,000.00

• 873.

  Andrew Olshan

  North Carolina Center for Birth Defects Research and Prevention

  9/1/2002 - 11/30/2008

  Sponsor: Centers for Disease Control and Prevention (CDC)

  Funding: $ 850,000.00

• 874.

  Andrew Olshan

  North Carolina Center for Birth Defects Research and Prevention

  9/1/2002 - 11/30/2008

  Sponsor: Centers for Disease Control and Prevention (CDC)

  Funding: $ 1,000,484.00

• 875.

  Andrew Olshan; Arthur Aylsworth; Jeannette Bensen; Anna Maria Siega-Riz

  North Carolina Center for Birth Defects Research and Prevention

  9/1/2002 - 11/30/2008

  Sponsor: Centers for Disease Control and Prevention (CDC)

  Funding: $ 600,000.00

• 876.

  Andrew Olshan; Arthur Aylsworth; Jeannette Bensen; Anna Maria Siega-Riz

  North Carolina Center for Birth Defects Research and Prevention

  9/1/2002 - 11/30/2008

  Sponsor: Centers for Disease Control and Prevention (CDC)

  Funding: $ 600,000.00

• 877.

  Thomas Shea

  AMGEN 960226: A Long-term Follow-up Study of Patients with Hematologic Malignan

  8/16/2002 - 8/15/2010

  Sponsor: Industry Sponsor

  Funding: $ 5,100.00

• 878.

  Thomas Shea

  AMGEN 960226: A Long-term Follow-up Study of Patients with Hematologic Malignan

  8/16/2002 - 8/15/2010

  Sponsor: Industry Sponsor

  Funding: $ 500.00

• 879.

  Thomas Shea

  AMGEN 960226: A Long-term Follow-up Study of Patients with Hematologic Malignan

  8/16/2002 - 8/15/2010

  Sponsor: Industry Sponsor

  Funding: $ 300.00

• 880.

  Thomas Shea

  AMGEN 960226: A Long-term Follow-up Study of Patients with Hematologic Malignan

  8/16/2002 - 8/15/2010

  Sponsor: Industry Sponsor

  Funding: $ 200.00

• 881.

  Terry Magnuson; Courtney Griffin

  Courtney T. Griffin/Fellow Genetic and Cellular Analysis of Retromer Components

  8/1/2002 - 7/31/2005

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 48,928.00

• 882.

  Terry Magnuson; Courtney Griffin

  Fellow:C Griffin--Genetic and Cellular Analysis of Retromer Components

  8/1/2002 - 7/31/2005

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 46,420.00

• 883.

  Terry Magnuson; Courtney Griffin

  Genetic and Cellular Analysis of Retromer Components/Fellowship: Courtney Griffin

  8/1/2002 - 7/31/2005

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 38,320.00

• 884.

  Nancy Raab-Traub

  Tumor Associated Herpesvirus Conference

  8/1/2002 - 7/31/2007

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 15,000.00

• 885.

  Nancy Raab-Traub

  Tumor Associated Herpesvirus Conference

  8/1/2002 - 7/31/2007

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 15,000.00

• 886.

  Nancy Raab-Traub

  Tumor Associated Herpesvirus Conference

  8/1/2002 - 7/31/2007

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 14,648.00

• 887.

  Jenny Ting

  Immune Mechanisms of Transplant Rejection and Acceptance-Role of CITA Isoforms in Graft Rejection

  7/15/2002 - 6/30/2008

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 363,750.00

• 888.

  Jenny Ting

  Immune Mechanisms of Transplant Rejection and Acceptance-Role of CITA Isoforms in Graft Rejection

  7/15/2002 - 6/30/2008

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 363,750.00

• 889.

  Jenny Ting

  Immune Mechanisms of Transplant Rejection and Acceptance-Role of CITA Isoforms in Graft Rejection

  7/15/2002 - 6/30/2008

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 363,750.00

• 890.

  Jenny Ting

  Immune Mechanisms of Transplant Rejection and Acceptance-Role of CITA Isoforms in Graft Rejection

  7/15/2002 - 6/30/2008

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 363,750.00

• 891.

  Jenny Ting

  Immune Mechanisms of Transplant Rejection and Acceptance-Role of CITA Isoforms in Graft Rejection

  7/15/2002 - 6/30/2008

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 355,202.00

• 892.

  Jenny Ting; John Lich

  Identification and biologic consequences of CIITA-regulated non-MHC class II genes

  7/1/2002 - 6/30/2005

  Sponsor: American Cancer Society (ACS)

  Funding: $ 118,000.00

• 893.

  Paul Manis; Oliver Adunka; Craig Buchman; Emily Buss; Richard Cheney; Marion Couch; Charles Finley; Douglas Fitzpatrick; John Grose; Joseph Hall; Andrew Olshan; Jiri Prazma; Scott Randell; Brent Senior; Jonathan Serody; Carol Shores

  Research Training in Otolaryngology

  7/1/2002 - 6/30/2013

  Sponsor: NIH National Institute on Deafness and Other Communication Disorders (NIDCD)

  Funding: $ 121,825.00

• 894.

  Terry Magnuson

  Genetic Regulation of Patterning in the Mammalian Embryo

  6/1/2002 - 5/31/2003

  Sponsor: March of Dimes Foundation

  Funding: $ 57,448.00

• 895.

  Bill Marzluff; David Fenstermacher

  Support for Infomax Bioinformatics System for the UNC University System

  5/1/2002 - 6/30/2005

  Sponsor: University of North Carolina General Administration (UNC GA)

  Funding: $ 150,000.00

• 896.

  Bill Marzluff; David Fenstermacher

  Support for Infomax Bioinformatics System for the UNC University System

  5/1/2002 - 6/30/2005

  Sponsor: University of North Carolina General Administration (UNC GA)

  Funding: $ 150,000.00

• 897.

  Bill Marzluff; David Fenstermacher

  Support for Infomax Bioinformatics System for the UNC University System

  5/1/2002 - 6/30/2005

  Sponsor: University of North Carolina General Administration (UNC GA)

  Funding: $ 150,000.00

• 898.

  Norman Sharpless

  Melanoma in p16INK4a and p19ARF Deficient Mice

  2/15/2002 - 11/30/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 31,013.00

• 899.

  Norman Sharpless

  Melanoma in p16INK4a and p19ARF Deficient Mice

  2/15/2002 - 11/30/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 1,579.00

• 900.

  Norman Sharpless

  Melanoma in p16INK4a and p19ARF Deficient Mice

  2/15/2002 - 11/30/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 130,918.00

• 901.

  Norman Sharpless

  Melanoma in p16INK4a and p19ARF Deficient Mice

  2/15/2002 - 11/30/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 130,918.00

• 902.

  Norman Sharpless

  Melanoma in p16INK4a and p19ARF Deficient Mice

  2/15/2002 - 11/30/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 130,918.00

• 903.

  Norman Sharpless

  Melanoma in p16INK4a and p19ARF Deficient Mice

  2/15/2002 - 11/30/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 130,918.00

• 904.

  Terry Magnuson

  Allelic Series of Genomic Modifications in ES Cells

  1/21/2002 - 12/31/2007

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 327,375.00

• 905.

  Terry Magnuson

  Allelic Series of Genomic Modifications in ES Cells

  1/21/2002 - 12/31/2007

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 327,375.00

• 906.

  Terry Magnuson

  Allelic Series of Genomic Modifications in ES Cells

  1/21/2002 - 12/31/2007

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 327,375.00

• 907.

  Terry Magnuson

  Allelic Series of Genomic Modifications in ES Cells

  1/21/2002 - 12/31/2007

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 327,375.00

• 908.

  Terry Magnuson

  Allelic Series of Genomic Modifications in ES Cells

  1/21/2002 - 12/31/2007

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 261,900.00

• 909.

  Terry Magnuson

  Allelic Series of Genomic Modifications in ES Cells

  1/21/2002 - 12/31/2007

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 57,782.00

• 910.

  Thomas Shea

  PG-018 Phase III, Multicenter Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Determine The Efficacy And Safety of Is

  10/15/2001 - 12/31/2002

  Sponsor: Industry Sponsor

  Funding: $ 6,000.00

• 911.

  Thomas Shea

  PG-018 Phase III, Multicenter Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Determine The Efficacy And Safety of Is

  10/15/2001 - 12/31/2002

  Sponsor: Industry Sponsor

  Funding: $ 50,000.00

• 912.

  Thomas Shea

  PG-018 Phase III, Multicenter Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Determine The Efficacy And Safety of Is

  10/15/2001 - 12/31/2002

  Sponsor: Industry Sponsor

  Funding: $ 58,000.00

• 913.

  Thomas Shea

  PG-018 Phase III, Multicenter Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Determine The Efficacy And Safety of Is

  10/15/2001 - 12/31/2002

  Sponsor: Industry Sponsor

  Funding: $ 6,000.00

• 914.

  Andrew Olshan

  Drinking Water Disinfection By-Products and Male Reproductive Health: Semen Quality and Sperm Biomarkers

  10/1/2001 - 9/30/2006

  Sponsor: United States Environmental Protection Agency (EPA)

  Funding: $ 500,000.00

• 915.

  Andrew Olshan

  Drinking Water Disinfection By-Products and Male Reproductive Health: Semen Quality and Sperm Biomarkers

  10/1/2001 - 9/30/2006

  Sponsor: United States Environmental Protection Agency (EPA)

  Funding: $ 242,592.00

• 916.

  Andrew Olshan

  Drinking Water Disinfection By-Products and Male Reproductive Health: Semen Quality and Sperm Biomarkers

  10/1/2001 - 9/30/2006

  Sponsor: United States Environmental Protection Agency (EPA)

  Funding: $ 40,000.00

• 917.

  Terry Magnuson

  Animal Modeling of Human Susceptibility to Complex Disease

  9/30/2001 - 9/29/2003

  Sponsor: Centers for Disease Control and Prevention (CDC)

  Funding: $ 808,868.00

• 918.

  Bill Marzluff

  Genomics Moveable Equipment

  9/30/2001 - 9/29/2004

  Sponsor: Health Resources and Services Administration (HRSA)

  Funding: $ 1,377,260.00

• 919.

  Yue Xiong; Theresa Allid

  Fellowship--Theresa Allio--p53 and Genome Stability in Spermatogenesis

  9/30/2001 - 8/31/2002

  Sponsor: NIH National Institute of Environmental Health Sciences (NIEHS)

  Funding: $ 17,165.00

• 920.

  Yue Xiong; Theresa Allid

  Fellowship--Theresa Allio--p53 and Genome Stability in Spermatogenesis

  9/30/2001 - 8/31/2002

  Sponsor: NIH National Institute of Environmental Health Sciences (NIEHS)

  Funding: $ 20,098.00

• 921.

  Hank Van Deventer; Jenny Ting

  Migration of Mature and Immature Dendritic Cells

  9/22/2001 - 8/31/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 130,617.00

• 922.

  Hank Van Deventer; Jenny Ting

  Migration of Mature and Immature Dendritic Cells

  9/22/2001 - 8/31/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 65,309.00

• 923.

  Hank Van Deventer; Jenny Ting

  Migration of Mature and Immature Dendritic Cells

  9/22/2001 - 8/31/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 130,617.00

• 924.

  Hank Van Deventer; Jenny Ting

  Migration of Mature and Immature Dendritic Cells

  9/22/2001 - 8/31/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 130,617.00

• 925.

  Hank Van Deventer; Jenny Ting

  Migration of Mature and Immature Dendritic Cells

  9/22/2001 - 8/31/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 130,617.00

• 926.

  Hank Van Deventer; Jenny Ting

  Migration of Mature and Immature Dendritic Cells

  9/22/2001 - 8/31/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 65,308.00

• 927.

  Tom Egan; Jenny Ting

  Ischemic Injury in Cadaver Donors For Lung Transplant

  9/20/2001 - 7/31/2006

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 323,098.00

• 928.

  Tom Egan; Jenny Ting

  Ischemic Injury in Cadaver Donors For Lung Transplant

  9/20/2001 - 7/31/2006

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 291,000.00

• 929.

  Tom Egan; Jenny Ting

  Ischemic Injury in Cadaver Donors For Lung Transplant

  9/20/2001 - 7/31/2006

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 74,994.00

• 930.

  Tom Egan; Jenny Ting

  Ischemic Injury in Cadaver Donors For Lung Transplant

  9/20/2001 - 7/31/2006

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 291,000.00

• 931.

  Thomas Shea

  LCCC9919: Pilot Trial of Non-Myeloablative Allogeneic Bone Marrow Transplantation in High Risk Malignant Diseases

  9/5/2001 - 9/30/2002

  Sponsor: Industry Sponsor

  Funding: $ 30,000.00

• 932.

  Jenny Ting; Glenn Matsushima

  Role of class II MHC antigens in Neurologic Diseases

  8/15/2001 - 7/31/2007

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 326,074.00

• 933.

  Jenny Ting; Glenn Matsushima

  Role of class II MHC antigens in Neurologic Diseases

  8/15/2001 - 7/31/2007

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 326,074.00

• 934.

  Jenny Ting; Glenn Matsushima

  Role of class II MHC antigens in Neurologic Diseases

  8/15/2001 - 7/31/2007

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 326,074.00

• 935.

  Jenny Ting; Glenn Matsushima

  Role of class II MHC antigens in Neurologic Diseases

  8/15/2001 - 7/31/2007

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 326,074.00

• 936.

  Jenny Ting; Glenn Matsushima

  Role of class II MHC antigens in Neurologic Diseases

  8/15/2001 - 7/31/2007

  Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)

  Funding: $ 326,074.00

• 937.

  Andrew Olshan

  Gene-Environment Interaction in Head and Neck Cancer

  7/18/2001 - 6/30/2008

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 868,790.00

• 938.

  Andrew Olshan

  Gene-Environment Interaction in Head and Neck Cancer

  7/18/2001 - 6/30/2008

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 972,351.00

• 939.

  Andrew Olshan

  Gene-Environment Interaction in Head and Neck Cancer

  7/18/2001 - 6/30/2008

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 994,653.00

• 940.

  Andrew Olshan

  Gene-Environment Interaction in Head and Neck Cancer

  7/18/2001 - 6/30/2008

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 1,017,466.00

• 941.

  Andrew Olshan

  Gene-Environment Interaction in Head and Neck Cancer

  7/18/2001 - 6/30/2008

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 755,891.00

• 942.

  Jenny Ting; Susan Strohlein

  Postdoctoral Flshp:Susanna Greer--Promoter specific control of CITA regulates MHC class II in demyelination

  7/1/2001 - 7/31/2003

  Sponsor: National Multiple Sclerosis Society (NMSS)

  Funding: $ 119,725.00

• 943.

  Jenny Ting; Susan Strohlein

  Postdoctoral Flshp:Susanna Greer--Promoter specific control of CITA regulates MHC class II in demyelination

  7/1/2001 - 7/31/2003

  Sponsor: National Multiple Sclerosis Society (NMSS)

  Funding: $ 1,000.00

• 944.

  Linda Spremulli; William Marzluff

  Symposium on RNA Biology IV, RNA; Tool and Target

  7/1/2001 - 10/31/2001

  Sponsor: North Carolina Biotechnology Center (NCBC)

  Funding: $ 5,000.00

• 945.

  David Rubenstein; Gary Johnson

  ADHESION JUNCTION REGULATION IN NORMAL AND DISEASED SKIN

  7/1/2001 - 6/30/2012

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 358,065.00

• 946.

  David Rubenstein; Gary Johnson

  ADHESION JUNCTION REGULATION IN NORMAL AND DISEASED SKIN

  7/1/2001 - 6/30/2012

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 358,065.00

• 947.

  David Rubenstein; Gary Johnson

  ADHESION JUNCTION REGULATION IN NORMAL AND DISEASED SKIN

  7/1/2001 - 6/30/2012

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 384,366.00

• 948.

  David Rubenstein; Gary Johnson

  ADHESION JUNCTION REGULATION IN NORMAL AND DISEASED SKIN

  7/1/2001 - 6/30/2012

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 350,940.00

• 949.

  David Rubenstein; Gary Johnson

  Adhesion Junction Regulation in Normal and Diseased Skin

  7/1/2001 - 7/31/2013

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 409,108.00

• 950.

  Andrew Olshan

  Intl. Conference on Male-Mediated Developmental Toxicity

  6/27/2001 - 5/31/2002

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 15,000.00

• 951.

  Shelton Earp; Paul Godley; Gwen Sancar

  NCCU/UNC Lineberger Partnership in Cancer Research

  5/11/2001 - 4/30/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 220,570.00

• 952.

  Shelton Earp; Paul Godley; Gwen Sancar

  NCCU/UNC Lineberger Partnership in Cancer Research

  5/11/2001 - 4/30/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 227,189.00

• 953.

  Shelton Earp; Paul Godley; Gwen Sancar

  NCCU/UNC Lineberger Partnership in Cancer Research

  5/11/2001 - 4/30/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 234,625.00

• 954.

  Shelton Earp; Paul Godley; Gwen Sancar

  NCCU/UNC Lineberger Partnership in Cancer Research

  5/11/2001 - 4/30/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 241,663.00

• 955.

  Shelton Earp; Paul Godley; Gwen Sancar

  NCCU/UNC Lineberger Partnership in Cancer Research

  5/11/2001 - 4/30/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 150,000.00

• 956.

  Shelton Earp

  NCCU/UNC Lineberger Partnership in Cancer Research

  5/11/2001 - 4/30/2006

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 214,027.00

• 957.

  Jenny Ting

  Effects of Immune Response and Cytokines on Remyelination

  4/1/2001 - 3/31/2005

  Sponsor: National Multiple Sclerosis Society (NMSS)

  Funding: $ 483,328.00

• 958.

  Jenny Ting

  Effects of Immune Response and Cytokines on Remyelination

  4/1/2001 - 3/31/2005

  Sponsor: National Multiple Sclerosis Society (NMSS)

  Funding: $ 33,000.00

• 959.

  Shelton Earp; Albert Baldwin

  25th Annual Scientific Symposium: Regulatory Mechanisms in Human Cancer

  4/1/2001 - 4/30/2001

  Sponsor: North Carolina Biotechnology Center (NCBC)

  Funding: $ 2,500.00

• 960.

  Bill Marzluff

  High Throughput Genome Analysis System

  4/1/2001 - 3/31/2002

  Sponsor: NIH National Center for Research Resources (NCRR)

  Funding: $ 135,000.00

• 961.

  Shelton Earp

  25th Annual Scientific Symposium: Regulatory Mechanisms in Human Cancer

  4/1/2001 - 4/30/2001

  Sponsor: North Carolina Biotechnology Center (NCBC)

  Funding: $ 1,000.00

• 962.

  Jenny Ting

  Effects of Immune Response and Cytokines on Remyelination

  4/1/2001 - 3/31/2005

  Sponsor: National Multiple Sclerosis Society (NMSS)

  Funding: $ 457,347.00

• 963.

  Jenny Ting

  Class II MHC Gene Control and Disease Relevance Conference

  3/22/2001 - 3/21/2002

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 33,500.00

• 964.

  Jenny Ting

  Class II MHC Gene Control and Disease Relevance Conference

  3/22/2001 - 3/21/2002

  Sponsor: NIH National Institute of Allergy and Infectious Diseases (NIAID)

  Funding: $ 3,000.00

• 965.

  Jonathan Serody

  026-MK-0991 A Multicenter Double Blind randomized Comparative Study to Evaluate te Safety Tolerability and Efficacy of MK0991 versus (Amphotericin B)

  3/16/2001 - 9/15/2002

  Sponsor: Industry Sponsor

  Funding: $ 19,625.00

• 966.

  Jonathan Serody

  026-MK-0991 A Multicenter Double Blind randomized Comparative Study to Evaluate te Safety Tolerability and Efficacy of MK0991 versus (Amphotericin B)

  3/16/2001 - 9/15/2002

  Sponsor: Industry Sponsor

  Funding: $ 14,625.00

• 967.

  Terry Magnuson; Yijing Chen

  Allelic Series of Mutations at Murine Smad4 Locus: Fellow: Yijing Chen

  3/1/2001 - 2/29/2004

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 50,116.00

• 968.

  Terry Magnuson; Yijing Chen

  Allelic Series of Mutations at Murine Smad4 Locus: Fellow: Yijing Chen

  3/1/2001 - 2/29/2004

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 1,788.00

• 969.

  Terry Magnuson; Yijing Chen

  Allelic Series of Mutations At Murine Smad4Locus

  3/1/2001 - 2/29/2004

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 48,148.00

• 970.

  Terry Magnuson; Yijing Chen

  Generating allelic series of mutations at murine SMAD4 locus -- Fellowship: Yijing Chen

  3/1/2001 - 2/29/2004

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 40,996.00

• 971.

  Terry Magnuson; Yijing Chen

  Generating allelic series of mutations at murine SMAD4 locus -- Fellowship: Yijing Chen

  3/1/2001 - 2/29/2004

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 1,000.00

• 972.

  David Siderovski; Gary Johnson

  G-Protein coordination by RGS12 and RGS14

  2/1/2001 - 1/31/2006

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 45,568.00

• 973.

  David Siderovski; Gary Johnson

  G-Protein coordination by RGS12 and RGS14

  2/1/2001 - 1/31/2006

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 258,751.00

• 974.

  David Siderovski; Gary Johnson

  G-Protein coordination by RGS12 and RGS14

  2/1/2001 - 1/31/2006

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 232,876.00

• 975.

  David Siderovski; Gary Johnson

  G-Protein coordination by RGS12 and RGS14

  2/1/2001 - 1/31/2006

  Sponsor: NIH National Institute of General Medical Sciences (NIGMS)

  Funding: $ 25,875.00

• 976.

  Mark Graham; Lisa Carey

  LCCC9818: A Non-Randomized Phase II Study of Multimodality Therap for Stage IIB, IIA/B or Initially Presenting Stage IV Breast Cancer with 4 cycles of

  12/11/2000 - 12/10/2002

  Sponsor: Industry Sponsor

  Funding: $ 83,060.00

• 977.

  Mark Graham; Lisa Carey

  LCCC9818: A Non-Randomized Phase II Study of Multimodality Therap for Stage IIB, IIA/B or Initially Presenting Stage IV Breast Cancer with 4 cycles of

  12/11/2000 - 12/10/2002

  Sponsor: Industry Sponsor

  Funding: $ 38,980.00

• 978.

  Mark Graham; Lisa Carey

  LCCC9818: A Non-Randomized Phase II Study of Multimodality Therap for Stage IIB, IIA/B or Initially Presenting Stage IV Breast Cancer with 4 cycles of

  12/11/2000 - 12/10/2002

  Sponsor: Industry Sponsor

  Funding: $ 38,980.00

• 979.

  Mark Graham; Lisa Carey

  LCCC9818: A Non-Randomized Phase II Study of Multimodality Therap for Stage IIB, IIA/B or Initially Presenting Stage IV Breast Cancer with 4 cycles of

  12/11/2000 - 12/10/2002

  Sponsor: Industry Sponsor

  Funding: $ 38,980.00

• 980.

  Mark Graham; Lisa Carey

  LCCC9818: A Non-Randomized Phase II Study of Multimodality Therap for Stage IIB, IIA/B or Initially Presenting Stage IV Breast Cancer with 4 cycles of

  12/11/2000 - 12/10/2002

  Sponsor: Industry Sponsor

  Funding: $ 18,200.00

• 981.

  Thomas Shea

  LCCC 9929: Phase II Study of Sequential High Dose Ifosfamide, Carboplatin, and Etoposide in Patients with Relapsed Hodgkin's and Non-Hodgkin's Lymphom

  12/10/2000 - 12/9/2002

  Sponsor: Industry Sponsor

  Funding: $ 25,000.00

• 982.

  Thomas Shea

  LCCC 9929: Phase II Study of Sequential High Dose Ifosfamide, Carboplatin, and Etoposide in Patients with Relapsed Hodgkin's and Non-Hodgkin's Lymphom

  12/10/2000 - 12/9/2002

  Sponsor: Industry Sponsor

  Funding: $ 25,000.00

• 983.

  Thomas Shea

  LCCC 9929: Phase II Study of Sequential High Dose Ifosfamide, Carboplatin, and Etoposide in Patients with Relapsed Hodgkin's and Non-Hodgkin's Lymphom

  12/10/2000 - 12/9/2002

  Sponsor: Industry Sponsor

  Funding: $ 25,000.00

• 984.

  Thomas Shea

  LCCC 9929: Phase II Study of Sequential High Dose Ifosfamide, Carboplatin, and Etoposide in Patients with Relapsed Hodgkin's and Non-Hodgkin's Lymphom

  12/10/2000 - 12/9/2002

  Sponsor: Industry Sponsor

  Funding: $ 23,750.00

• 985.

  Terry Magnuson; Jay Vivian

  Fellowship: Jay L.Vivian--Generation of ENU-Induced Mutations at Murine Smad2 Locus

  12/1/2000 - 11/30/2003

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 45,692.00

• 986.

  Terry Magnuson; Jay Vivian

  Fellowship: Jay L.Vivian--Generation of ENU-Induced Mutations at Murine Smad2 Locus

  12/1/2000 - 11/30/2003

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 2,456.00

• 987.

  Terry Magnuson; Jay Vivian

  Generation of ENU-Induced Mutations at Murine Smad2 Locus

  12/1/2000 - 11/30/2003

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 40,196.00

• 988.

  Terry Magnuson; Jay Vivian

  Generation of Enu-induced Mutations at Murine SMAD2 Locus: Fellowship - Jay Vivian

  12/1/2000 - 11/30/2003

  Sponsor: NIH National Institute of Child Health and Human Development (NICHD)

  Funding: $ 32,416.00

• 989.

  Thomas Shea

  LCCC 9929: Phase II Study of Sequential High Dose Ifosfamide, Carboplatin, and Etoposide in Patients with Relapsed Hodgkin's and Non-Hodgkin's Lymphom

  11/1/2000 - 11/1/2002

  Sponsor: Industry Sponsor

  Funding: $ 49,200.00

• 990.

  Thomas Shea

  LCCC 9929: Phase II Study of Sequential High Dose Ifosfamide, Carboplatin, and Etoposide in Patients with Relapsed Hodgkin's and Non-Hodgkin's Lymphom

  11/1/2000 - 11/1/2002

  Sponsor: Industry Sponsor

  Funding: $ 36,900.00

• 991.

  Jonathan Serody

  Immunotherapy for Metastatic Breast Cancer

  9/30/2000 - 9/29/2002

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 261,225.00

• 992.

  Jonathan Serody

  Immunotherapy for Metastatic Breast Cancer

  9/30/2000 - 9/29/2002

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 261,900.00

• 993.

  Young Whang; H Shelton Earp

  Functional Analysis PTEN in Prostate Cancer

  9/16/2000 - 8/31/2005

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 130,102.00

• 994.

  Young Whang; H Shelton Earp

  Functional Analysis PTEN in Prostate Cancer

  9/16/2000 - 8/31/2005

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 130,154.00

• 995.

  Young Whang; H Shelton Earp

  Functional Analysis PTEN in Prostate Cancer

  9/16/2000 - 8/31/2005

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 65,105.00

• 996.

  Young Whang; H Shelton Earp

  Functional Analysis PTEN in Prostate Cancer

  9/16/2000 - 8/31/2005

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 130,265.00

• 997.

  Young Whang; H Shelton Earp

  Functional Analysis PTEN in Prostate Cancer

  9/16/2000 - 8/31/2005

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 130,325.00

• 998.

  Young Whang; H Shelton Earp

  Functional Analysis PTEN in Prostate Cancer

  9/16/2000 - 8/31/2005

  Sponsor: NIH National Cancer Institute (NCI)

  Funding: $ 65,104.00

• 999.

  Joseph Pagano

  EBV Vectors for Targeted Gene Therapy of B-Lymphomas

  9/10/2000 - 8/31/2005

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 355,800.00

• 1000.

  Joseph Pagano

  EBV Vectors for Targeted Gene Therapy of B-Lymphomas

  9/10/2000 - 8/31/2005

  Sponsor: NIH National Heart, Lung, and Blood Institute (NHLBI)

  Funding: $ 356,423.00